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1 Introduction 
1.1 Membranes 
A common property of all eukaryotic cells is the presence of a plasma membrane which 
separates the cell content from the environment (Figure 1.1) (Alberts, 2008; Singer & Nicolson, 
1972; Gulbins, 2006). This plasma membrane not only represents a physiological barrier of the 
cell which allows the maintenance of an internal homeostasis; it is also highly selective and has 
direct influence on the entry and release of substances. The uptake of metabolically relevant 
molecules and their release as well as the signal transduction into the cell and vice versa is 
tightly regulated by the composition of the plasma membrane. Membranes were not only 
restricted to the cell surface, they can also be found inside the cell, where they contribute to the 
development of organelles. Most (plasma) membranes consist of the same weight proportions 
of lipids and proteins (Philips et al., 2009). They build up a lipid bilayer in which different proteins 
are integrated or associated with (Figure 1.1). Furthermore, membranes can be distinguished by 
the presence of three main lipid classes, glycerolphospholipids, sterols (cholesterol) and 
sphingolipids. The composition of each membrane differs from each other due to their diverse 
functions in different cell types they have to fulfil (e.g. hepatocytes, T cells and neurons). The 
plasma membrane additionally shows an asymmetric arrangement of their lipids between the 
inner and outer leaflet. Mechanisms like flip-flop events, lateral diffusion and the vesicular/ 
specific transport of lipids contribute to this feature (Holthuis et al., 2005; Gulbins et al., 2006, 
Dupy & Engelmann, 2008). Apart from that, some lipid species are also involved in signalling 
pathways (Fernandis & Wenk, 2007). 
 
 
 
 
Figure 1.1: Plasma membrane model. Depicted is a 3D fluid-mosaic model of the plasma membrane, which is 
a lipid bilayer in that many different proteins are integrated or associated with. Different lipid classes, e.g. 
phospholipids, cholesterol and sphingolipids (GSL) build up the membrane, facilitate sorting of proteins into 
domains upon their physical properties. Segregation leads to generation of the mosaic structure and more 
detailed membrane organisation. ECM- extracellular matrix; GSL- Glycosphingolipids. (Adopted and modified 
from Pietzsch, J. 2004; Nicolson et al., 2015) 
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1.2 Lipids 
Lipids are one of the main classes of biological molecules besides carbohydrates, nucleic acids 
and proteins. They are essential components of cell membranes, important for cellular integrity, 
serve as energy storage, or as signalling molecules involved in signalling pathways. Furthermore, 
they can be characterized by their amphiphilic character resulting from the carbanion-based 
condensation of thioesters, or on the other hand by carbocation-based condensation of 
isoprene units (Fahy et al., 2009). In this respective, lipids can be further divided into the 
following sub-classes i.e. fatty acids, glycerolipids, glycerophospholipids, prenol lipids, 
polyketides, saccharolipids, sphingolipids and sterol lipids (Fahy et al., 2005; 2009). 
1.3 Sphingolipids 
Sphingolipids (SL) are one family of eukaryotic membrane lipids, characterized by a high 
structural variety. They are amphipathic molecules and constituted as a tripartite. In short, SLs 
consist of a head-group and a sphingoid base (most often C18, Holthuis et al., 2001) which is 
linked by N-acylation to a fatty acid of varying chain length (C12-36) which can be additionally 
saturated or non-saturated (Figure 1.2) (Sandhoff, 2010; Mencarelli and Martinez-Martinez, 
2012). 
 
 
 
Figure 1.2: Common structure of sphingolipids. Shown is a C24:1 Ceramide (d18:1-24:1); a C24:1 fatty acid 
(blue) is amide-linked to the C2-atom of a C18:1 sphingoid base (red) and a (H)-head-group (grey R). The fatty 
acid chain length varies between C12 and C36, whereas the sphingoid base commonly consists of 18 C-atoms. 
 
Depending on the (polar) head group bound to the C1-atom of the sphingoid base one can 
subdivide them into three main classes: ceramides, phosphosphingolipids and 
glycosphingolipids (Figure 1.3) (Lahiri et al., 2007). Ceramide, the simplest sphingolipid carries a 
hydrogen atom attached to the sphingoid base. Ceramides are the precursors of all complex 
sphingolipids, its derivatives and the two known signalling molecules ceramide-1-phosphate 
(C1P) and sphingosine-1-phosphate (S1P) (Hannun et al., 2002). Next, sphingomyelin (SM) and 
ceramide phosphoethanolamine (CPE) are the main representatives of the 
phosphosphingolipids and display eponyms due to the bound head-groups phosphocholine 
(PC) and phosphoethanolamine (PE) (Figure 1.3). Glycosphingolipids (GSL) represents the last 
group of SLs, which can be further divided into cerebrosides, globosides and gangliosides 
depending on the carbohydrate connected by a -linkage to the sphingoid base (Figure 1.3; 
Merill, 2011). Briefly, cerebrosides also called monoglycosylceramides contain only one sugar 
residue. Globosides contain at least two sugar side chains, which can be a combination of the 
following: D-glucose, D-galactose and N-acetylgalactosamine. Moreover, gangliosides are the 
third sub-type of GSLs. They carry more than one sugar molecule on their side chain in 
combination with one or more sialic acids (Kolter et al., 2002; Merill, 2011). While cerebrosides 
and globosides were referred to as neutral sphingolipids, gangliosides belong to the group of 
acidic glycosphingolipids due to the presence of at least one sialic acid.  
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Figure 1.3: The sphingolipid Ceramide and possible derivatives. Ceramide displays the key intermediate and 
central backbone of complex sphingolipids and its derivatives. The most basic structures of glycosphingolipids 
which in turn themselves are precursor for complex gangliosides were shown on the right side. Sphingomyelin, 
main component of membranous myelin sheaths is depicted in the upper part. In the lower part and on the left 
side, the two main signalling molecules sphingosine-1- phosphate and ceramide-1-phosphate were represented 
(Adopted and modified from Yamashita et al., 2011). 
 
1.3.1 Ceramide 
Ceramide is the simplest sphingolipid and key intermediate in the sphingolipid metabolism. It 
is composed of a sphingoid base, a fatty acid of varying chain length (C12 to C36) and a 
hydrogen atom as the head-group (Figure 1.2 and 1.3) (Grösch et al., 2012; Hannun et al., 2011). 
On the basis of the incorporated type of sphingoid base, ceramides can be further classified as: 
dihydroceramides (sphinganine), phytoceramides (phytosphingosine) and ceramide 
(sphingosine) (Figure A1; Pruett et al., 2008; Alfatah et al., 2019). Finally, the generation of 
ceramides can either be accomplished by activation of de novo synthesis or by constitutive 
degradation of complex sphingolipids (salvage pathway) (Chapter 1.3.1.1 and 1.3.1.2, Figure 1.4). 
1.3.1.1 De novo synthesis 
The de novo biosynthesis of ceramide occurs exclusively on the cytoplasmic leaflet of the 
endoplasmic reticulum (ER) and is driven by the stepwise action of many enzymes (Figure1. 4) 
(Mandon et al., 1992; Tidhar & Futerman, 2013). The first step displays the condensation of L-
serine and palmitoyl-CoA to form the sphingoid base 3-ketodihydrosphingosine (3-keto-
sphinganine) (Figure 1.4, upper box). The reaction represents the rate-limiting step of the de 
novo synthesis and is catalysed by the serine palmitoyl transferase (SPT) (Hanada et al., 2003) 
which in turn is regulated by ORMDL proteins (Orm like) (Mandon et al., 1992; Breslow et al., 
2010). Consistent with the preference of the SPT for saturated fatty acids, the abundance of 
palmitoyl-CoA and L-serine, sphingoid bases predominantly with C18 carbons were formed. 
Subsequently, 3-ketodihydrosphingosine is reduced by the 3-ketophinganine reductase, in a 
NADPH-dependent reaction to form sphinganine (Figure 1.4, upper box; Stoffel et al., 1968). In 
the third step, the N-acylation of dihydrophingosine with fatty acids of varying chain length is 
catalysed by the presence of (dihydro)- ceramide synthases (CerS), more precisely a family of 
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sphinganine N-acyl-transferases (Figure 1.4 upper part, yellow box, Morell et al., 1970; Guillas et 
al., 2001; Kolter, 2011) and results in the formation of dihydroceramide. Next, the 
dihydroceramide desaturase (DES) converts dihydroceramide to ceramide by insertion of a trans 
4,5 double bond (Rother et al., 1992; Fabrias et al., 2012). Finally, ceramide can be used for the 
generation of more complex sphingolipids (Figure 1.4, middle box). Therefore, ceramide is 
transported through vesicular transport or non-vesicular transport by the ceramide transport 
protein (CERT, van Meer & Holthuis, 200; Hanada et al., 2003 (2)) to the Golgi apparatus, the 
site of complex SL biosynthesis. 
 
 
 
Figure 1.4: Sphingolipid metabolism. Depicted is the schematic representation of the sphingolipid metabolism 
with main steps of biosynthesis and degradation. It starts with the de novo synthesis of ceramides in the ER and 
proceeds with the generation of either complex glycosphingolipids in the Golgi apparatus or the generation of the 
bioactive molecules S1P and/or C1P. The salvage pathway of sphingolipids occurs in endolysosomes and results 
in the breakdown of higher order SLs (Adopted and taken from Ogretmen & Hannun, 2004). 
 
1.3.1.2 Salvage pathway 
An alternative pathway besides the de novo synthesis exists that accelerate the formation of 
ceramides, by degradation of higher order sphingolipids, the salvage pathway (Figure 1.4, 
middle and lower box, pink arrows; Kitatani et al., 2008; Kolter, 2011; Bikman et al., 2011). This 
second source is also essential to prevent the cell for accumulation of toxic sphingolipid species. 
The salvage pathway is restricted to late endosomes and/or lysomes and utilises the stepwise 
action of glycosidases, starting from the non-reducing end thereby giving rise to the formation 
of ceramide (Sandhoff & Kolter 2003). Furthermore, the degradation is highly dependent on the 
presence of sphingolipid activator proteins (SAPs, Schultze & Sandhoff, 2014). Mutations within 
the SAPs or other degrading enzymes could cause severe lysosomal lipid storage diseases also 
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known as sphingolipidoses. An exception illustrates the degradation of SM, which is hydrolysed 
by a family of sphingomyelinases (Marchesini et al., 2004). Moreover, those enzymes are 
distinguished by their preference for acidic, alkaline or neutral pH where they show the highest 
catalytic activity (Tayama et al., 1993; Hannun & Obeid., 2008). The resulting head-groups and 
PC can either be re-used or further processed (Sandhoff & Kolter, 2003). The remaining 
ceramide in turn is further degraded by acid ceramidases which results in the formation of 
sphingosine and fatty acids (Figure 1.4, lower box) (Linke et al., 2001; Hannun & Obeid, 2008). 
Thereafter, sphingosine can be further degraded into its building blocks, or ‘salvaged’ by 
phosphorylation thereby generating S1P (Spiegel & Milstien, 2003; Ogretman & Hannun, 2004) 
or reused as the sphingoid base leading to the formation of ceramide by N-acylation processed 
by ceramide synthases (see Chapter 1.4). Finally, 50- 90 % of the SLs re-generated in the salvage 
pathway are used for the synthesis of new SLs (Kitatani et al., 2008). 
1.3.2 Sphingosine-1-phosphate and Ceramide-1-phosphate 
Sphingosine-1-phosphate displays an important intermediate within the sphingolipid 
metabolism; and is generated from sphingosine by phosphorylation of the primary hydroxyl 
group at the C1 atom (Figure 1.3 and 1. 4) (Spiegel & Milstien, 2003). Incidentally, sphingosine is 
exclusively generated in the salvage pathway, by degradation of higher order SLs and not by 
the de novo synthesis of ceramide. This implicates that a tightly controlled turnover of complex 
SL has developed to cover the actual needs of S1P of the cell (Kitatani et al., 2008; Mao & Obeid, 
2008). 
Mammalian cells harbour two specific kinases, sphingosine kinase 1 and 2 (SPHK1 or-2) which 
catalyse the reaction. Both enzymes show a ubiquitous expression pattern, they differ in their 
intracellular localization (plasma membrane, nucleus) and substrate specificity (Wattenberg et 
al., 2010; Hatoum et al., 2017). Newly generated S1P can function as an intracellular signalling 
molecule, which was shown to be involved in the regulation of histone acetylation (Spiegel & 
Milstien, 2011; Hait et al., 2009; Hatoum et al., 2017). Apart from that, the majority of generated 
S1P is released into the extracellular space by specialized transporter, where it contributes to 
the maintenance of a S1P gradient, crucial for lymphocyte trafficking (Proia & Hla, 2010). 
Moreover, it is capable of interacting with five G-protein coupled receptors (GPCRs) (Regard et 
al., 2008), termed S1PR1-5, in a form as a second messenger, thereby transducing intracellular 
signals which regulate cellular proliferation and survival, for example (Proira & Hla, 2010; 
Hatoum et al., 2017). Next, degradation, i.e. dephosphorylation of S1P is achieved by the action 
of several lipid phosphate phosphatases and two S1P-specific phosphatases which catalyse the 
regeneration of sphingosine (Zamora-Pineda et al., 2016). Additionally, breakdown of S1P into 
its building blocks phosphoethanolamine and hexadecanal is catalysed by S1P lyase (Zhou et 
al., 1998). 
Another bioactive molecule which can be generated upon phosphorylation is C1P- ceramide-1-
phosphate. (Figure 1.3 and 1.4, middle box). The formation of C1P is catalysed by the enzyme 
ceramide kinase (CERK) in the Golgi apparatus (Lamour et al., 2007). C1P is then subsequently 
delivered to the plasma membrane by C1P transfer protein (Simanshu et al., 2013). Moreover, 
C1P can either act as an intracellular second messenger, e.g. it was shown to directly interact 
and activate cPLA2 (cytosolic phospholipases A2), which in turn enhances arachidonic acid 
formation that triggers inflammatory response (Pettus et al., 2004; Lamour et al., 2007). Apart 
from that it could also act extracellular, e.g. necessary for the regulation of cell growth and 
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survival (Ordonez et al., 2018) or as an important key player in the regulation of macrophage 
chemotaxis (Arana et al., 2010). 
1.4 Ceramide synthases 
Ceramide represents the common backbone of all higher order sphingolipids (GSLs) and is 
therefore suggested to be the main important sphingolipid species in SL metabolism (Ogretman 
& Hannun, 2004). In the early 1970s Morell & Randin (1970) characterized the first biochemical 
dihydroceramide synthase activity. Nevertheless, the genes encoding the ceramide synthases, 
the central enzymes in the SL metabolism were identified more than 20 years later in yeast 
strains (D’ Mello et al., 1994). There the lag1 and lac1 gene were proven to be essential for 
ceramide synthesis and the name, Lass – longevity assurance gene, arises from the resulting 
phenotype (Guillas et al., 2001; Teufel et al., 2009); but was re-named into CerS according to 
their biochemical function (Pewzner-Jung et al., 2006). After their discovery and detailed 
examination in yeast, further protein database-based searches lead not only to the identification 
of homologs in mammals (Mus musculus), furthermore it turned out that CerSs are encoded 
throughout the animal kingdom, e.g. Drosophila melanogaster, Danio rerio (Voelzmann & 
Bauer, 2010). 
To date, the mammalian family of ceramide synthases consist of six members (CerS1-6). All are 
multi-pass transmembrane proteins, with predicted 5-8 transmembrane domains, depending 
on the underlying algorithm used for prediction (Levy et al., 2010; Tidhar et al., 2012). 
Furthermore, their expression is mainly restricted to the ER (Barz & Walter, 1999; Kremser et al., 
2013) with the N-terminus facing the ER lumen (Tidhar et al., 2018). Additionally, there is some 
literature available that point into the direction that some CerS are also present in the Golgi 
apparatus and mitochondria/ mitochondria associated membranes (Hirschberg et al., 1993; 
Voelzmann & Bauer, 2010; Gault et al., 2010; Levy et al., 2010). Basically, all of them share the 
same common feature, the synthesis of ceramides (Mullen et al., 2012). 
1.4.1 Protein domains and motifs 
CerS family members share the presence of several common functional domains and motifs 
(Figure 1.5). As they are lag1p homologues, all of the mammalian CerS contain a TLC domain 
(TRAM-Lag-CLN8, Figure 1.5, green region) and all, except CerS1, contain a HOX (homeobox) 
domain (Figure 1.5, red circles; Levy et al., 2010). 
 
 
 
 
Figure 1.5: Schematic representation of domain organisation of CerS. Illustrated is the putative domain 
structure of mammalian CerS2, N (NT) - as well C-terminus (CT) are indicated. Homeobox domain (red circles) 
present in all CerS, except CerS1, is N-terminally located. TLC domain harbours the lag1 domain with the two 
highly conserved histidine residues essential for catalytic activity. 
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TLC domain and the lag1 motif 
The translocation-associated membrane (TRAM) - motif is present in proteins which facilitate the 
translocation of proteins. More precisely, they are components of the translocon, a gated 
channel at the ER membrane (Ng et al., 2010; Fukushima et al., 2018). Even though the lag1 
domain shows high sequence similarity to TRAM, Barz & Walter (1999) found no evidence in 
cell-culture based experiments that support the assumption that CerS are also involved in the 
structural organisation of the co-translational complex. 
The lag1 domain- contains a 52 aa residue stretch, which shows high sequence homology to 
the yeast lag1 motif (Jiang et al., 1998). In addition it was also shown that only 15 % of the TLC 
domains are highly conserved and that some distinct mutations within this region, more 
precisely within the lag1 domain results in the loss of enzymatic activity (Figure 1.6, essential 
amino acid residues are marked by an arrow; Spassieva et al., 2006; Tidhar et al., 2012). 
 
 
  Lag1 domain  [ ] 
 
Figure 1.6: Lag1 domain of CerS. Depicted is the highly conserved, 52 amino acids residues in size, lag1 
domain, of mammalian CerS. Highly conserved residues were shown in bold faces, conserved residues were not 
highlighted and ‘x’ displays non-conserved residues. Arrows indicate that upon its mutation the catalytic activity 
is lost (Adopted and modified from Spassieva et al., 2006). 
 
 
On the other hand, not much is known about the functions of the CLN8 motif. It shows high 
sequence similarity to the ceroid-lipofuscinosis neuronal 8 protein, which is part of a family with 
further seven members (Winter & Ponting, 2002). Their genetic mutations lead to the 
development of a lysosomal storage disease where auto fluorescent material accumulates 
within the lysosomes, which give rise to degeneration of the central nervous system (CNS) (Getty 
& Pearce, 2010). Furthermore it is suggested that the CLN8 protein might act as a lipid sensor 
in lipid homeostasis (Winter & Ponting, 2002). 
 
1.4.1.1 The homeodomain (HOX) 
Another highly conserved motif, evolutionary present since cnidarias (Voelzmann & Bauer, 2010) 
and present in many CerS is the homeodomain. On the mammalian system, all CerS, except 
CerS1, contain this N-terminally located domain. Its function is controversially discussed 
(Voelzmann & Bauer, 2010). Usually, homeotic genes - master regulators (transcription factors) 
involved in the specification of the body plan, the determination of the cell fate and further 
developmental processes (McGinnis et al., 1984; Gehring et al., 1994) - are characterized by the 
presence of a homeodomain. In contrast to the homeodomain of CerS where the first 15 amino 
acids (aa) residues are missing (Mesika et al., 2007), they usually contain 60 aa necessary for 
DNA binding (Gehring 1993). Moreover, nuclear magnetic resonance (NMR) analyses of CerS5 
and 6 reveal that both homeodomains have the probability to adopt a 3-helical structure like 
those of other homeotic genes (Voelzmann et al., 2016; Sociale et al., 2018). Additionally it was 
shown that schlank in Drosophila contains two nuclear localization signals (NLS) within the 
homeodomain, a monopartite-like NLS (NLS1, RPKK, aa78–81) and a bipartite-like NLS (NLS2, 
RLDKKK-X19-RLRR, aa97–125) (Voelzmann, et al., 2016). 
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1.4.2 Expression pattern and substrate specificity 
Northern Blot analyses and quantitative real-time PCR experiments of various mouse tissues 
reveal that each CerS is characterized by a unique expression pattern, with partial overlaps 
(Mizutani et al., 2005; Levy et al., 2010). Moreover, all CerS catalyse the acylation of sphinganine 
by fatty acyl-CoAs, which results in the formation of ceramide. Each CerS utilizes a specific 
subset of fatty acid chain length of C14-C36 (Sandhoff, 2010; Mencarelli and Martinez-Martinez, 
2012) for N-acylation. Finally, this results in a broad spectrum of ceramide species available for 
GSL synthesis in the different tissues (Lahiri & Futerman, 2007; Levy et al., 2010). 
1.4.3 CerS1 and CerS1-deficient mice 
CerS1 is mainly expressed in skeletal muscle and the predominant CerS in brain besides CerS2 
(Zhao et al., 2011; Ginkel et al., 2012). Additionally, it shows high substrate specificity towards 
C18 acyl-CoAs (Levy et al., 2010). Upon its mutation, which leads to CerS1 deficiency in mice, 
they suffer under Purkinje cell degeneration, accumulation of lipofuscin and cerebellar ataxia, 
which is in line with decreased levels of myelin-associated glycoprotein (MAG) in the brain and 
shrinkage of cerebellum (Ginkel et al., 2012). 
1.4.4 CerS2 and CerS2- deficient mice 
Ceramide synthase 2 is encoded on chromosome 3 at segment 3F2 on the antisense strand 
between the genes annexin A9 and SETdomain (bifurcated1) in the mouse genome. From the 
transcribed mRNA of 1981 bp a protein of 380 aa residues is translated with a putative mass of 
37 kDa (NCBI, UniprotKB). The genomic organization shares common features with those of a 
housekeeping gene (Mizutani et al., 2005; Laviad et al., 2008). The first exon and the first part 
of the second exon are the 5’ untranslated region (UTR). The last part of exon 11 harbours the 
3’ UTR with the polyA signal. A homologous gene of the mouse cers2 is also encoded in the 
human genome by the hcers2 gene, which is localized on chromosome 1. Expression pattern 
analysis of mouse tissue by Western Blot, qRT-PCR and Northern Blot (Kremser, 2016; Mullen et 
al., 2012; Schiffmann et al., 2013) indicate that it is not only almost present in every tissue, but 
also the most abundant with predominant expression in liver, lung and brain (Mizutani et al., 
2005; Becker et al., 2008; Kremser, 2016.). Moreover, CerS2-deficient mice (CerS2gt/gt) have been 
intensively studied and the results reveal that the lack of ceramide-species play important roles 
in many physiological processes (Imgrund et al., 2009/2011; Pewzner-Jung, et al., 2010 i/ii). They 
maintain brain myelination, cellular homeostasis of the liver and neutrophil migration. Deletion 
of CerS2 results in the lack of corresponding SL species (C22 and C24/C24:1) and accumulation 
of C16 and C18 SL, which might be based on a compensatory mechanism or basically due to an 
increased C16 acyl-CoA level. Furthermore, those mice show a de-regulated S1P-level/gradient 
which mainly affects the emigration of mature lymphocytes from the thymus into the circulation 
(blood, lymph node) (Rieck et al., 2017). 
1.4.5 CerS3 and CerS3- deficient mice 
Ceramide synthase 3 is mainly expressed in skin (keratinocytes) and its deficiency leads to 
defects in the maintenance of the transepidermal water barrier and by this to a transepidermal 
water loss which causes early lethality of new born mice (Jennemann et al., 2012; Eckl et al., 
2013). The severe phenotype can be explained by the unique substrate specificity of CerS3 that 
mainly uses ultra-long-chain acyl-CoAs (≥ C26) for SL biosynthesis (Park & Park, 2015; Kihara, 
2016).  
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1.4.6 CerS4 and CerS4- deficient mice 
CerS4 is characterized by a broad expression pattern, but strongest in skin (Ebel et al., 2014 i/ii) 
and substrate specificity towards C18-C20 acyl-CoA. Two independent, but simultaneously 
generated CerS4-deficient mouse lines were published and both draw the conclusion that 
ceramide synthase 4 deficiency results in an age-related hair loss which is based on an altered 
sebum composition (reduced C18 and C20 SL) in the skin (Ebel et al., 2014; Perters et al., 2015). 
1.4.7 CerS5 and CerS5- deficient mice 
Ceramide synthase 5- deficiency does not result in an obvious phenotype (Gosejacob et al., 
2016). The mice are viable and fertile. Under normal conditions, CerS5 is mainly expressed in 
white adipose tissue (WAT), testes and thymus (Gosejacob et al., 2016) and utilises C16 fatty 
acids for N-acylation (Levy, 2010; Mizutani et al., 2005). After challenging CerS5-deficient mice 
in a high fat diet, mice show reduced weight gain and simultaneously a reduction in WAT 
inflammation pointing into the direction that CerS5 might contribute to ameliorate obesity and 
its side effects (Gosejacob et al., 2016). Additionally, in vitro analyses reveal that the deletion of 
nearly the entire homeodomain does not affect the catalytic function of the protein (Mesika et 
al., 2007). 
1.4.8 CerS6 and CerS6- deficient mice 
Similar to CerS5, CerS6 has the same substrate specificity against C16 fatty acids, but also against 
C14 and shows the highest expression pattern in kidney and intestine (Laviad et al., 2008; Ebel 
et al., 2014). Furthermore, CerS6-deficiency results in the reduction of C16 ceramide species and 
the mice show behavioural defects, like clasping of the hind limbs (Ebel et al., 2014). Moreover, 
it was shown that loss of CerS6 increases the development of experimental autoimmune 
encephalomyelitis (EAE) (Eberle et al., 2014; Helke et al., 2018). 
1.5 Drosophila melanogaster ceramide synthase - schlank 
In contrast to the mammalian system where six CerS are expressed, the fruit fly Drosophila 
melanogaster expresses only one ortholog, the schlank gene (Voelzmann & Bauer, 2010; 
Voelzman et al., 2016; Sociale et al., 2018). Furthermore, it shares protein domain similarities 
regarding the presents of the homeodomain and similarities regarding the presence of the TLC 
domain with the lag1 motif essential to maintain its catalytic activity. Moreover, mutations in the 
catalytic domain results in the characteristic of different phenotypes, including reduced 
triacylglycerol (TAG) level, developmental delay or early lethality (Bauer et al., 2009; Wulf, 2015). 
In a recent publication, Sociale et al. (2018) could show that the homeodomain of the schlank 
protein is membrane-bound, shuttled to the inner nuclear membrane. 
Moreover they could show in detailed analysis that the HOX domain interacts with the promoter 
region of different genes i.e. lipase3 (lip3) and magro. Upon mutation of the bipartite NLS2 
signal (RLDKKK-X19-RLRR, RLDKKK-X19-ALAR) within the homeodomain, it loses its function to 
interact with these regions. Additionally, it was shown that schlank shuttling depends on the 
energy status of the fly, i.e. under feeding conditions. The homeodomain of the schlank enzyme 
then suppresses lip3 expression, however under starvation schlank is released from the 
promoter region of lip3, which results in increased lip3 protein expression and consequently 
TAG lipolysis (Sociale et al., 2018). 
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1.6 Ceramides and energy metabolism 
Mice represent one of the most widely used model organisms to study human diseases and 
their underlying genetics and molecular mechanisms (Speakmann, 2013). One main field 
investigated in those studies is the characterization of the energy homeostasis/ metabolism, i.e. 
the energy expenditure and the main factors involved in regulation and dysfunctions leading to 
obesity and its comorbidities (Speakmann, 2013). Basically, energy metabolism summarizes all 
processes and reactions (catabolism and anabolism) involved in food intake and breakdown 
into its building blocks to obtain energy for cell growth, survival and reproduction (Galgani & 
Ravussin, 2008). Furthermore, energy metabolism of each organism is influenced by several 
factors; basal expenditure in combination with physical activity, thermoregulation and the 
genetic background. During evolution, e.g. periods of fasting and feeding, a tightly controlled 
multi-factoral network has developed, which is responsible for the regulation of energy intake 
and expenditure (Galgani & Ravussin, 2008). This network is composed on the one hand of the 
central nervous system, i.e. the hypothalamus, which regulates appetite and food intake (Yeo & 
Heisler, 2012) by the release of hormones. Further members of this circuit are the peripheral 
organs, such as the gastrointestinal tract, including liver and pancreas as well as the adipose 
tissue (WAT and brown adipose tissue (BAT)) and muscle, which provide and receive information 
and signals regarding the energy status (Seoena-Collazo et al., 2015). Basically, even more than 
90 % of the body energy is stored in form of TAG in adipose tissue despite the restricted capacity 
to store proteins and carbohydrates for energy production; where the latter one can be further 
converted and stored as glycogen in liver and muscle (Véret, 2011). Upon saturation of glycogen 
storages, glucose can also be converted to TAG and subsequently stored in liver and adipose 
tissue (Véret, 2011). Regardless the genetic background, increased energy consumption 
(physical activity, fasting state) is accompanied by the depletion of energy storages to maintain 
cellular processes. On the other hand excessive energy intake (high-fat/caloric-diet), more than 
required for energy expenditure, is stored in form of fat (TAG) molecules in adipose tissue. If 
the over nutrition becomes chronically, the organism gained more fat, which in turn results in 
the onset of obesity (Galgani & Ravussin, 2008). The development of an obese state in turn is a 
major risk factor for the development and onset of various diseases such as cardiovascular 
disease and type 2 diabetes as well as atherosclerosis. 
1.6.1 Ceramide and sphingolipids in the development of metabolic disorders 
Ceramide as the key intermediate in sphingolipid metabolism represents not only a membrane 
component, which facilitates structural integrity, recent publications indicate that ceramides are 
also involved in the regulation of various cellular processes such as cell growth, proliferation 
and apoptosis (Bartke & Hannun, 2009), e.g. as a second messenger (Bikman & Summers, 2011). 
Furthermore, it turned out that there is a correlation between the appearance of certain 
sphingolipid species and obesity-associated disorders, e.g. atherosclerosis, cardiovascular 
disease and type 2 diabetes. These findings further highlight the need to elucidate their 
implication (Holland & Summers, 2008; Bellini et al., 2015). 
1.6.1.1 Ceramide and type 2 diabetes 
Increasing investigations reveal a strong relationship between the development of type 2 
diabetes (T2D) and excessive levels of circulating/accumulating lipids, e.g. free fatty acids (FFA), 
diacylglycerol (DAG) and phosphatidic acid, concomitant with an altered lipid metabolism, 
highlighting ceramides as a further important mediator of lipotoxicity and -cell dysfunction 
(Bellini et al., 2015). Under normal conditions, the adipose tissue is the main storage for free 
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fatty acids resulting from dietary-intake (Hajer et al., 2008). Diet-induced obesity results in an 
overload of adipocytes. Increasing free fatty acid levels accumulate in other peripheral tissue 
such as liver, pancreas, muscle and serum. There free fatty acids provide an additional source 
of acyl CoA used for sphingolipid synthesis, which results in increased sphingolipid levels. A 
direct cause of all these alterations results in insulin resistance and thereby the onset of T2D. 
Usually, insulin facilitates glucose uptake by regulating the translocation of glucose transporter 
from intracellular storages to the plasma membrane in adipose tissue and muscle. In liver, insulin 
signalling prevents the release of glucose, inhibits gluconeogenesis, which results in the storage 
of glucose as glycogen (Holland & Summers, 2008). Further investigations reveal that elevated 
ceramide levels antagonize insulin function thereby inducing insulin resistance (Chavez & 
Summers, 2012). Activation of insulin receptor upon extracellular binding of insulin results in a 
conformational change and autophosphorylation of the insulin receptor. This in turn leads to 
the recruitment and phosphorylation of further downstream molecules, e.g. IRS (insulin receptor 
substrates). Activated IRSs facilitate further activation of phosphatidylinositol 3-kinase (PI3K), 
which contributes to the activation of Akt/PKB (protein kinase B) and their downstream 
signalling cascades and targets (Bellini et al., 2015; Ng et al., 2017). Investigations elucidate that 
Akt/PKB is a direct target of ceramide thereby inducing insulin resistance (Bandet et al., 2019). 
Ceramide can either interact with protein phosphatase - PP2A, leading to its activation, which 
prevents further activation of Akt/PKB by mediating its dephosphorylation (Hage et al., 2014, 
Cazzolli et al., 2001). On the other hand, ceramide was shown to alter insulin signalling, by 
ceramide-dependent activation of an atypical PKC (Protein kinase C). Activated PKC prevents 
translocation of Akt/PKB to the plasma membrane (Powell et al., 2003; Turban&Hajduch, 2011). 
1.6.1.2 Diet-induces obesity and the role of ceramide synthase deficient mice 
With the generation and analysis of ceramide synthase knockout mice the question raises 
whether the overall altered ceramide content causes insulin resistance or the increase in a 
specific ceramide species. Experiments regarding the expression of CerS2 in liver, white adipose 
tissue and skeletal muscle of obese human and mouse model indicate a positive correlation 
between cers6 mRNA expression and the grade of obesity (Turpin et al., 2014). Additionally, 
they showed that CerS6-deficient mice, fed a high-fat-diet (HFD) were protected from diet-
induced obesity and glucose intolerance (Turpin et al., 2014). These findings were also 
supported by results obtained from Raichur et al (2019). Here, obese mouse mutants (ob/ob) 
and obese HFD-mouse models were treated with CerS6 antisense oligonucleotides (ASO) to 
knockdown CerS6. ASO treatment results in down-regulation of CerS6 expression and 
subsequent reduction in subcutaneous and visceral fat reduced C16:0 ceramide plasma levels 
as well as improved glucose tolerance and insulin sensitivity (Raichur et al., 2019). Further data 
existing from analysis of -cell function showing that elevated ceramide levels, resulting from 
high palmitate and glucose content and increased CerS4 expression, induces activation of PP2A 
(Veret et al., 2014) and inhibits nuclear translocation of the transcription factors PDX-1 and Mafa, 
thereby causing the loss of pancreatic -cell function (Poitout et al., 2008; Veret et al., 2014). 
Haplo-insufficient expression of CerS2 results in increased ratio of fat to lean mass and mild 
insulin resistance, which was shown by Raichur and colleagues (2014). Moreover they could 
verify that elevated CerS6 expression and C16:0 ceramide levels than the loss of very-long chain 
ceramides causes these alterations. CerS2gt/gt mice showed an even more pronounced 
phenotype regarding insulin resistance and C16:0 ceramide levels (Park et al., 2014).  
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1.7 Immune system 
The immune system shows the ability of a multi-cellular organism to protect themselves from a 
broad spectrum of pathogens, e.g. bacteria, viruses and parasites, which can cause severe 
infections (Kenneth et al., 2012; Iwasaki & Ruslan, 2015; Lodish et al., 2016). This host-defence 
complex system has formed during the course of evolution and comprises a coordinated 
interaction of various structures (e.g. skin barrier, effector cells) and processes (e.g. chemokine 
production, phagocytosis) (Dranoff, 2004; Kenneth et al., 2012; Lodish et al., 2016). The 
mammalian immunity can be further subdivided into the innate and adaptive immune system 
(Kenneth et al., 2012). 
The majority of all immune responses depict a coordinated and highly connected response of 
both pathways. The innate immune response against bacteria for example, is mainly mediated 
by phagocytic cells (dendritic cells (DCs), macrophages), which stimulate/ activate the adaptive 
immune response and thus activate the clonal expansion of highly specific T lymphocytes and 
the production of antibodies by B cells (Janeway et al., 2001; Kenneth et al., 2012). 
B cells, also known as B lymphocytes, belong to the group of effector cells of the adaptive 
immune system and they are characterized by the generation and secretion of specific 
antibodies upon their activation (Cano & Lopera, 2013; Nutt et al., 2015). 
During maturation, T lymphocytes either differentiate into the lineage of CD4+ or CD8+ T cells. 
Primarily, CD8+ T cells further differentiate into cytotoxic T cells when they develop their effector 
functions (Cox et al., 2013). On the other hand, CD4+ T cells differentiate into T helper (Th) cells 
of various sub-lineages, more precisely into Th1, Th2, Th17, Th9, Tfh and Treg (Cano & Lopera, 
2013; Carbo et al., 2014). The differentiation into one of these lineages depends on the type of 
antigen presenting cell (APC) in combination with its activation state, but depends also on the 
type of antigen and cytokines present in the microenvironment (Cox et al., 2013).  
1.7.1 Thymus 
The thymus is a flat- two-lobed organ. Each lobe is surrounded by a capsule, and can be further 
subdivided into lobules, where each lobule is separated by trabeculae, a strand of connective 
tissue (Garland, 2001). Additionally, each lobule consists of two main regions, the cortex and the 
medulla (Figure 1.7). 
 
 
Figure 1.7: Thymus. Histological section of H&E staining from thymus (left) and graphical overview (right) of 
detailed thymic organization (Figure adopted and modified from “Location, Structure, and Histology of the 
Thymus” von Philschatz. Lizenz: CC BY 4.0).  
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1.7.2 T cell development - Thymopoiesis 
The T cell development can be divided into several stages each requiring a distinct 
microenvironment provided by the thymus, more precisely by thymic stromal cells, thymic 
epithelial cells, endothelial cells, fibroblasts and their expression of chemokines (Figure 1.8; 
Takahama, 2006; Nitta & Suzuki, 2016). 
 
 
 
Figure 1.8: T cell development. Bone marrow derived (BMD) progenitor cells enter the thymus at the cortico-
medullary junction and give rise to the group of CD4/CD8 double-negative (DN) cells. Upon differentiation they 
migrate into the subcapsular zone (SCZ) and back to the cortex and transform into DN1(CD44+CD25-), 
DN2(CD44+CD25+), DN3(CD44-CD25+) and DN4(CD44-CD25-). Afterwards they differentiate into CD4/CD8 
double positive (DP) thymocytes and undergo positive selection, via TCR:self-peptide-MHC signalling. Positive 
selection is mediated by cortical epithelial cells (cEC) which induce, upon appropriate signalling, the development 
into either CD4 or CD8 lineage. Immature single positive (SP) thymocytes enter the medulla and interact with 
medullary epithelial cells (mEC) or dendritic cells (DC) in a second control point, the negative selection 
(development of self-tolerance). Mature SP cells migrate to the cortico-medullary junction an leave the thymus to 
become naïve T cells circulating in the periphery. (Adopted and modified according to Takahama, 2006; Cano & 
Lopera, 2013; Nitta & Suzuki, 2016). 
 
Initially, bone marrow derived (BMD) progenitors enter the thymus at the well-defined cortico-
medullary junction and migrate to the cortex. Each differentiation step can be monitored by the 
cell surface expression of different markers e.g. CD25, CD44 and CD4 as well as CD8 (Godfrey 
et al., 1993; Ceredig & Rolink, 2002). BMD progenitors belong to the group of CD4/CD8 double 
negative thymocytes that undergo various differentiation steps from double negative (DN) 
stage to the double positive (DP) stage and finally give rise to the stage of mature single positive 
(SP) thymocytes, which leave the thymus and enter secondary lymphoid organs (e.g. spleen and 
lymph nodes). Moreover, cells of each differentiation step colonize a distinct area of the thymus 
(Figure 1.8; Zuniga-Pflücker, 2004). First, the DN stage can be further divided into DN1 (CD44+/ 
CD25-), DN2 (CD44+/ CD25+), DN3 (CD44-/CD25+) and DN4 (CD44-/ CD25-). Stage DN2 and 
DN3 are characterized by the V(D)J rearrangement at the TCR, , and  loci. Successful 
rearrangement of the TCR -chain results in differentiation of the cells into the DN4 stage, which 
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undergo further differentiation and proliferation to become double positive thymocytes (Figure 
8, left side) (DP= TCR+, CD4+/CD8+/CD44-/CD25-) (Singer & Bosselut, 2004). Upon positive 
selection, a control point for DP thymocytes, only those receive further survival signals that 
express a functional TCR which has low/intermediate avidity/affinity in binding of a self-peptide 
presented on an MHC I or II molecules by cortical epithelial cells. According to the interaction 
with either MHC class I or class II molecules, DP cells in turn down-regulate either CD8 or CD4 
and thereby differentiating into immature CD8+ or CD4+ single positive cells (Figure 8, Medulla, 
SP cells are CD4+ or CD8+- CD62Llow/CD69high) (Takahama 2006, Takaba & Takayanagi, 2017). 
Interestingly, 95 % to 99 % of all DP cells were eliminated during the step of positive selection 
(Cano & Lopera, 2013). Single positive (SP) thymocytes enter the medulla and interact with auto-
antigen presenting cells (mTecs, DCs) to become mature single positive thymocytes (CD4+ or 
CD8+- CD62Lhigh/CD69intermediate) (Klein et al., 2014). 
The positive selection by cortical epithelial cells in combination with the negative selection by 
DCs and macrophages give rise to the generation of a T cell repertoire capable to distinguish 
between self and non-self (foreign, Figure 1.8). Any dysregulation in the development and 
generation of T cells or the thymus can cause immunodeficiency (lack of T cells) or 
autoimmunity (auto reactive T cells) (Klein et al., 2014; Takaba & Takayanagi, 2017). Finally, naïve 
T cells leave the thymus and enter secondary lymphoid tissues e.g. spleen and lymph nodes. 
1.7.3 S1P signalling and thymic egress 
Thymocytes that have successfully undergone positive and negative selection developed into 
mature single positive T cell (CD4+ or CD8+- CD62Lhigh/CD69intermediate) which enter the circulation 
and become part of the adaptive immune system (Saba, 2017). 
The process of thymic emigration largely depends on the maintenance of an S1P gradient 
between the thymic interstitium and the blood (Proia & Hla, 2017). First, high S1P level at the 
cortical junction the exit site for thymocytes, is generated by neural crest-derived pericytes and 
to a minor extend also by vascular endothelial cells (Resop et al., 2016; Saba, 2017). On the other 
hand, activity of intracellular S1P lyase in DCs (and thymocytes) and to minor extend in thymic 
epithelial cells results in low interstitial S1P concentration (Schwab, 2005; Resop et al., 2016). This 
chemical gradient is highly essential for chemotaxis of mature thymocytes, i.e. to exit the thymus 
and enter the periphery (Schwab et al., 2005; Yanagida & Hla, 2017). This condition can also be 
monitored by appearance of certain cell surface marker. Immaturity is depicted by expression 
of: S1PR1low/CD69high/CD61Lintermediate. After maturation where thymocytes become sensitive to 
S1P, they start expression of the S1P receptor (S1PR1) (Carlson et al., 2006; Resop et al., 2016). 
Furthermore, CD69 expression is mutually antagonized by S1PR1 expression, and expression of 
CD62L also increases, which represents another important factor for homing mature thymocytes 
to peripheral lymphatic tissues (Resop et al., 2016). To this end, mature thymocytes are recruited 
along the S1P gradient to the perivascular space from which they had entered the thymus 
(Yanagida & Hla, 2017). Based on even higher S1P levels in the blood (generated by erythrocytes) 
(Saba, 2017), thymocytes transmigrate across the vessel wall, enter the blood circulation and 
become naïve T cells (Saba, 2017). Even though Resop (et al., 2016), Zamora-Pineda (et al., 2016) 
and colleagues could show, that S1P lyase in DCs is essential to maintain S1P gradient, whereas 
the exact intrathymic distribution and the contribution of other present cell types need to be 
elucidated (Zamora-Pineda, et al., 2016; Yanagida & Hla, 2017). 
All these findings were further supported by experiments performed with mice deficient in S1PR1 
(S1PR1-/-) (Resopt et al., 2016; Matloubian et al., 2004) in hematopoietic stem cells. Briefly, those 
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mice have almost no naïve T cells in the blood and periphery (Resop et al., 2016). Furthermore, 
they verified that CD69low but not CD69high thymocyte migrate towards the S1P gradient in 
combination with high expression of CD62Lhigh (L-selectin), necessary for homing cells to 
peripheral lymphoid tissues (Feng et al., 2002; Shiow et al., 2006; Resop et al., 2016). 
Despite these findings it was shown that maintenance of ceramide, i.e. sphingolipid metabolism 
by ceramide synthases is additionally necessary to regulate the S1P homeostasis/ gradient 
(Newton et al., 2015). In detail, it was shown that CerS2 is a potent regulator in these homeostasis 
and that upon its deficiency, the S1P gradient is disrupted (Pewzner-Jung et al., 2010 i ; Rieck et 
al., 2017). Moreover, CerS2gt/gt mice show elevated S1P levels within the thymic interstitium and 
significantly increased levels in the plasma (Rieck et al., 2017). Furthermore, this marginal 
distortion is sufficient that mature single positive CD4 or CD8 thymocytes respond and 
internalize S1P-bound-S1PR1, which in turn results in the accumulation of thymocytes at the exit 
site, next to a T cell lymphopenia in the periphery (Rieck et al., 2017). 
1.8 Manipulation of gene function 
1.8.1 Conventional gene targeting via homologous recombination 
One way to analyse gene function is the manipulation of the gene of interest, caused by 
ubiquitous deletion or alteration, i.e. upon the insertion and expression of a non-conditional 
construct. 
However, depending on the essentiality of the given gene during embryonic development or 
adulthood, the non-conditional approach could cause early lethality or lead to the development 
of pleiotropic effects, which in turn interfere with the analyses of the desired gene and preclude 
the generation of a new mouse line (Rajewsky & Kühn, 1996). Another possibility to bypass this 
problem is the application of a conditional approach which allows the analysis of the desired 
gene in a tissue and/or developmental (time) specific manner (Schultze et al., 1996; Rickert et 
al., 1995). To facilitate the functionality, the approach requires two different recombinase-driven 
systems, the Cre/loxp and Flp/frt (Kuhn et al., 1995; Feil et al., 2009; Bouabe & Okkenhaug, 2013). 
First, the Cre-recombinase (causes recombination) is derived from the bacteriophage P1 
(Sternberg & Hamilton, 1981; Hoess et al., 1982) and the Flp (Flippase) from the yeast 
Saccharomyces cerevisiae (McLeod et al., 1986). Both recombinase proteins form dimers in the 
activated stage, capable to recognize a specific 34 bp long sequence. This in turn consists of an 
asymmetric 8 bp long core, depicting the orientation that is flanked by 13 bp long inverted 
repeats (Lewandowski, 2001). Furthermore, the core sequence is termed loxP-site (locus of X 
over P1) or frt-sites (Flp-recognition target) respectively. Each recombinase specifically 
recognizes its sites of action (loxP/frt) and mediate different kinds of recombination (Bouabe & 
Okkenhaug, 2013). If the desired DNA sequence is flanked by two sites pointing in identical 
direction, Cre causes a deletion. However, it should be considered, that after recombination one 
of the recognitions sites remain in the genomic locus (Kano et al., 1998; Lam & Rajewsky, 1998; 
Lewandowski, 2001), but the inserted loxP/frt sites do not interfere with the expression of the 
gene. On the other hand, sites with opposite directions cause inversion of flanked region. 
Furthermore, the recombination mechanism of the Flp/frt system is analogous to Cre/loxP and 
describes an alternative tool, which can be combined with the latter one to enhance the 
conditional approach. To achieve manipulation of gene function in mice, a gene-targeting-
vector construct with desired mutation and loxP/frt-sites has to be generated and inserted via 
homologous recombination into embryonic stem cells (ESCs), following blastocyst injection. 
After generation of mice, which harbour the mutated allele flanked by loxP/frt sites, animals can 
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be crossed with mice expressing the Cre/Flp-recombinase under the control of a specific 
promoter. This in turn allows not only a tissue/cell type specific expression, but also a temporally 
manipulation upon application of Cre-ER(T) approach, where the Cre-recombinase is coupled 
to a modified estrogen-receptor (ER) and thus Cre-mediated recombination only occurs after 
administration of Tamoxifen (artificial modified estrogen) (Feil, 1996). The Cre/loxP and Flp/frt 
systems have become a powerful tool to analyse and investigate the cellular and molecular 
functions of a given gene (Bouabe & Okkenhaug, 2013). 
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2 Aim of the study 
The ceramide synthase (CerS1-6) gene family encodes a key enzyme in lipid metabolism of 
eukaryotes. They are highly conserved and catalyse the formation of ceramides, which can act 
as bioactive lipids and secondly are precursors for all complex sphingolipids. All ceramide 
synthases harbour a highly conserved lag1 domain necessary for the catalytic function and all 
CerS, except CerS1, additionally contain a homeodomain (HOX) whose role is controversially 
discussed, but under intensive investigations to unravel its functions. Ceramide synthases differ 
in their expression pattern and substrate specificity towards the fatty acyl-CoAs used for N-
acylation. 
Most of the studies done so far have been performed with CerS2gt/gt mice that carry a gene 
trap insertion within the genomic locus of cers2. This in turn results in the complete loss of the 
mCerS2 protein (i.e. lag1 domain and homeodomain) accompanied by complete loss of 
function (Imgrund et al., 2009; Pewzner-Jung et al., 2010 i/ii), which causes the development 
of severe phenotypes in the mice, e.g. hepatocellular carcinoma, demyelination/ myelin sheath 
defects and T cell lymphopenia. 
For this reason, two new conditional transgenic mouse lines had to be generated by 
homologous recombination in order to study the functions of each protein domain 
independently from each other: the CerS2H212A/H213/A and the CerS2Del79-120 mouse line. This 
involved the construction of the two conditional gene targeting constructs, their transfection 
into embryonic stem (ES) cells, as well as the screening of positive ES cells clones, i.e. 
verification of correct homologous recombination. Finally, generation of the conditional 
CerS2H212A/H213/A and the CerS2Del79-120 transgenic mice results after blastocyst injections and 
subsequent breeding with Cre-recombinase-expressing mice. 
The conditional CerS2H212A/H213/A mouse line should offer the possibility to analyse the 
phenotypes arising from the loss of catalytic activity independently from those caused by the 
homeobox domain; and the CerS2Del79-120 mouse line should shed light on the function of the 
homeodomain. In order to pursue and further investigate the endogenous expression of the 
mutated proteins, an IRES-eGFP reporter cassette was additionally integrated after the stop-
codon of each manipulated cers2-coding sequence. Detailed analysis of hepatic alterations, 
lipid and energy metabolism as well as the immune status of the mice was to be carried out in 
this PhD thesis. This included biochemical, histological and immunological approaches as well 
as the analyses of the transcriptome and feeding behaviour of the mice. 
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3 Material 
Materials used for this thesis, except explicitly mentioned, were already described before 
(Degen 2003; van Uelft 2012; Ginkel 2013). 
3.1 Buffer, stock solutions and cell culture media 
Chemicals, enzymes and radioactivity 
All standard chemicals for the preparation of commonly used buffers and solutions were of 
analytical grade and purchased from the following companies: Difco, Fluka, GibcoBRL, 
Invitrogen, Merck, PAA, Roche, Roth, Serva and Sigma. Enzymes and nucleotides were ordered 
from Roche, New England Biolabs, MWG-Biotech or Promega. Furthermore, all buffer and 
stock solutions were prepared with double distilled water (ddH2O) and stored at room 
temperature (RT) if not mentioned otherwise. The pH was adjusted either with 1N HCl or 1N 
NaOH. Radioactivity (P32) for Southern blot analysis was purchased from Hartman Analytic 
GmbH under consideration of the calibration date and the half-life of the isotope. 
3.1.1 Nucleic acid sample preparation buffer and stock solutions 
3.1.1.1 Genomic DNA preparation buffer and stock solutions 
ES-lysis buffer (pH 8.0)  50 mM  NaCl 
    20 mM  Tris-HCl 
    100 mM EDTA 
    0.5 % (w/v) SDS 
    2 mM  CaCl2 
      Steril filtrate, aliquots 
Add the following prior usage: 
    50 µl/ml  Proteinase K 
    100 µl/ml RNase200 
Laird Buffer   100 mM Tris-HCl 
    200 mM NaCl 
    5 mM  EDTA 
    0.2 % (w/v) SDS 
    200 µg/µl Proteinase K 
TE Buffer (pH 8.0)  10 mM  Tris-HCl 
    1 mM  EDTA 
      Autoclave 20 min at 121°C 
Proteinase K –    20 mg/m l Proteinase K 
Stock Solution     Store at -20°C 
RNase 2000   0.2 %  RNase A (Roche) 
    2000 U/ml RNase T1 (Roche) 
      ad 10 ml ddH2O, aliquots, store at -20°C 
Sodium acetate (pH 4.8) 3 M  Sodium acetate 
      Autoclave 20 min at 121°C  
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3.1.1.2 Plasmid preparation 
Alkaline Lysis buffer I  50 mM  Glucose 
(pH 8.0)   25 mM  Tris-HCl 
    10 mM  EDTA 
      Autoclave 20 min at 121°C, store at 4°C 
Add the following prior usage: 
    3 µl/ml  RNase 2000 
Alkaline Lysis buffer II  0.2 M  NaOH 
    1 % (w/v) SDS 
Alkaline Lysis buffer II  5 M  Potassium acetate 
(pH 5.5)   3 M  Glacial acetic acid 
3.1.1.3 Agarose gel electrophoresis buffer 
DNA Sample Buffer (6x) 0.25 % (w/v) Bromophenol blue 
    0.25 %  (w/v) Orange G 
    30 % (v/v) Glycerol 
TAE Buffer (pH 8.0)  2 M  Tris 
(50x)    100 mM EDTA 
    35.5 ml  Glacial acetic acid 
      Adjust pH with acetic acid 
TBE Buffer (pH 8.3)  1 M  Tris 
(10x)    0.83 M  Boric acid 
    10 mM  EDTA 
3.1.1.4 Southern Blot buffer 
Depurination Buffer  0.25 M  HCl 
Denaturation Buffer  0.5 M  NaOH 
    1.5 M  NaCl 
SSC (20×)   3 M  NaCl (pH 7.5) 
    0.3 M  Trisodium citrate 
 
3.1.2 Protein preparation buffer; and stock solutions 
3.1.2.1 Immunoblot analysis buffer 
APS (10%)   10 %  APS (Ammoniumpersulfat) 
      Store at 4 °C 
Blocking Buffer   5 % (w/v) Milk powder in TBS-T 
CompleteTM- (25x)  1 tablet  CompleteTM (Roche) 
    2 ml   distilled water 
      Store at -20°C  
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Urea Sample Buffer  40 mM  Tris-HCl (pH 6-8) 
(2x)    1 mM  EDTA 
    9 M  Urea 
    5 % (v/v) SDS 
    0.01 % (w/v) Bromphenol blue 
    5 % (v/v) 2-Mercaptoethanol 
Stacking Gel Buffer  0.5 M  Tris-HCl 
(pH 6.8)   0.4 % (v/v) SDS 
      Store at 4°C 
Separation Gel Buffer  1.5 M  Tris-HCl 
(pH 8.8)   0.4 % (v/v) SDS 
      Store at 4°C 
SDS Running Buffer (10x) 0.25 M  Tris-Base 
(pH 8.8)   1.92 M  Glycine 
    1 % (v/v) SDS 
      Autoclave 20 min at 121°C 
Transfer Buffer (pH 8.3) 20 mM  Tris Base 
    150 mM Glycine 
    20 % (v/v) Methanol 
PonceauS staining solution 0.2 % (w/v) Ponceau S 
    1 % (v/v) Acetic acid 
TBS (pH 7.5)   100 mM Tris- HCl 
(10x)    1.5 M  NaCl 
TBS-T (1x)   Dilution of 1:10 in ddH2O 
    0.1 %  Tween20 
3.1.2.2 Immunofluorescence microscopy solutions (IF) 
Blocking Solution   5 % NGS PBS or Oldenburg buffer 
Dako       Fluorescence mounting medium, Dako 
Oldenburg buffer (pH 7.6) 50 mM  Tris-base 
    256 mM NaCl 
    3 % (w/v) Triton X-100 
3.1.3 Bacterial cell culture; buffer and stock solutions 
3.1.3.1 Antibiotics for used for cultivation 
Ampicillin Stock  50 mg/ml Ampicillin in ddH2O 
      Sterile filtrate and store at -20°C 
      Final concentration 100 µg/ml 
Chloramphenicol Stock 20 mg/ml Chloramphenicol in ethanol abs 
      Sterile filtrate and store at -20°C 
      Final concentration 20 µg/ml  
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Kanamycin A Stock  25 mg/m l Kanamycin A in ddH2O 
      Sterile filtrate and store at -20°C 
      Final concentration 25 µg/ml 
Tetracycline Stock  10 mg/ml  Tetracycline in ddH2O 
      Sterile filtrate and store at -20°C 
      Final concentration 10 µg/ml 
3.1.3.2 Solution for generation of chemically or electro- competent cells 
LB0 Agar (1 l)   10 g  Bacto-Trypton 
    5 g  Yeast- Extract 
    10 g  NaCl 
    15 g  Agar 
      Autoclave 20 min at 121°C 
LB0 Medium (1 l)  10 g  Bacto-Trypton 
    5 g  Yeats-Extract 
    10 g  NaCl 
      Autoclave 20 min at 121°C 
CaCl2 Stock   100 mM CaCl2 
3.1.4 Embryonic stem cell culture; medium, buffer and stock solutions 
ES- EDTA (pH7-8)  5 mM  EDTA in ES-PBS- (Invitrogen) 
      Substitution of 200 µl 10 N NaOH 
      Autoclave 20 min at 121°C 
ES- Gelatine Stock  1 %  Pork Skin, Type A Gelatine 
      Autoclave 20 min at 121°C and store at 4°C 
2i ES medium   500 ml  GlasgowMEM 
    5 %  FCS 
    1mM  Sodium pyruvate (100 mM, Gibco) 
    1 x  non-essential amino acids (100 x, Invitrogen) 
    1 x  Penicillin/Streptomycin (100 x, Gibco) 
    1 x  L-Glutamine 
    0.007 % (v/v) 2- Mercaptoethanol 
    0.1 %  LIF (1000 U/ml) 
    1 µM  MEK1-2 inhibitor (Millipore) 
    3 µM  GSK3 inhibitor (Miltenyi Biotec) 
ES freezing medium (2x) 17.5 ml  2i ES medium 
    2.5 ml  FCS 
    5 ml  DMSO 
2i ES selection medium 350 µg/ml G418 Stock solution in 2i ES medium 
G418 Stock   50 mg/ml G418 Sulphate 
    100 mM PIPES 
      Sterile filtrate and store at -20°C 
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2-Mercaptoethanol Stock 0.7 %  2-Mercaptoethanol in ES- H2O 
      Store at -20°C 
ES- Trypsin   400 ml  PBS- 
    1 mM  ES-EDTA- solution (1.85 g/l , pH8.0) 
    1 %  Chicken serum 
    0.025 % Trypsin 
HBS Buffer   in  PBS- 
    0.02 M  Hepes 
    2.5 M  Glucose 
      Store at -20°C 
KCl Solution   0.56 %  KCl 
3.1.5 Cell culture; medium, buffer and stock solutions 
MEF medium    500 ml  GlasgowMEM 
    1 %  L-glutamine (1 %) 
    1 %  Non- essential amino acids 
    1 %  Sodium pyruvate 
    10 %  FBS 
    1 %  2-Mercaptoethanol 
    1 %  Penicillin/Streptomycin, store at 4 °C 
HEK medium   500 ml  DMEM 
    10 %  FBS 
    1 %  Non- essential amino acids 
    1 %  Penicillin/Streptomycin, store at 4 °C 
2 x MEF freezing medium   MEF medium supplemented with 20 % DMSO 
      and 10 % FCS. 
2 x HEK freezing medium   HEK medium supplemented with 20 % DMSO 
      and 30 % FCS. 
Poly L-lysine stock   1 mg/ml  Poly L-lysine in ddH2O 
Poly L-lysine working solution  50 mg/ml Poly L-lysine 
3.1.6 FACS experiments; buffer and stock solutions 
LymphoprepTM   Density gradient medium (Stem cell technologies) 
 
Red blood cell (RBC) lysis buffer 
(pH 7.6)   142 mM NH4Cl 
    100 µM  EDTA 
    1 mM  NaHCO3 
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3.1.7 Lipid Biochemistry 
3.1.7.1 Ceramide synthase activity assay 
BSA (fatty acid free)     Sigma-Aldrich 
Dihydrosphingosine, D-erythro, [4,5-3H] Biotrend Chemicals GmbH 
Sphinganine     Sigma-Aldrich 
NBD-sphinganine    Avanti Polar Lipids 
(omega(7-nitro-2-1,3-benzoxadiazole- 4-yl)(2S,3R)-2 aminooctadecane-1,3-diol)  
AcylCoAs      Avanti Polar Lipids 
HEPES- KOH (pH 7.4)  0.5 M  HEPES 
      Adjusted the pH 7.4 with KOH (2 M) 
Homogenization Buffer 20 mM  HEPES/KOH7 
    25 mM  KCl 
    0.25 M  Sucrose 
      2 mM  MgCl2 
      Store at -20°C 
   Add fresh 
    1 mM  PMSF 
    1 µl/ml  Aprotinin (200 
U/ml) 
    1 µl/ml  Leupeptin (1 
mg/100µl) 
 
Reaction Buffer  20 mM  HEPES/KOH 
    25 mM  KCl 
    0.25 M  Sucrose 
      2 mM  MgCl2 
           0.34 mg/ml  BSA (fatty acid free), store at -20 °C 
 
3.1.8 Histological staining solutions 
3.1.8.1 Hematoxylin and eosin staining (H&E) 
Eosin staining solution  0.1 % (w/v) EosinY 
      Filtered solution can be used several times 
Hematoxylin   0.1 %  Mayer’s Hemalum solution 
 
3.1.8.2 Oil Red O 
OilRedO® stock solution A 0.5 g  OilRedO® 
    100 ml  99 % isopropanol 
OilRedO® stock solution B 60 ml  OilRedO® stock solution A 
    40 ml  ddH2O 
      Incubate for 24 h and filtrate, storage at RT  
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3.2 Antibodies 
3.2.1 Primary antibodies 
Antigen Host Dilution Company 
    
CerS2 Rabbit 1:750 (IB) Kremser et al., 2013 
CerS4 Rabbit 1:300 (IB) Ebel et al., 2014 
CerS5 Sheep 1:2000 (IB) Gosejacob et al., 2016 
CerS6 Mouse 1:500 (IB) Santa Cruz Biotechnology 
GAPDH Mouse 1:10.000 (IB) Millipore 
GAPDH Rabbit 1:10.000 (IB) Millipore 
GFP Chicken 1:500 Abcam 
V5 Mouse 1:1000 (IB) Invitrogen 
3.2.2 Secondary antibodies 
 Antigen Host Dilution Company 
     
Alexa Fluor 488 Rabbit Goat 1:1000 (IF) Invitrogen 
Alexa Fluor 562 Mouse Goat 1:1000 (IF) Invitrogen 
HRP conjugate Mouse Goat 1:10.000 (IB) Dianova 
HRP conjugate Rabbit Goat 1:10.000 (IB) Dianova 
HRP conjugate Sheep Goat 1:10.000 (IB) Dianova 
3.2.3 FACS antibodies 
Target Clone Conjugate Host Use Company 
      
CD3  Fluorochrome  FC Biolegend 
CD4 GK1.5 / RM4 Fluorochrome Rat FC Biolegend 
CD8a 53-6.7 Fluorochrome Rat FC Biolegend 
CD19  Fluorochrome  FC Biolegend 
CD25 7D4 / PC61 Fluorochrome Rat FC Biolegend 
CD45 30- F11 Fluorochrome Rat FC Biolegend 
CD45.1 A20 Fluorochrome Mouse FC Biolegend 
CD62L MEL14 Fluorochrome Rat FC Biolegend 
CD69 H1.2F3 Fluorochrome 
Armenien 
hamster 
FC Biolegend 
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3.3 Primer molecules 
All oligonucleotides were ordered from MWG Eurofins, HDSL and diluted to 100 pmol/µl. 
 
Primer Sequence (5‘  3‘) Application 
 
  
5’SB BAC for ATGTGCCTAACGGGAAACAG Amplification of 5‘SB 
probe (477 bp) 
5’SB BAC rev ATGTGGCCAGAAACAAGACC 
3’SB BAC for GTTTAACTACGCGGGATGGA Amplification of 3’SB 
probe (415 bp) 
3’SB BAC rev GAGTTGCAGCATGACAAGGA 
Ctrl 2 for (3’HR for) GTACAAGTAAAGCGGCCTCG Genotyping of 3’ HR 
region (bp) in ES 
cells/ mice Ctrl 3 rev (3’HR rev) CATCATAGAACTGGCGTGTG 
HA_loxP_2_for TAGGGCTTCGTGTTGGTCTT Genotyping of CerS2-
ES cells and mice 
HA_loxP_1_rev CCGCTGGTCTGGTAGAAATG 
5’ctrl for (5’HR for) GGGATCTGTGCAGGGTTTTC Genotyping of 5’ HR 
region (bp) in ES 
cells/ mice 5’ctrl rev (5’HR rev) CGATGGAGAAATTGGCAAGC 
USP_Flp TAAGGTCCTGGTTCGTCAGTTTGTGG Verification of 
presence of Flp 
recombinase in mice DSP_Flp GTGATATTATCCCATTCCATGCGGGG 
Pgk1_for GCTGTTCTCCTCTTCCTCATCTCC Verification of 
presence of PGK-Cre 
recombinase in mice Int-Cre_rev TCCATGAGTGAACGAACCTGGTCG 
del79-120_for GAGGCTGAGGACTCAGCATC Verifcation of deletion 
in CerS2Del mice 
del79-120_rev CCCACTTCCCAGTACTCACA 
PvuII_alt_for GCTCTTCAGCATTGCCTCTG 
Verification of point 
mutation in CerS2H/A 
mice 
PvuII_alt_rev CTGTGAGGAAGCCTAACCTC 
HA_Cre_rev CGCGTGAATTTCGACGGTAT 
Nnt- WT for GGGCATAGGAAGCAAATACCAAGTTG 
Verification of NNT 
mutation in mice Nnt- Mut for GTGGAATTCCGCTGAGAGAACTCTT 
Nnt-com rev GTAGGGCCAACTGTTTCTGCATGA 
frt_SalI/AsiSi_for ACGCGTCGACGCGATCGCCAACCGCGCCACTCAGAG Amplification of 5’HR-
SOE fragment 
(379bp) frt_AatII_rev TGCTGACACCGACGTCACCCGCGCACAGACTTACT 
frt_AatII_for GTGCGCGGGTGACGTCGGTGTCAGCATCACCTAAGG Amplification of 3’HR-
SOE fragment 
(570bp) frt_SalI_rev GCGTGTCGACCAATGGTGCGCTGGGGGA 
E3-11wt MfeI for TTACAATTGTCTTCCTGAGGCTGAGGACT Amplification of 
genomic region of 
exon3 to exon11 E3-11wt MfeI rev AATCAATTGAACCACAAGGGAGGCCTAAG 
E3-11 PspOMI_ for TTAGGGCCCTCTTCCTGAGGCTGAGGACT Amplification of 
genomic region of 
exon3 including tga E3-11 BstEII/PspOMI rev TAAGGGCCCGGTAACCCTAGGACAATGGTTCAGTCATTC 
E3-11 H/A for GAACAGATCATCGCAGCTGTGGCCACTATC Introduction of H/A 
mutagenesis 
E3-11 H/A rev GATAGTGGCCACAGCTGCGATGATCTGTTG 
3’ HR_XhoI_for CCGCTCGAGCTGCCTCCCACATCAATGCA Amplification of 3’HR 
region, insertion of 
XhoI/ApaI resctrion  
site 3’HR_ApaI_rev TTGGGCCCATGCCAAACTTGAAGGCAA 
IRES_SapI/AsiSI for 
CAAGCGGAAGAGCGCCCAAGCGATCGCCAACCGCGCC 
ACTCAGAG Amplification of 3’frt-
SOE fragment (571bp 
IRES_NdeI rev AGCCTGCGACCATATGACCCGCGCACAGACTTACT 
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Primer Sequence (5‘  3‘) Application 
 
  
IRES_NdeI for TGTGCGCGGGTcatatgGTCGCAGGCTTTCACCCAT 
Amplification of 5’frt-
SOE fragment (388bp) 
IRES_BstEII/ClaI rev taatcgataggtaaccCTAGGACAATGGTTCAGTCATTC 
3.4 Plasmids 
Plasmid Description Company 
   
loxP frt dualneo frt 
loxP 
Contains neomycin cDNA controlled by a dual 
(pro- and eukaryotic) promoter, flanked by frt 
and loxP sites 
H. Wende (MDC Berlin) 
pBSK_IRES_eGFP 
eGFP expression vector with internal ribosomal 
entry site 
Tress, 2006 
pDTA pDTA containing mammalian expression vector H. Wende (MDC Berlin) 
pCDNA3.1 TOPO 
Blunt 
Cloning and expression vector, suitable for 
mammalian cell culture systems 
Invitrogen 
pCDNA3.1 V5-His-
TOPO 
Cloning and expression vector; suitable for the 
mammalian cell culture systems. Expression 
lead to generation of C-terminally V5/6xHis 
tagged proteins. 
Invitrogen 
3.5 Hybridization probes 
Probe Description Application 
   
Internal CerS2 
probe 
400 bp fragment that binds within the coding 
region of CerS2 (exon 8-10) 
CerS2 Southern Blot 
eGFP probe 
Digestion fragment of GFP from the IRES-
eGFP vector 
CerS2 Southern Blot 
3.6 Bacterial artificial chromosomes 
BAC Description Source 
   
BMQ 325-K4 Comprise the genomic sequence of CerS2 Sanger Institut 
3.7 Eukaryotic cell lines 
Cell line Description Reference 
   
HM1 
Murine embryonic stem cells isolated from agouti-
coloured-male blastocysts (SV129P2/OlaHsd line) 
Magin et al., 1992 
HEK-293T human embryonic kidney cells Own stock 
Macrophages 
Murine macrophages derived by differentiation of 
primary bone marrow cells 
Primary cell culture 
CerS2 
H212/213A 
HM1 founder line for blastocyst injection, 
heterozygous for mutated CerS2 allele, based on 
homologous recombination with CerS2H/A-
exchange vector  
Bickert et al., 2018, 
Present study 
CerS2 del 79-120 
HM1 founder line for blastocyst injection, 
heterozygous for mutated CerS2 allele, based on 
homologous recombination with CerS2 del-
exchange vector 
Bickert et al., 2018, 
Present study 
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3.8 Bacterial strains 
Strain Description Reference 
   
E. coli XL1-
blue 
recA1, endA1, gyrA96, thi-1, (mcr)A183,  (mcrCB-hsd 
SMR-mrr)173, supE44, relA1, lac[F‘proAB lacIqZ M15 
Tn10, (Tetr 12.5 μg/ml)] 
Bullock et al., 1987 
DH10B 
F‘mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 lacX74 recA1 deoR 
araD139 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
Invitrogen 
Liu et al., 2003 
Top10 
F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 
recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 
nupG 
Invitrogen 
DH5 
F-φ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 end A1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 tonA 
(confers resistance to phage T1) 
Invitrogen 
DY380
mcrA ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 
deoR recA1 endA1 araD139 ∆(ara, leu)7697 galU gal490 
pgl∆8 rpsLnupG λ(cI857ind1) ∆{(cro-bioA)<>tetRA}(TetR) 
like DH10B,  Red+ 
Liu et al., 2003 
3.9 Transgenic mouse lines 
Mouse line Description Reference 
   
CerS2floxH212/213A 
 
The CerS2 coding region is flanked by loxP 
sites, after Cre-mediated recombination the 
CerS2H212/213A mutation is expressed under 
control of endogenous promoter. 
Bickert et al., 2018, 
Present study 
CerS2 H/A 
Derived from an ES cell clone in which the 
genomic locus of CERS 2 was mutated by the 
insertion of the CerS2 H212/213A vector. 
Expresses the CerS2 H212/213A mutation and 
eGFP reporter; leads to the exchange of two 
histidine residues to alanine residues at 
position 212 and 213 of the CerS2 peptide 
sequence. 
Bickert et al., 2018, 
Present study 
CerS2floxDel79-120 
The CerS2 coding region is flanked by loxP 
sites. After Cre-mediated recombination the 
mutated CerS2 del79-120 protein is expressed, 
which lacks 42 amino acid residues (aa79-120) 
within the peptide sequence. 
Bickert et al., 2018, 
Present study 
CerS2 Del 
Derived from an ES cell clone in which the 
genomic locus of CERS 2 was mutated by the 
insertion of the CerS2 del79-120 vector. 
Expressed a homeodomain-truncated CerS2 
protein (aa79-120) and eGFP repoter; 
controlled by endogenous cers2 promoter. 
Bickert et al., 2018, 
Present study 
Deleter-FLPe 
Ubiquitous expression of Flp-recombinase; 
controlled by human β-actin promoter. 
Rodriguez et al.,2000 
PGK-Cre 
Ubiquitous expression of Cre-recombinase; 
controlled by the PGK-promoter. 
Lallemand et al.,1998 
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3.10 DNA ladder and Protein marker 
 
3.11 Lipid Standards for TLC Analyses 
Lipid standards were ordered from Avanti polar lipids. 
Lipid standard Application 
  
NBD-Sphinganine (D18:1) TLC 
Cholesterol (Chol) TLC 
Cholesterol ester (CE) TLC 
Diacylglycerol (DAG) TLC 
Triacylglycerl (TAG) TLC 
Free fatty acid (FFA) (C16:O) TLC 
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4 Methods 
Unless explicitly mentioned otherwise, all standard laboratory methods used in this thesis were 
carried out and prepared as previously described (van Uelft, 2012; Ginkel, 2013; Bickert, 2016). 
4.1 Nucleic acid biochemistry 
4.1.1 Analytical plasmid preparation (Mini prep, quick & dirty) 
The analytical plasmid preparation method provides a fast and rapid technique for the 
purification and analysis of plasmid DNA from bacteria. 
2 ml LB-selection medium was inoculated with a single colony of transformed bacteria and 
cultured overnight (ON) (180 rpm, 37°C). 1.5 ml of the bacteria culture was harvested in a 
centrifugation step (1 min, 13,000 rpm). The supernatant was discarded and the bacteria pellet 
re-suspended in 100 µl alkaline lysis buffer I. Then, 200 µl of alkaline lysis buffer II was added, 
the mixture was inverted several times (lysis of membrane) and incubated for 2 min at RT. Next, 
150 µl of alkaline lysis buffer III was added, to precipitate proteins, cell debris and other cellular 
components. The mixture was inverted for several times, followed by a centrifugation step 
(10 min, 13.000 rpm, RT). The supernatant was subsequently transferred into a fresh tube 
containing 0.5 ml isopropyl alcohol (or 70 % ethanol). Samples were vigorously mixed and the 
plasmid-DNA precipitated in a centrifugation step (10 min, 13.000 rpm). The supernatant was 
removed, the pellet air-dried and resuspended in 100 µl ddH2O. 
4.1.2 Preparative plasmid isolation (Midi prep) 
The preparation of plasmid-DNA in pure and high amounts was performed according to the 
standard protocol of either the Jetstar Plasmid Purification Midi Kit (Genomed) or the 
PureLink™ HiPure Plasmid Midiprep Kit (Invitrogen). 50 ml of LB-selection medium was 
inoculated and cultured overnight (180 rpm, 37°C). The plasmid was resuspended in 100 µl to 
150 µl TE buffer and stored at -20°C. 
4.1.3 Endotoxin-free preparation (Maxi prep) 
Isolation of high, pure and endotoxin-free DNA amounts, suitable for the transfection of 
embryonic stem (ES) cells, was performed using the EndoFree MaxiKit (Qiagen). The purified 
plasmid DNA was resuspended in 200 µl sterile endotoxin-free TE buffer and stored at -20°C. 
4.1.4 Isolation of genomic DNA 
4.1.4.1 Isolation of genomic DNA from embryonic stem cells 
The verification of homologous recombination in embryonic stem (ES) cells after 
electroporation was done by PCR reaction (see chapter 4.5). To isolate genomic DNA, the half 
amount of a 48-well plate, confluent covered with HM1 cells, was transferred into a fresh PCR 
tube after trypsinization. Cells were centrifuged (5 min, 13.000 rpm) and the supernatant was 
discarded. Next, the cell pellet was resuspended in 40 µl PCR-lysis buffer (1x) supplemented 
with 0.4 µl Proteinase K and incubated at 55°C for 2 h. The cell lysate was gently mixed before 
setting up the PCR reaction. For Southern blot analysis, the genomic DNA extracted from a 
confluent T25 cell culture flask was used. The medium was removed and the cells washed twice 
with PBS-. Immediately, 1.5 ml ES-lysis buffer was added and the cells were incubated for 1 h 
on a seesaw (RT). The solid, jelly-like suspension was then transferred to a fresh 15 ml Falcon 
tube and incubated at 55°C ON. The genomic DNA isolation was performed by 
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phenol/chloroform extraction. After adding 2 ml Roti® -Phenol/Chloroform the suspension 
was thoroughly mixed and centrifuged (15 min, 6.000 rpm, RT) resulting in two phases. The 
lower organic phase was left intact and the upper aqueous phase was transferred to a fresh 
tube containing 3 ml ice-cold isopropyl alcohol. The suspension was inverted several times 
until the DNA precipitates. The visible genomic DNA clot was picked with a sterile tip, 
transferred to a fresh tube containing 500 µl 70 % ethanol and precipitated by centrifuged 
(5 min, 6.000 rpm). Next, the DNA pellet was washed again with 70 % ethanol and then air-
dried. Finally, the genomic DNA was resuspended in 200 µl TE buffer and incubated at 55°C 
for at least ON.  
4.1.4.2  Isolation of genomic DNA from tail tips and ear clip biopsies 
The genotype of transgenic mice used in the experiments was determined by PCR on genomic 
DNA level (chapter 3.2). To isolate genomic DNA, 400 µl Laird buffer supplemented with 4 µl 
Proteinase K was added to the tail tips or ear clip biopsies. The tissue lysis was performed at 
55°C ON. After a centrifugation step (13.000 rpm, 10 min, RT), the supernatant was transferred 
to a fresh reaction tube containing 0.5 ml isopropyl alcohol. The suspension was vigorously 
mixed and the DNA precipitated by centrifugation (13.000 rpm, 10 min, 4°C). Furthermore, the 
supernatant was removed and the DNA pellet washed with 0.5 ml of 70 % ethanol (13.000 rpm, 
5 min). Next, the supernatant was discarded, the DNA pellet air-dried and resuspended in 
100 µl ddH2O. Finally, 1 to 2 µl of this DNA solution were used for further PCR analyses. 
4.1.5 Photometric estimation of DNA/RNA concentration 
Quantification of nucleic acid (DNA or RNA) concentration was performed with the 
NanoDrop2000 from Peqlab. Based on the absorption maximum of DNA or RNA at 260 nm 
the device not only displays the amount of nucleic acid in comparison to a blank control, it 
also determines the purity of the sample by the ratio of 260 nm/ 280 nm. 
4.1.6 Sequence validation 
Validation of correct base pair composition of plasmids, vector fragments and PCR products 
was performed in a sequencing reaction (GATC Biotech). 
4.2 Molecular cloning 
4.2.1 Restriction digestion, dephosphorylation and ligation 
Restriction digestion - The digestion of template DNA (vector, PCR product) was performed 
with type II restriction endonucleases. The cleavage occurs at or near specific recognition sites, 
which results in the generation of blunt or sticky ends (cohesive ends) at the cutting sites. A 
standard protocol has a reaction volume of 20 µl containing 1-2 µg DNA, 2 U of the restriction 
endonuclease and was incubated at the corresponding temperature (most often 37°C) for 1 to 
2 h. Depending on the enzymes that were used, single or double digestions reactions were 
also performed. 
Dephosphorylation - Next, dephosphorylation of the vector backbone with alkaline 
phosphatase (Roche) was performed to prevent self-ligation events. Usually, 1 µg vector 
backbone was incubated with 1 µl alkaline phosphatase and 1 µl RAPiD buffer (10 x) in a final 
volume of 10 µl, for 10 min at 37°C. For inactivation of the enzyme, the reaction mixture was 
incubated at 72°C for 2 min. 
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Ligation - Ligation of DNA fragments (vector and insert) for the generation of new 
recombinant DNA sequences was performed with the T4-DNA-ligase (NEB). Usually, the ratio 
between vector and insert was 1:7 that was incubated with 1 µl T4-DNA-ligase, 2 µl T4-DNA-
ligase buffer in a final volume of 20 µl. The ligation was incubated at 18°C ON. 
4.2.2 Generation of competent cells, transformation and “Recombineering” 
The transformation describes a method that allows the uptake of extra-chromosomal DNA by 
prokaryotes. The membranes of those cells have been chemically modified to achieve the 
artificial competence. Usually there are two main methods for the generation of competent 
cells. First, it can be achieved through the application of calcium chloride and second through 
electroporation. 
Recombineering - Recombineering displays a method that allows the partial exchange/ 
homologous recombination of/between bacterial DNA (plasmid, BAC) and an introduced 
linear dsDNA containing two short homology arms (Liu et al. 2003, Zhang et al., 1998). Based 
on this technique, the RecET system (plasmid) from the Rac pro-phage (GeneBridges) is 
needed which promotes the homologous recombination in electro competent cells. 
4.2.2.1 Generation of CaCl2 competent cells 
The generation of chemically competent cells starts with the inoculation of 3 ml LB0 medium 
with a single colony of the desired E.coli strain at 37°C, ON (225 rpm). Next, 0.5 ml of the pre-
culture was used to inoculate another 50 ml LB0 medium. The culture was incubated again at 
37°C in a shaker-incubator at 225 rpm and the OD600 determined every 30 to 60 minutes. 
When the culture reaches a value of 0.4 to 0.6 the culture flask was cooled on ice and the 
bacteria were harvested (10 min, 3.000 rpm, 4°C). The supernatant was carefully discarded, the 
cell pellet resuspended in 20 ml cold 0.1 M CaCl2 and left on ice for at least 20 min. After 
another centrifugation step (10 min, 3.000 rpm, 4°C), the supernatant was discarded and the 
cell pellet carefully resuspended in 3 ml 0.1 M CaCl2 The bacteria suspension was incubated on 
ice for at least one hour and then supplemented with glycerol (20 % end concentration). 
Finally, aliquots of 50 µl volume were prepared and snap frozen in liquid nitrogen for long-
term storage (-80°C). 
Transformation - The transformation represents the uptake of newly generated plasmids into 
bacteria. Chemically-competent E.coli (50 µl) were thawed on ice and gently mixed with the 
ligation reaction. The mixture was incubated on ice for another 20 min before the heat shock 
was applied (1 min, 42°C). Afterwards, 250 µl LB0 medium was added and the cells incubated 
in a shacking heat block at 37°C for 1 h. Finally, bacteria were grown on LB agar plates 
supplemented with appropriate antibiotic at 37°C ON. The selection of positive clones was 
performed with an analytical plasmid preparation (see chapter 3.1.1) followed by enzymatic 
digestion of 3 µl vector DNA and analysis of resulting fragments in an agarose gel. 
4.2.2.2 Generation of electro-competent cells (BAC) 
The generation of electro-competent cells starts with the inoculation of 3 ml LBChl medium with 
a single colony of the desired E.coli strain at 37°C, ON (225 rpm). Next, 2 ml of the pre-culture 
were used to inoculate another 100 ml LBChl medium. The culture was further incubated at 37°C 
in a shaker-incubator at 225 rpm. Finally, with an OD600 value of 0.7 the culture was cooled on 
ice and the cells were harvested (2 x 50 ml, 10 min, 2.900 xg, 4°C). The supernatant was 
carefully discarded and the cell pellet resuspended in 40 ml glycerol solution (10 %). The cells 
were again centrifuged (10 min, 4.000 xg, 4°C), the supernatant removed and the cells 
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resuspended in 40 ml glycerol solution (10 %). This step was repeated and the cell suspension 
centrifuged at 5.800 xg, 10 min at 4°C. Cells were resuspended in 40 ml glycerol solution (10 %). 
Next, the cells were harvested for 10 min at 7.300 xg, 4°C. The supernatants were very carefully 
removed and the two cell pellets recombined and resuspended in 40 ml glycerol (10 %). After 
a final centrifugation step (10 min, 9.000 xg, 4°C) the supernatant was fully removed and the 
cells resuspended in 400 µl glycerol (50 %). Aliquots containing 26 µl of BACs were prepared 
and snap frozen in liquid-nitrogen for long term storage (-80°C). 
4.2.2.3 Electroporation 
The generation of CerS2-BAC- containing E.coli with the pRedET plasmid was carried out 
according to the manufacturer’s instructions (Gene Bridges). Briefly, one aliquot of cells (BAC) 
were thawed on ice and 1 µl pRedET plasmid added. Next, the suspension was transferred to 
a pre-cooled electroporation cuvette and the electroporation was performed (1350 V, 10 µF, 
5 ms). Finally, the cells were resuspended in 1 ml LB0 medium and incubated for 1 h at 30°C. 
Cells were grown on LB agar plates supplemented with Tetracycline (30 µg/ml) 
/Chloramphenicol (15 µg/ml) at 30°C overnight. 
4.2.2.4 Recombineering procedure 
The recombineering procedure was also performed according to the manufacturer’s 
instructions (Gene Bridges). An ON culture of E.coli containing the CerS2-BAC and pRedET 
plasmid was prepared in LB medium supplemented with Tet/Chl (30°C). The next day, a fresh 
1.4 ml culture was inoculated with 30 µl ON culture and incubated for 2 h at 30°C. Next, 50 µl 
10 % L-arabinose were added and the culture incubated for 45 min at 37°C, which leads to the 
expression of the inducible pRedET plasmid. Furthermore, cells were prepared for 
electroporation procedure (3 x 30 s, 11.000 rpm, 4°C). After each centrifugation step, the 
supernatant was removed and the cell pellet resuspended in 1 ml ddH2O, except for the last 
step. Here the supernatant was removed; the cells resuspended in the remaining water and 
transferred to a pre-cooled electroporation cuvette. Additionally, 100 µg or 200 µg of the 
linearized vector was added and the electroporation performed (1350 V, 5 ms). Afterwards, 
1 ml LB0 medium was added and the cells incubated for 50 min at 37°C. Cells were plated on 
LB agar plates containing Tetracycline (10 µg/ml) and Kanamycin (25 µg/ml) and grown at 30°C 
ON. 
4.2.2.5 Preparation of glycerol stocks 
Glycerol stocks were prepared for long-term storage of the desired plasmid DNA. Therefore, 
850 µl of an ON culture were mixed with 150 µl of sterile 100 % (v/v) glycerol solution in a safe-
lock cap. The glycerol stock was stored at -80°C until usage. Prevent the cap from freezing and 
thaw cycles. For recovery, the cap was opened under sterile conditions and a sterile pipette tip 
was used to scrape some of the frozen material from the top of the glycerol stock. The tip in 
turn was directly used to inoculate 2 ml of LB medium supplemented with antibiotic. The 
culture was grown ON at 37°C. 
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4.3 Eukaryotic cell culture 
4.3.1 Cell counting and calculations (Neubauer chamber) 
The determination of correct cell number in suspension was performed using a 
hemocytometer (Neubauer chamber). The device is a microscopic slide with a grid and an 
appertaining cover slip, which in combination form a space of defined volume. The resulting 
space can be filled with the cell suspension of interest. Furthermore, the grid (3x3 mm) consists 
of four large squares (each 1x1 mm) and each large one consists of 16 smaller squares. Usually, 
four large squares were counted to determine the cell concentration per ml (see formula). 
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
= (∑ 𝑥𝑖
4
𝑖=1
 ) ÷ 4 × 104  ×  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Equation 1: The cell concentration per ml is the average number of counted cells of four squares multiplied by 
104 multiplied by the dilution factor. (104 describes the total volume of one square, 1 mm x 1 mm x 0.1 mm; 
0.1 mm3 = 1 ml). 
For cell culture and immunological experiments, the total cell numbers in the analysed 
compartments were obtained by counting. The numbers of lymphocyte populations in thymus, 
spleen and blood were obtained by flow cytometric analyses (see Chapter 4.11) and calculated 
based on their relative frequencies. 
4.3.2 HEK cell culture 
HEK293T cells were maintained in a humidified incubator at 37°C with 5 % CO2. The cells were 
cultured in DMEM supplemented with 10 % fetal bovine serum (FBS). To maintain the viability 
of the cell line, medium was replaced daily or every second day and the cells sub-cultured 
once confluent (90 %). Therefore, the medium was removed, the cells washed with 1 x PBS- 
and 1/10 of the culture volume of trypsin/EDTA solution was added. The cell culture dish was 
gently rotated and incubated for 2-3 min at 37°C. Additionally, it was necessary to tap the 
plate at the bottom to detach remaining cells. Subsequently, preheated medium was added 
and the cell suspension drawn in a pipette and rinsed two to four times to dissociate cell 
aggregates. Finally, the appropriate volume of cell suspension was transferred to a fresh cell 
culture dish and filled up to final volume with preheated medium. 
4.3.3 MEF cell culture 
Immortalized mouse embryonic fibroblasts (MEFs) derived from CerS2gt/gt mice were already 
generated (M van Uelft, Master thesis). Cells were maintained in a humidified incubator at 37°C 
with 5 % CO2. The cells were cultured in Glasgow-MEM supplemented with 10 % FBS and 1 % 
P/S on untreated cell culture dishes. To maintain their viability, cells were split at a confluence 
of 80 to 90 % and the medium replaced daily or every second day. 
4.3.4 Transient transfection with Metafectene (S10 cell culture dish) 
The transient transfection of almost confluent S10 cell culture dishes was prepared with the 
Metafectene Kit according to the manufacturer’s instructions (Biontex). Metafectene, a cationic 
lipid transfection agent covers the DNA and facilitates its internalization. The transfection 
mixture consists of two different solutions. Solution A contains 15.7 µg DNA diluted in 700 µl 
1 x PBS-. Component B contains 63.16 µl Metafectene reagent in 700 µl 1 x PBS-. After an 
incubation step of 5 min at RT, solution A was gently added to the transfection reagent and 
incubated for 15 min at RT. During the incubation step, cells were prepared. In detail, the 
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medium was removed and the cells washed with 1 x PBS-. Next, 11.7 ml DMEM (w/o FBS, w/o 
Pen/Strep) was put on top of the cells and the transfection solution added drop-wise. The 
transfection was carried out for 5 h at 37°C. Finally, the medium was replaced by complete 
DMEM and cells were incubated for 24 h in a humidified incubator at 37°C, 5 % CO2. 
4.3.5 HM1 embryonic stem cell culture (mouse) 
HM1 embryonic stem cells had been isolated from agouti-coloured, male mice blastocysts 
from the mouse strain Sv129P2/OlaHsd (Magin et al., 1992). They grow on gelatine-coated 
culture dishes in the presence of soluble LIF, MEK 1 and GSK3 (2i WT medium). To maintain 
viability of ES cells, 2i-WT medium was replaced daily or every second day. 
4.3.5.1 Gelatine coating of cell culture ware 
Cell culture ware (plates, flasks) were coated with 0.1% gelatine to allow a better adhesion of 
HM1 ES cells. The appropriate volume of 0.1% gelatine working solution was used to prepare 
the cell culture ware. Gelatine solution was incubated for at least 15 min at 37 °C. Afterwards, 
the gelatine solution was removed and the cell culture ware ready for the cultivation of HM1 
ES cells. 
4.3.5.2 Passaging of HM1 ES cells 
After complete removal of the medium, the cells were washed with an appropriate amount of 
1 x PBS-. Next, pre-warmed trypsin/EDTA solution was added (1/7 vol.), the culture flask gently 
rocked to ensure entire coverage of the cells and incubated for 5 min at 37°C. The culture flask 
or dish was then tapped at the bottom to detach remaining cells. The reaction was stopped 
after addition of 2 volumes of 2i-ES medium. The cells were transferred to a fresh falcon tube 
and centrifuged for 5 min, 800 rpm, RT. Finally, the medium was removed; the cells 
resuspended in 2i-ES medium by pipetting up and down to obtain single cell suspension. 
According to the dilution factor, the appropriate volume of cells was transferred to a new 
gelatine- coated- culture dish containing pre-warmed 2i-ES medium. 
4.3.5.3 Cryo conservation 
For future experiments (blastocyst injection, karyotyping etc.) and as a general back up, it was 
necessary to store some aliquots of the cell lines in use. The cryopreserved cells were kept in 
a combination of the cryoprotective agent DMSO and complete medium. 
Initially, the medium was removed, cells were washed in 1 x PBS- and then trypsinized. The cell 
suspension was transferred to a fresh falcon tube and centrifuged for 5 min, at 800 rpm, RT. 
Next, the supernatant was removed and the cells resuspended in the appropriate amount of 
freezing medium. Finally, 1 ml aliquots of the cell suspension were generated in cryogenic 
storage vials and placed in a freezing container, which allows a gradual freezing of the cells 
(1°C/min). Aliquots were incubated for two days at -80°C and then transferred to a liquid 
nitrogen freezer for long-term storage. 
4.3.5.4 Electroporation 
The stable transfection of HM1 ES cells was performed by electroporation. The gene targeting 
vector (200-350 µg) was cleaned up with the Qiagen-Endo free Maxi-prep kit, linearized by 
restriction digestion and resuspended in endotoxin-free TE buffer (80 µl). Next, the cells of a 
confluent culture dish (T75) were harvested; following centrifugation resuspended in HBS-
buffer and the cell concentration was determined. Finally, 0.8 ml HBS-buffer containing 
3 x 107cells and the linearized targeting vector were transferred into a fresh pre-cooled 
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electroporation cuvette and the electric pulse applied (0.8 kV, 3 µF; time const. 0.1, Biorad 
GenePulser). Afterwards, the cells were incubated for 10 min at RT and resuspended in 20 ml 
complete 2i-ES growth medium and seeded in different dilutions. 
4.3.5.5 Selection of stable integration and homologous recombination 
The antibiotic selection of HM1 cells having the neomycin resistance gene stable integrated 
was performed 24 h after electroporation by the application of 2i-ES medium supplemented 
with G-418 (350 µg/ml). The medium was changed every second day and the selection period 
finished ten days after application of G-418 for the first time. Ideal cell clones were picked 
under the microscope with a 200 µl pipette and each dissociated in 96-well flat bottom dish, 
which was coated with gelatine before. Once the dish was confluent (80 %), the culture was 
split in half. Half of the culture was used for genotyping analysis (3’HR PCR) and the other half 
was transferred into a fresh dish (48-well flat bottom dish). Positive clones were further 
expanded to 24-well (5’HR PCR analysis)  12-well  6-well flat bottom dish. Each positive 
clone from a 6-well plate was again split in half. Each half was sub cultured on a T25 cell culture 
flask. The cells of one confluent T25 flask were cryopreserved (3 x 1ml) and the other half 
further expanded on three T25 culture flasks for karyotyping analysis, genomic DNA 
preparation and cryopreserved for blastocyst injections. 
4.3.5.6 Karyotyping 
Karyotype analysis for each positive ES cell clone was prepared to check for chromosomal 
anomalies, such as aneuploidy. The application of colcemid results in the arrest of cells in the 
metaphase of the cell division cycle, where the chromosomes are most condensed. 
Therefore, the cells were fed 2 h before with fresh medium which was replaced by 2 ml 2i-ES 
medium containing 20 µl colcemid (Demecolcine (10 µg/ml), Sigma) and incubated for 1 h at 
37°C. Thereafter, the cells were washed twice with pre-warmed 1 x PBS- and trypsinized and 
the reaction stopped by medium addition. The cell suspension was centrifuged (5 min, 
800 rpm) and the supernatant removed. Initially, 1 ml 0.56 % KCl solution was added dropwise 
and the pellet resuspended by flicking the tube. Afterwards, 3 ml KCl were additionally added 
and the suspension incubated for 10 min at RT. Cells were centrifuged (5 min, 800 rpm), the 
supernatant removed, then incubated with 2 ml methanol : acetic acid solution (3:1) for 5 min 
at RT. The procedure was repeated after centrifugation (5 min, 800 rpm). Finally, a minimum 
of three slides per clone were prepared and the cells dropped from at least 10 cm above the 
surface of the slide. Afterwards, the slides were stained with Giemsa solution and fixed in 
Entellan Neu (Merck). Counting of chromosomes of about 20 cells under a microscope ensures 
selection of clones with mostly 40 chromosomes, needed for blastocyst injection. 
4.4 Generation, handling and analysis of transgenic mice 
4.4.1 Generation of the CerS2Flox, CerS2H212A/H213A & CerS2Del79-120 vector 
The generation of both exchange vectors was performed with standard cloning techniques 
using enzymatic modifications. Plasmid DNA was cut with restriction endonucleases (NEB) and 
the backboned dephosphorylated with alkali phosphatase (RAP, Roche), followed by T4 DNA 
ligase mediated ligation. Thereafter, transformation into chemically competent bacteria, 
growth and clone selection was performed as described (see Chapter 4.2).  
Methods 
36 
4.4.1.1 Generation of the conditional CerS2H212A/H213A vector 
1st step: (pCR2.1 TOPO:5’SOE) 
The first step depicts the generation of the the 5’ homology region (HR) entry side. Initially, 
two DNA fragments (379bp/570bp) flanking the 5’HR were generated in a PCR reaction on the 
basis of the BAC vector (frt_SalI/AsiSi_for and frt_AatII_rev; frt_AatII_for and frt_Sal_rev). In a 
following overlap extension PCR reaction, with both PCR fragments as templates and the 
application of the external forward and reverse primer, generation of the full-length 5’SOE 
fragment (924bp) was achieved, which was directly cloned into the pCR2.1 TOPO vector 
(Invitrogen). The external forward and reverse primer introduce an additional SalI restriction 
side which was needed for further cloning steps. Additionally, the introduction of an AatII 
restriction side within the DNA fragment was necessary for the insertion of the 5’ HR region in 
a recombineering step. Third, we additionally inserted an AsiSI restriction at the 5’ end, 
downstream of SalI as a backup. 
2ndstep: (dual loxP/frt-Neo:5’SOE) 
Next, after linearization of the dual loxP/frt-Neo vector with SalI, the 5’SOE fragment was 
inserted upstream of the neomycin resistance cassette. 
3rd step: Truncation of Ampicillin resistance gene 
Afterwards, the ampicillin resistance gene was truncated via ScaI/PsiI double digestion. Both 
enzymes create blunt ends, which were ligated in a T4-DNA-ligase mediated step that results 
in the circularization of the vector. 
4th step: (5’SOE-frt-Neo_Amp:E3-11 genomic sequence) 
In the next step, the genomic sequence of exon three to eleven (E3-11 wt) was amplified by 
PCR (E3-11 wt MfeI for/ E3-11 wt MfeI rev) on the BAC-DNA and directly inserted into the TOPO 
Blunt vector (Invitrogen). The primer inserted on the 5’ and 3’ end of the fragment an MfeI 
restriction site. E3-11wt was subcloned by compatible end ligation (MfeI, EcoRI) between the 
loxP (locus of X over P1) and frt (flippase recognition target) site upstream of the neomycin 
cassette. 
5th step: (E3-11wt-frt-Neo_Amp:E3-11 H/A) 
Next, a second fragment containing the genomic region of exon 3 until the stop codon was 
amplified via PCR (E3-11 PsPOMI_for/ E3-11 BstEII/PspOMI_rev) and subcloned into the TOPO 
Blunt vector. The generation of the point mutations, H212A and H213A, create an additional 
PvuII restriction site and were introduced by mutagenesis PCR (E3-11 H/A for and E3-11 H/A 
rev, Figure A2). The resulting fragment was inserted between the loxP and frt site downstream 
of the Neo cassette by PspOMI/NotI compatible end cloning. 
6th step: Recombineering of the 5’ homology region (5’HR-Neo:CerS2) 
After linearization of the frt_Neo_D Amp:CerS2-vector with AatII, it served as a retrieval vector 
in a recombineering- mediated gap repair step using electrocompetent, CerS2-BAC/ pRedET 
containing, E. coli. The recombination procedure extended the 5’ HR to its full length. 
7th step: (pDTA:3’HR) 
Briefly, the 3’ homologous region (3’HR) needed for homologous recombination in ES cells 
was amplified via PCR (3’HR_XhoI_for/ 3’HR_ApaI_rev) from the BAC. The resulting fragment 
was subcloned into pDTA (diphtheria toxin A) containing vector upon double restriction 
digestion with XhoI/ApaI.  
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8th step: (pBSK-IRES-eGFP:3’HR-pDTA) 
Next, the 3’HR-pDTA fragment was subcloned by XhoI/PsiI restriction into the pBSK vector, 
downstream of the IRES-eGFP cassette (IRES- internal ribosomal entry side, eGFP- enhanced 
green fluorescent protein). 
9th step: (IRES-eGFP/3’HR-pDTA:frt-SOE) 
In this step, we generated the entry site for the 5’HR-Neo:CerS2 vector which was generated 
during the first six steps of the cloning procedure. Initially, two DNA fragments homologous 
to the 5’ and 3’ region of the 5’HR-Neo:CerS2 vector were amplified by PCR (IRES_SapI/AsiSI 
for;IRES_NdeI rev and IRES_NdeI for;IRES_BstEII/ClaI rev). In the next step, both DNA fragments 
serve as templates for an overlap extension PCR to generate the full-length frt-SOE fragment 
needed for the final ligation step. The external forward/ reverse primer (IRES_SapI/AsiSI for 
and IRES_BstEII/ClaI rev) used in the second PCR reaction additionally inserted a SapI/AsiSI 
restriction site upstream and a BstEII/ClaI restriction site downstream of the fragment. Finally, 
the frt-SOE fragment was inserted upstream of the IRES-eGFP-3’HR-pDTA cassette by 
SapI/ClaI restriction. Additionally, the insertion leads to the desired deletion of a NotI 
restriction site. 
10th step: (CerS2H212/213A vector) 
The final step was initially designed as a recombineering step which should combine both 
generated plasmids. Briefly, after generation of electro-competent E3-11wt-frt-Neo_Amp: E3-
11 H/A/pRedET containing cells, the recombineering step with NdeI linearized IRES-eGFP/3’HR-
pDTA:frt-SOE did not results in the generation of any positive clone. Therefore we changed 
our strategy and performed a normal T4-DNA-ligase mediated ligation. After restriction of 
both plasmids with AsiSI/BstEII, we subcloned the 5’HR-Neo:CerS2 fragment upstream of the 
IRES cassette which results in the generation of the final CerS2H212A/2H13A gene targeting 
vector. 
4.4.2 Generation of the conditional CerS2Del 79-120 vector 
The generation of the conditional gene-targeting vector was completed on the basis of the 
CerS2H212A/H213A targeting vector and cers2 DNA fragments amplified from the BAC clone. 
Finally, the final vector carries a deletion of amino acid 79 to amino acid 120 within the 
homeodomain of the CerS2 protein. With this approach we attempted to generate a truncated 
CerS2 protein, which should be not affected in its catalytic activity. 
1st step: (TOPO blunt: E3-11, aa79-120) 
The first step includes the amplification of exon 3 to 11 in a PCR reaction in the basis of the 
BAC vector and directly inserted into the TOPO Blunt vector. Afterwards, the coding sequence 
for amino acid residues 79 to 120 was deleted in a two-step mutagenesis PCR. 
2nd step: (dual loxP/frt-Neo: E3-11, aa79-120) 
In this step, the truncated coding region from E3-11, aa79-120 was cloned into the dual 
loxP/frt- Neo vector by compatible end cloning with NotI/PspOMI. 
3rd step: (Cers2Del79-120 vector) 
Next, the mutated sequence was subcloned by BsiWI/BstEII restriction into the conditional 
CerS2H212A/H213A gene targeting vector. The insertion of the mutated E3-11,aa79-120 fragment 
leads to the replacement of the E3-11 H/A coding region. The CerS2Del79-120 gene-targeting 
vector represents the final vector.  
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4.4.3 Generation and breeding of mice 
A detailed description for the generation of transgenic mice based on ES cells and blastocyst 
injection was published some years ago by Nagy et al., 2003. The injection of correct 
recombined ES cell clones into C57BL/6N blastocysts, as well as the implantation of these 
manipulated cells in pseudo-pregnant mice was done by W. Krzyzak, LIMES GRC. The 
identification of genetically modified mice after injection through homologous recombination 
is based on the fur colour marker (agouti). Sv129/OlaHsd ES cells are characterized by the 
inhibition of melanine production in the hair follicle, which in turn results in the dominant 
expression of agouti-colored fur. Therefore, only high-extent fur coloured chimeras (male) 
were bred with C57BL/6N female mice to obtain heterozygous transgenic mice. Those mice in 
turn where either crossed with ubiquitious Flp-recombinase expressing mice (Rodriguez et al., 
2000) resulting in the deletion of the neomycin cDNA or in case of the conditional deletion, 
heterozygous males (CerS2+/floxH212/213A and CerS2+/flox-del79-120) were mated to female PGK-Cre 
(Lallemand et al., 1998) recombinase expressing mice for ubiquitious deletion of the wild type 
DNA sequence via the Cre/loxP system. Afterwards, heterozygous CerS2+/H212/213A:PGK-Cre 
and CerS2+/del79-120:PGK-Cre mice were bred with C57BL/6N mice to outcross PGK-Cre from 
the genome. Thereafter, interbreeding of heterozygous mice from each mouse line resulted in 
homozygous transgenic CerS2H212A/H213A or CerS2Del79-120 mice. CerS2+/flox-delNeo (HA or 
del79-120):Flp mice were backcrossed with C57BL/6N mice to increase the C57BL/6 
background and to delete the Flp-recombinase. Genotyping of mice for correct homologous 
recombination was verified by PCR analyses (see chapter 4.5). 
4.4.4 Mouse handling 
All mice were kept under standard housing conditions with a 12 h/12 h dark-light cycle in a 
specific pathogen free environment (SPF) and with water and food ad libitum. The cages were 
renewed once a week. If not mentioned otherwise, experimental animals were killed by cervical 
dislocation. Tissues were dissected and directly used for further analyses or snap-frozen and 
stored at -80°C for future experiments. Additionally, if not mentioned otherwise 6 to 10-week 
old males with a genetic background of 75 % C57BL/6N were used in all experiments. 
4.4.4.1 Measurement of food intake 
The following experiments were performed with littermates from heterozygous breedings (WT 
and +/H/A). For analysis, male as well as female mice were used and the experiment started 
at the age of eight weeks. All animals were kept in IVCs (individually ventilated cages), with 
stainless steel grid, wood shavings and nesting material. The mice were fed a normal chow 
(LASQCdiet®Rod16, LASvendi) containing 16.9 % protein, 4.3 % fat and 4.3 % fibres. Sterile 
water from one drinking tube was also available ad libitum. 
First, animals were separated at an age of eight weeks and acclimated to individual cages for 
5 days. Afterwards, food and water intake was measured every day for a period of 14 days (to 
the nearest of 0.1 g). Food spillage was under detection level <1g/d and not taken into account. 
The food was renewed every second day. The body weight was measured once a week and 
started three weeks prior the beginning of the test. 
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4.5 Polymerase chain reaction (PCR) 
Analyses of homologous recombination in embryonic stem (ES) cell clones and genotyping of 
transgenic mice was performed by polymerase chain reaction (PCR). It describes an in vitro 
method for the amplification of a defined and short nucleotide sequence; in which double-
stranded DNA, harbouring the region of interest, serves as the template for the reaction (Mullis 
and Faloona, 1987). The programs and reaction mixture used for each PCR are listed below as 
well as the expected fragment sizes for the respective alleles. The following concentrations of 
ingredients were applied (unless indicated otherwise): dNTPs (10 mM each), MgCl2 (25 mM), 
primer molecules (100 pmol/µl), Taq-Polymerase (5 U/µl). 
 
4.5.1.1 PCR analysis for verification of 3’ homologous recombination in ES cell clones 
Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 2 min 1 
MgCl2 3 µl  95°C 30 s 
34 dNTPs 0.5 µl  65°C 60 s 
2 ctrl for (3’HR for) 0.1 µl  72°C 2:10 min 
3 ctrl rev (3’HR rev) 0.1 µl  72°C 10 min 1 
H20 15.1 µl     
Go-Taq polymerase 0.2 µl     
DNA 1 µl     
Fragment size: CerS2 wild type allele: --- bp, CerS2H/A or CerS2 Del allele: 1.9 kb. 
 
4.5.1.2 PCR analysis for verification of 5’loxP homologous recombination in ES cell 
clones 
Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 5 min 1 
MgCl2 2 µl  95°C 60 s 
34 dNTPs 1 µl  58°C 30 s 
HA loxP for_2 (LoxP for) 0.2 µl  72°C 90 s 
HA loxP rev_1 (LoxP rev) 0.2 µl  72°C 10 min 1 
H20 15.25     
Go-Taq polymerase 0.25 µl     
DNA 1 µl     
Fragment size: CerS2 wild type allele: 402 bp; Flox allele: 484 bp; H/A or Del allele: 519 kb. 
 
4.5.1.3 5’ Long Amp PCR – Analysis of 5’ external homologous recombination 
Component Volume  Temperature Time Cycles 
Long Amp buffer (5x) 5 μl  94°C 1 min 1 
dNTPs 0.75 µl  94°C 30 s 
30 5’ ctrl for 0.1 µl  61°C 30 s 
5’ ctrl rev 0.1 µl  68°C 3min 20 s 
DMSO 0.75 µl  68°C 10 min 1 
H20 15.6     
LongAmp polymerase 0.2 µl     
DNA 1 µl     
Fragment size: CerS2 HA/ or Del allele: 5.6 kb. 
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4.5.1.4 Verification of the CerS2 H212/213A point mutation (Nested PCR) 
A) Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 2 min 1 
MgCl2 2 µl  95°C 30 s 
34 dNTPs 1 µl  59°C 30 s 
PvuII_alt_for 0.2 µl  72°C 90 s 
HA_Cre_rev 0.2 µl  72°C 5 min 1 
H20 15.35     
Go-Taq polymerase 0.25 µl     
DNA 1 µl     
Fragment size: CerS2 wild type allele: --- bp, CerS2H/A allele: 1200 bp. 
 
B) Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 2 min 1 
MgCl2 2 µl  95°C 30 s 
34 dNTPs 1 µl  58°C 30 s 
PvuII_alt_for 0.2 µl  72°C 30 s 
PvuII_alt_rev 0.2 µl  72°C 5 min 1 
H20 15.35     
Go-Taq polymerase 0.25 µl     
DNA 1 µl     
Fragment size: CerS2 wild type allele: 343 bp, CerS2H/A allele: 343 bp (after PvuII digestion 
222 bp and 121 bp). 
 
4.5.1.5 Verification of the CerS2 D79-120 allele 
Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 2 min 1 
MgCl2 1 µl  95°C 30 s 
30 dNTPs 0.5 µl  60°C 30 s 
del79-120_for 0.5 µl  72°C 1 min 
del79-120_rev 0.5 µl  72°C 5 min 1 
H20 15.3     
Go-Taq polymerase 0.2 µl     
DNA 2 µl     
Fragment size: WT allele: 887 bp; Del allele: 762 bp. 
 
4.5.1.6 Flp genotyping PCR 
Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 5 min 1 
MgCl2 2 µl  95°C 60 s 
34 dNTPs 1 µl  58°C 60 s 
USP_Flp 0.2 µl  72°C 90 s 
DSP_Flp 0.2 µl  72°C 10 min 1 
H20 15.25     
Go-Taq polymerase 0.25 µl     
DNA 1 µl     
Flp recombinase allele: 1200 bp fragment. 
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4.5.1.7 PGK-Cre PCR 
Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  94°C 5 min 1 
MgCl2 2 µl  94°C 30 s 
35 dNTPs 0.2 µl  60°C 50 s 
Pgk1_for 0.2 µl  72°C 90 s 
Int-Cre_rev 0.2 µl  72°C 10 min 1 
H20 16.3 µl     
.Go-Taq polymerase 0.1 µl     
 DNA 1 µl     
PGK-Cre recombinase allele: 500 bp fragment. 
 
4.5.1.8 NNT genotyping PCR 
When breeding mice with C57BL/6J background we were aware to check for the mutation of 
the NNT (nicotinamide nucleotide transhydrogenase) gene to avoid mitochondrial redox 
abnormalities that could interfere with our analyses of the lipid metabolism. 
Component Volume  Temperature Time Cycles 
Go-Taq buffer (5x) 5 μl  95°C 5 min 1 
MgCl2 3 µl  95°C 60 s 
30 dNTPs 0.5 µl  58°C 60 s 
WT for 0.1 µl  72°C 60 s 
Mut for 0.1 µl  72°C 5 min 1 
Com rev 0.1 µl     
H20 14 µl     
Go-Taq polymerase 0.2 µl     
DNA 1 µl     
Fragment size: wild type allele: 579 bp, NNT allele: 793 bp. 
 
4.5.1.9 Mutagenesis PCR 
The generation of the designed deletion or point mutation within the homeodomain/ lag1 
domain of the cers2 gene, was done with the PCR-based DpnI-mediated-mutagenesis 
method. The insertion of the mutation is performed by the presence of two complementary 
long-chain oligonucleotides that carry the desired mutation. After amplification of the whole 
vector in a standard PCR reaction the template is cleaved by DpnI. Next, verification of 
amplification was done by analysis of 10 µl of the PCR reaction in an agarose gel. The remaining 
40 µl were incubated with DpnI to digest remaining plasmid (1 h, 37°C) and then directly 
transformed into competent E.coli cells. 
 
Component Volume  Temperature Time Cycles 
GC buffer (5x) 10 μl  98°C 30 s 1 
DMSO 1.5 µl  98°C 10 s 
19 dNTPs 1.0 µl  55°C 30 s 
Primer A 0.12 µl  72°C 30 s/kb 
Primer B 0.12 µl  72°C 15 min 1 
H20 ad 50 µl     
Phusion polymerase 0.5 µl     
DNA template plasmid 15 ng     
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4.6 Radioactive Southern blot hybridisation 
For Southern blot analyses, genomic DNA from wild type, CerS2H212A/H213A- and CerS2Del79-120-
ES- cell clones was extracted as described before (see chapter 3.1.4.1). Depending on the 
genotype, different digestions were performed following standard protocols. Verification of 
correct and single insertion of the corresponding exchange vector into the genomic locus of 
cers2 was carried out with two different internal probes in combination with internal/external 
restriction digestion. After electrophoretic separation on an agarose gel, the gel was incubated 
in depurination buffer at RT for 10 min. Next, the agarose gel was rinsed in ddH2O and 
incubated in denaturation buffer for 30 min at RT. The transfer of genomic DNA onto Hybond-
N+ membrane (Amersham Biosciences, UK) was performed overnight. The sample slots were 
marked and the membrane washed with 2 x SSC. Application of UV-light to the membrane 
results in fixation and cross-linking of the DNA. The internal probes (50 ng) were diluted in 
30 µl ddH2O. Next, 5 µl of random hexamer primer solution was added and incubated at 100°C 
for 5 min. Afterwards, 2 µl Klenow polymerase (1 U/ml), 10 µl labelling buffer (containing non-
radioactive dATP, dGTP and dTTP) as well as 2 µl -32P-dCTP (Hartmann Analytic) were added 
and incubated at 37°C for 45 min, which results in the generation of radioactively labelled 
probes. Hybridization of the probes with the membrane was performed in QuickHyb solution 
(Stratagene) at 68°C for 2 hours. To remove unbound-probes, the membrane was washed 
several times in decreasing amount of SSC buffer containing 0.1 % SDS at 68°C (2 x SSC down 
to 0.1 x SSC). Finally, an X-ray film was exposed to the membrane at -70°C overnight and 
analysed afterwards. 
4.7 DIG Southern blot 
The CerS2-BAC containing bacteria were analysed according to the manufacturer’s instruction 
of the DIG High Prime SB labelling Kit (Roche). Briefly, large scale plasmid purification was 
prepared following the protocol of the PureLink HiPure Plasmid Maxiprep Kit (Invitrogen). 
Next, 2 µg of BAC were digested with desired enzyme according to the protocol of NEB 
overnight at 37°C. The fragments were separated by agarose gel electrophoresis, transferred 
on PureLink HiPure Plasmid Maxiprep Kit onto Hybond.-N membrane and cross-linked. After 
hybridization probe, labelling and analysis of the corresponding DNA fragments was prepared 
following the DIG High Prime Kit. 
 
4.8 Protein Biochemistry 
4.8.1 Protein extraction 
4.8.1.1 Generation of cell culture lysates 
Cells, HEK cells and MEFs, were grown on S10 cell cultures dished to yield appropriate amounts 
for immunoblot analysis. Once confluent (80-100 %), the medium was removed and the cells 
washed with 1 x PBS-. Next, 500 µl 1 x PBS- was added, the cells scraped from the plate and 
centrifuged (2 min, 1.000 rpm, 4°C). The supernatant was removed, the cell pellet resuspended 
in 250 µl pre-cooled homogenisation buffer and passed 10 times through a 27 G needle. 
Subsequently, the cell lysate was centrifuged (10 min, 960 rpm, 4°C) and the supernatant 
transferred to a fresh reaction tube and stored at -80°C. Protein concentration was prepared 
following manufacturer’s instructions of the BCA assay kit (Sigma-Aldrich). 
  
Methods 
43 
4.8.1.2 Generation of tissue lysates 
Mouse tissue homogenates were generated using a Precellys homogenizer. Therefore, 1 ml/g 
wet weight of homogenisation buffer, supplemented with protease inhibitor cocktail 
(complete, PMSF, aprotinin and leupeptin), was added and the cells homogenized. Next, cell 
debris was removed in a centrifugation step (10 min, 13.000 g, 4°C) and the supernatant 
transferred to a fresh reaction tube. Storage of tissue homogenates was performed at -80°C 
and the protein concentration determined with the BCA assay kit (Sigma-Aldrich). 
4.8.2  Quantification of protein concentration 
The BCA method was used for the determination of the protein concentration of cell and tissue 
homogenates. All measurements were carried out in duplicates and all following steps 
prepared according to manufacturer´s instructions (BCA assay kit, Sigma-Aldrich). The OD550 
was determined and the amount of protein calculated as a function of the OD value (y-axis) 
and the corresponding concentration (x-axis) drawn in a graph. 
4.8.3 Immunoblot analysis 
4.8.3.1 SDS- PAGE and transfer of proteins 
Depending on the type of 
lysate (tissue, cells) 25 µg 
up to 50 µg of protein 
lysate were mixed with 2 x 
Urea buffer, filled up to a 
final volume of 20 µl with 
water and heated for 
10 min at 75°C. Next, the 
protein lysate was 
separated by SDS-PAGE in 
1 x SDS running buffer 
(stacking gel 20 mA/gel; separating gel 25 mA/gel). All applied gels were of the following 
composition as summarized in the table. Briefly, the stacking gel causes a concentration of the 
samples in front of the separating gel, whereas the separating gel leads to the separation of 
the proteins regarding their molecular mass. The transfer of proteins onto nitrocellulose 
membranes (Hybond-ECL, GE Healthcare) was performed with the wet transfer method in 
transfer buffer for 2 hours (150 mA, 4°C). Finally, the transfer was verified by Ponceau S staining. 
4.8.3.2 Immunoblot analysis via chemiluminescence (ECL) 
To avoid unspecific antibody-binding, the membrane was incubated in blocking solution for 
1 h at RT. Afterwards; the primary antibody solution was prepared in blocking solution and the 
membrane incubated overnight at 4°C. The antibody solution was removed and the 
membrane washed with TBS-T (3 x 10 min). Next, the membrane was incubated with secondary 
antibody solution prepared in TBS-T and incubated for 1 h at RT. Afterwards, the secondary 
antibody solution was discarded and the membrane washed with TBS-T for several times. 
Finally, the membrane was incubated with Amersham ECL Prime Western Blotting Detection 
reagent (GE Healthcare) and developed using the VersaDoc imaging system (Bio-Rad). 
Afterwards, the membrane was washed with TBS-T and stored either at 4°C/in TBS-T or was 
air-dried and placed between two Whatman-papers for further analyses.  
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4.8.3.3 Regeneration of membranes 
For further immunodetection analyses of already analysed membranes, it was necessary to 
remove the antibody complexes. Initially, the membrane was equilibrated in TBS-T, when air-
dried before, and then incubated in Restore PLUS Western Blot stripping buffer solution 
(ThermoFisher Scientific) for 10 min at RT. Finally, the membrane was incubated with fresh 
stripping buffer solution (10 min, 37°C), then washed with TBS-T (2 x 10 min) and then ready 
for further analyses. 
4.8.4 Immunofluorescence analysis 
Dilutions and references of all antibodies used for immunofluorescence analyses are described 
in Chapter 2.2. 
For immunofluorescence analysis of cell culture cells (HEK293T, pMEFs), 13 mm glass cover 
slips were PLL coated and placed into culture dish. 24 h after transfection or once confluent, 
the medium was removed and the cells washed with 1 x PBS-. Fixation of cells on cover slips 
was performed upon incubation in appropriate volume of 4 % PFA/PBS- solution for 5 min on 
ice and following incubation for 10 min at RT. Fixation solution was discarded and the cells 
washed with Oldenburg buffer. Perforation of membranes was achieved upon incubation of 
fixed cells in 400 µl ethanol for 5 min at -20°C. Cells were washed with Oldenburg buffer 
(2 x 10 min, RT), covered with 500 µ blocking solution and incubated for 1 hour at RT. Next, 
blocking solution was discarded and primary antibody solution (1st antibody, 5 % NGS, 
Oldenburg buffer) added and incubated either overnight at 4°C or at least for 1 h, RT. 
Afterwards, cells were washed with Oldenburg buffer (3 x 10 min, RT) and secondary antibody 
incubation performed for 1 h (RT) in blocking solution. Finally, staining solution was removed 
and nuclei stained by incubation in washing solution supplemented with 0.5 mg/ml 
bisbenzimide (1:1000, HOECHST 33258 stain, Sigma) for 10 min (RT).The staining solution was 
discarded, the cells washed three times with Oldenburg buffer and mounted with Glycerol 
mounting medium (Dako). Slides were imaged with a Laser Scanning Microscope (Zeiss). 
4.9 Lipid analysis 
4.9.1 Ceramide synthase activity assay 
The de novo generation of ceramides was determined in an in vitro ceramide synthase activity 
assay either with radioactive- or NBD- labelled substrate. All samples were performed as 
duplicates. 
4.9.1.1 Radioactive-labelled CerS assay 
First, cell homogenates of transfected/un-transfected HEK293T cells or primary MEFs were 
prepared as described (van Uelft, 2012). Initially, 12.5 µg of protein in a final volume of 50 µl 
homogenisation buffer was prepared. Next, the [3H] sphinganine/BSA/sphinganine solution 
was prepared and incubated for 20 min on ice. Each sample reaction consists of 
0.25 µl [3H] sphinganine, 0.1 µl sphinganine and 44.65 µl reaction buffer. Furthermore, 
acylCoA/HEPES solution (5 M) was prepared and stored at RT. The radioactive-labelled 
substrate solution was mixed with the protein homogenate and incubated for another 2 min 
at 37°C. After pre-incubation, the reaction was started by addition of 5 µl acylCoA/HEPES. Both 
solutions were mixed very well to achieve homogenous distribution of the components. After 
an incubation step of 20 min at 37°C, the reaction was terminated by the addition of 375 µl 
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chloroform/methanol (1:2, v/v). The solution was vigorously mixed (vortex) and lipid extraction 
performed according to the protocol of Bligh and Dyer (1959). 
4.9.1.2 NBD-labelled CerS assay 
First, cell homogenates of transfected/un-transfected HEK293T cells or primary MEFs were 
prepared in homogenisation buffer supplemented with protease inhibitors as described (see 
chapter 4.8.1.1). Next, 25 µg of homogenate were diluted in a final volume 50 µl 
homogenisation buffer and the 10 µM NBD- sphinganine (omega (7-nitro-2-1,3-
benzoxadiazol-4-yl)(2S,3R)-2-aminooctadecane-1,3-diol, Avanti Polar Lipids) solution 
prepared for each reaction (45 µl) as a master mix. After incubation of 2 min at 37°C, the NDB-
sphinganine was added to the protein homogenate and incubated for another 2 min at 37°C. 
The reaction was started upon addition of 50 µM acylCoA (Avanti Polar Lipids). After 
incubation of 20 min at 37°C the de novo synthesis was stopped and the lipids were extracted 
following addition of 375 µl chloroform/methanol (1:2, v/v). Finally, the solution was well mixed 
(vortex) and the lipid extraction performed according to the protocol of Bligh and Dyer. 
4.9.1.3 Lipid extraction (Bligh and Dyer) 
Lipid extraction started with the addition of 375 µl chloroform/methanol (1:2, v/v) solution. The 
solution was vigorously mixed and briefly centrifuged (1 min, 2.500 rpm). Next, 
125 µl chloroform were added to each sample, vigorously vortexed and centrifuged (1 min, 
2,500 rpm). Furthermore, 125 µl ddH2O were added, again vigorously vortexed and 
centrifuged (1 min, 3.000 rpm). After phase-separation, the lower organic phase was 
transferred to a fresh reaction tube and air-dried in a speed vac apparatus or under N2-flow 
in a heating module at 37°C. Finally, the lipids were resuspended in 15 µl chloroform/methanol 
(1:1) and stored at -20°C until HPTLC analyses were performed. 
4.9.2 High-performance thin layer chromatography (HPTLC) 
HPTLC analysis was used to separate and analyse different lipid classes from a diverse lipid 
mixture. The separation of the analytes is based on their solubility in the liquid mobile phase 
(solvent) and their affinity to the stationary phase. For TLC (thin layer chromatography) analysis, 
lipid extracts were dissolved in appropriate volume of chloroform/methanol (1:1, v/v). 
 [3H]-labelled lipids 
Radioactive-labelled lipids loaded on HPTLC silica gel 60 plates (Merck) were developed in 
chloroform/methanol/glacial acetic acid (190:9:1). Afterwards, the plate was air-dried and 
[3H] sphinganine/BSA/sphinganine mixture of known concentration (2 x 1 µl, 2 x 5 µl) was 
added to the plate for further quantification analyses. Finally, a [3H]-sensitive screen was put 
on top of the TLC plate and exposed for 20 to 24 h. Visualization was performed with the BAS 
reader (Fuji) and the AIDA software tool used for quantification purposes. 
NBD-labelled lipids 
Initially, TLC silica gel 60 plates (Merck) with applied NBD-labelled lipids were developed in 
chloroform/methanol/water (8:1:0.1, v/v) and air-dried. Afterwards, different volumes of NBD-
sphinganine standards were spotted onto the plate for quantification analyses. Finally, the 
fluorescence was detected using a Rolera MGI plus EMCCD camera (494/20 and 572/28 
emission filter) in combination with the GelPro analyser software (Media Cybernetics). 
Quantification of fluorescence intensity was performed with ImageJ. 
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4.9.3 Lipid extraction from mouse tissue (liver, muscle and WAT) 
Mouse tissues used for lipid extraction were collected and stored at -80°C. Prior to 
homogenisation in a Precellys® homogenizer (Peqlab Biotechnology), the wet weight was 
determined and the appropriate amount of tissue (50 mg wet weight/ml) transferred to a fresh 
precellys tube containing a small amount of ddH2O (3 x 10 sec, 5.000 rpm, RT). Afterwards, 
homogenates were transferred to fresh Pyrex screw cap tubes and filled up with ddH2O to a 
final volume of 800 µl. Next, samples were mixed with 3 ml chloroform/methanol (1:2, v/v). 
Afterwards, 1 ml chloroform were added and the solution mixed well by vortexing. Then, 1 ml 
ddH2O was added to each sample, followed by vigorous vortexing. After phase separation 
(2.500 rpm, 5 min, RT), the lower organic phase (1.8 ml) was transferred to a fresh glass screw 
cap tube. The solvent was evaporated under N2-flow at 37°C and the lipids extracts 
resuspended in small volume of 180 µl chloroform/methanol (1:1, v/v). 
For TLC analysis, 5 µl of lipid extracts (corresponding to 1 mg tissue) as well as 5 µl of lipid 
standard (cholesterol, cholesterol ester, DAG and TAG) were spotted onto the plate (HPTLC 
Silica gel 60, Merck) and developed in n-hexane/diethylether/acetic acid (70:30:1, v/v/v). 
Afterwards, the plates were air-dried and incubated in 10 % CuSO4/ 8 % H2PO4 solution until 
the plate was completely covered with the solution. Next, the plate was heated to 180°C for 
several minutes to visualize the separated lipids (Yao & Rastetter, 1985). Quantification was 
done with ImageJ. 
4.9.4 Lipid extraction from mouse feces 
Mouse feces were collected at different time points and stored at -80°C until further analysis. 
For lipid extraction, 100 mg feces were transferred to fresh tube and dried for 1 hour at 37°C. 
Afterwards, feces were ground using pestle, resuspended in 400 µl ddH2O and transferred to 
fresh Pyrex screw cap tube. Next, 1.5 ml chloroform/methanol (1:2, v/v) were added and the 
storage lipids extracted. 0.5 ml chloroform was added to each sample followed by the addition 
of 0.5 ml ddH2O. After each step, the lipid mixture was vigorously mixed by vortexing. For 
phase separation, the samples were centrifuged (10 min, 2.500 rpm, RT) and the lower phase 
transferred to a fresh glass screw cap tube. The solvent was evaporated and the remaining 
lipid extract resuspended in 100 µl chloroform/methanol (1:1, v/v). For TLC analysis of lipid 
composition see chapter 4.9.1.3. 
4.10 Histological analysis 
Mouse tissue samples were fixed in 4 % paraformaldehyde (PFA), methanol-free PBS for 24 h 
at 4°C. Afterwards, the tissues were embedded in paraffin. Microtome sectioning and the 
stainings were performed by Melanie Thielisch. 
Paraffin sections used for H&E, PAS, Elastica and IHC staining’s were deparaffinised and 
rehydrated as followed. First, the sections were incubated for 20 min at 60°C in the incubator. 
Next, the slides were incubated in Xylol (2 x, 10 min) and run through a descending alcohol 
series (2x 100 %, 96 %, 90 %, 80 %, 70 % and ddH2O). 
4.10.1 H&E (hematoxylin and eosin) staining 
The H&E staining is a combination of two single stainings and is one of the most widely used 
overview staining. First, hematoxylin stains all basophilic structures like the nuclei of cells blue 
and the counter staining with eosin, all acidophilic (eosinophilic) structures in red/pink and 
orange (cytoplasm, mitochondria, collagen and keratin). 
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Briefly, the sections were deparaffinised as described above and then incubated for 3 min in 
Mayer’s hemalum solution (VWR) and again washed three times in tap water. Next, the sections 
were incubated in Eosin-staining solution (VWR) for 3 min at RT and washed with tap water 
(3 x). Finally, the slides were shortly incubated in an ascending alcohol series. Entellan was 
dropped onto the slides and covered (air bubble-free) with a cover slip. 
4.10.2 PAS staining 
The periodic acid- Schiff (PAS) staining allows detection of polysaccharides such as glycogen 
or glycoproteins (mucos). For interpretation, glycogen, mucus substances, basement 
membranes and fungal organisms were magenta colored. The nuclei are stained in blue, by 
hematoxylin counter staining. 
First, the sections were deparaffinised as described and rinsed in distilled water. Then, the slides 
were incubated in periodic acid for 5 min (RT, Roth) and washed under running tap water for 
at least 3 min. Slides were again rinsed in distilled water, then incubated in Schiff’s reagent 
(15 min, RT, Roth) and washed with tap water. Next, the slides were rinsed in distilled water 
and incubated for 2 min in Mayer´s hemalum solution (VWR). Afterwards, the slides were 
washed in tap water, run through ascending alcohol series and mounted with Entellan. 
4.10.3 Elastica van Gieson Staining (Merck) 
This staining is a combination of the Weigert and Van Gieson Trichrome staining and highlights 
the connective tissue and elastic fibers. 
Deparaffinised slides were incubated for 10 min in Elastin solution according to Weigert’s 
protocol and rinsed under tap water. Next, slides were incubated for 5 min in a mixture of 
Weigert’s solution A and B (1:1) and rinsed with tap water. Finally, the sections were incubated 
for 2 min in Picrofuchsin solution, incubated for 1 min in 70 % ethanol and run through 
ascending alcohol series before they were mounted with Entellan. 
4.10.3.1 Immune histochemistry 
It describes a common application, where applied (conjugated) antibodies selectively bind 
their antigen and can be used in turn for detection. 
Sections that have been deparaffinised were incubated in 1.2 % H2O2/PBS solution for 10 min. 
After another incubation step in 10 mM sodium acid buffer (pH 6) for 40 min at 95°C, the 
sections were blocked in 1 % BSA/PBS-T additionally supplemented with 10 % donkey serum 
(30 min). The primary antibody was diluted in 1 % BSA/PBS-T solution and incubated overnight 
at 4°C. The staining solution was removed, slides washed with PSB- (3x 3 min) and then 
incubated with the secondary antibody solution (in PBS) for 1 hour at RT. The sections were 
again washed with PBS- (3x 3 min) and stained with NovaRED (Vectorlaboratories). Finally, a 
hematoxylin- counterstaining for nuclei was prepared and sections were mounted. 
4.10.4 Oil Red O staining 
The Oil Red O staining utilizes a lysochrom diazo dye for the staining of neutral, storage lipids 
(TAG, cholesterol ester) and also some lipoproteins. Preparation of frozen sections and the 
staining procedure were done by Melanie Thielisch. 
Briefly, fresh tissue was taken from a mouse which was killed by cervical dislocation. Next, the 
tissue was directly embedded in Tissue-Tek® O.C.T.TM compound (Sekura), frozen on dry ice 
and stored at -80°C. Cryo sections of 8- 10 µm thickness were prepared and mounted on glass 
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slide. Sections were incubated for 5 min (RT) in formalin and washed with tap water. Next, the 
slides were shortly equilibrated in 60 % isopropanol followed by an incubation step of 10 min 
in Oil Red O solution B for 10 min (RT). The staining reaction was terminated by incubation in 
60 % isopropanol. Finally, the slide was rinsed with distilled water and a counterstaining with 
Mayer´s hemalum solution (2 min) was performed. Afterwards, the slide was rinsed with 
distilled water and a drop of Kaiser’s glycerol gelatine added and covered with cover slip. 
 
4.11 Flow cytometry 
The flow cytometry is a laser-based technology which allows the counting, sorting and profiling 
of cells in a heterogeneous fluid mixture (e.g. tissue homogenate, blood sample). The analysis 
is based on the expression of a combination of specific antigens on the cell surface which were 
detected by antigen-specific-fluorochrome-conjugated antibodies. Thereby it is possible to 
specify not only the cell type, but also its biological function and developmental stage. 
Additionally, next to an extracellular, an intracellular staining of proteins is also possible. 
4.11.1 Dissection of thymus and spleen 
Mice killed by cervical dislocation were placed in dorsal recumbency and the prepping area 
cleaned with 80 % ethanol. Initially, the abdomen was opened with sterile dissection 
instruments and the spleen removed. Next, the thoracic cavity was opened and the thymus 
removed. Each organ was subsequently transferred to a fresh reaction tube containing 0.5 ml 
1 x PBS and stored on ice until FACS analysis were performed (see Chapter 4.11.4). 
4.11.1.1 Isolation of lymphocytes from thymi and spleen 
For the preparation of lymphocyte single cell suspension, thymi and spleens were prepared as 
described (3.10.2). Next, each organ was placed in a 40 µm cell strainer placed in a S10 cell 
culture dish which was filled with 8 ml ice-cooled PBS (1 x) and chilled on ice. To achieve single 
cell suspension, each organ was passed with gentle pressure through the cell strainer with a 
sterile plunger of a 10 ml syringe. The suspension was transferred to a fresh falcon tube, the 
cell strainer rinsed with 1 x PBS and also collected in the corresponding falcon. After 
centrifugation for 10 min at 1.200 rpm at 4°C, the supernatant was removed, the lymphocytes 
from thymi samples resuspended in 10 ml 1 x PBS and stored on ice. Lymphocytes from spleen 
samples were resuspended in 5 ml red blood cell (RBC) lysis buffer and incubated for 5 min at 
RT. The hypotonic buffer conditions results in the burst of erythrocytes whereas lymphocytes 
remain intact. The reaction was terminated after the addition of 30 ml PBS followed by a 
centrifugation step (1.200 rpm, 8 min, 4°C). Next, the supernatant was removed, lymphocytes 
resuspended in 10 ml PBS (1 x) and stored on ice. Finally, an aliquot from each sample was 
taken, mixed with Trypan blue and the cells counted (see Chapter 4.3.1). 
4.11.2 Blood collection by intracardiac puncture 
The blood collection as a terminal procedure by intracardiac puncture was performed with 
mice that had been anaesthetized (overdose) with isoflurane. The mouse was placed in dorsal 
recumbency and the prepping area cleaned with 80 % ethanol. Next, the heart was directly 
punctured, by inserting the needle (27G needle on a 1 ml syringe) at the base of the sternum 
under the left side to the xiphoid process. Finally, the blood was carefully withdrawn and the 
mice killed by cervical dislocation. Subsequently, the blood was transferred to a fresh reaction 
tube (1.5 ml) and gently mixed with 0.5 M EDTA (up to 50 µl/ 500 µl blood) to avoid 
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coagulation. In the next step, the blood was diluted with 1 x PBS supplemented with 2 % FCS 
and 2 mM EDTA to a final volume of 1.2 ml and was stored at RT until PBMCs isolation and 
FACS analysis were performed. 
4.11.3 Isolation of PBMCs from whole blood samples 
The isolation of PBMCs from whole blood samples was done by density gradient 
centrifugation. Diluted whole blood samples were carefully layered onto a 3 ml LymphoprepTM 
(density gradient medium, Stem cell technologies) that had been prepared in a fresh 15 ml 
falcon tube. In order to prevent the gradient from destruction during centrifugation step, the 
brakes from the centrifuge were switched off. After centrifugation (20 min, 800 x g, RT), the 
PBMC-containing interphase was carefully harvested and transferred to a fresh falcon tube 
containing 10 ml 1 x PBS. An additional centrifugation step was performed (10min, 300 x g, 4°C) 
and the supernatant carefully removed. The pellet was resuspended in 10 ml 1 x PBS and once 
more centrifuged (10 min, 120 x g, 4°C) to pelletize the PBMCs whereas the platelets-
containing supernatant can be carefully removed afterwards. Finally, the PBMCs were 
resuspended in 1 to 2 ml 1 x PBS and a small aliquot prepared to count the cells (Trypan blue 
added to exclude dead cells). The PBMC suspension was stored on ice until further experiments 
were performed. 
4.11.4 Flow cytometry 
As mentioned before, the flow cytometry represents a laser-based technology, which allows 
the simultaneously analysis of various parameters of a single cell suspension. First, cells were 
arranged by hydrodynamic focusing; and depending on their size and granularity, the laser 
light is differentially scattered and absorbed when passing two detector systems. First, the 
forward scatter detector (FSC) is placed in line with the laser beams and detects the light which 
passes the cells. Meaning, the bigger the cells are, the less light passes them and the less can 
be detected. This in turn gives information about size of the cells. The second detector, the 
sideward scatter detector (SSC) is arranged in a defined angle to the laser beams which allows 
the measurement of light that is scattered by the cells. The level of scattering in turn is based 
on e.g. the intracellular amount of granules or other membrane compartments and gives some 
information about the internal complexity. Additionally, each laser is able to excite several 
fluorochromes simultaneously. The emission of those fluorochromes were separated by 
specific band pass filters and measured by an additional set of detectors. 
4.11.4.1 Flow cytometric analysis of cell surface marker 
The staining of cell surface antigens for flow cytometric analyses was performed with 1 x 106 
cells. The appropriate amounts of single cell solution from each sample that have been 
prepared as described (Chapter 3.10.3 and 3.10.4) were transferred to flow cytometry tubes, 
containing 1 ml PBS (1 x). After a centrifugation step (8 min, 1.200 rpm, 4°C), the supernatant 
was removed and the cells resuspended in 100 µl PBS buffered antibody staining solution. The 
dilution of antibodies was prepared according to the manufacturer’s instructions. Incubation 
was performed for 20 min at 4°C in the dark. Next, the cells were diluted with 1 ml PBS (1 x) 
and again centrifuged (8 min, 1.200 rpm, 4°C). Afterwards, the supernatant was decanted, the 
cells resuspended in 200 µl PBS and stored on ice. The analysis of the cells was performed at 
the Canto II flow cytometer. In one experiment, propidium iodide (200 ng/ sample), was added 
to the samples directly before the measurement was started. Propidium iodide is a fluorescent-
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DNA intercalating dye and was used to stain dead cells as it can pass through porous 
membranes. 
4.12 Statistical analysis 
For statistical analysis of obtained data a two-tailed Student’s t-test for independent groups 
was performed. p-values lower than 0.05 were regarded as statistically significant. Values are 
presented as mean ± SEM. 
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5 Results 
The present thesis is divided into three parts. The first part focuses on in vitro experiments. The 
second part summarizes the cloning strategy and generation of two conditional mouse lines: 
CerS2H212A/H213A or CerS2Del79-120, later abbreviated as CerS2H/A or CerS2Del. The last section 
summarizes the characterization and analysis of the dysfunctions caused by the targeted 
mutations in vivo. Some of the experiments were done in cooperation with Dr. A. Bickert and 
Dr. P. Kern and already published (Bickert et al., 2018) prior to this thesis was finished. 
5.1 Bioinformatics analysis of ceramide synthase 2 
5.1.1 CerS2 transmembrane topology prediction studies and analyses suggest 
an ER-luminal orientation of the N-terminus and cytoplasmic localisation 
of the homeodomain 
Despite the intensive investigations done to elucidate the detailed functions of each ceramide 
synthase, e.g. consequences from a loss of function; not much is known about the 3D-structure 
and transmembrane topology of the whole protein. This may be explained by the lack of X-
ray crystallographic analyses. However, there are several software tools and databases 
available, which allow the prediction of domains and motifs, based on the comparison 
(blast/alignment) of similarities to already well-characterized proteins. 
All applied database searches, alignments, and experiments were performed to gain more 
insights into the protein structure and to avoid impairment of important sites necessary for the 
catalytic function of the CerS2 protein (Figure 5.1 A and B). This issue becomes even more 
crucial when mutation constructs of the CerS2 protein were generated, which probably affect 
the functionality of the homeodomain by leaving the protein structure and catalytic activity 
intact. 
So far it is already known, that the CerS2 protein consists of two domains, the homeodomain 
and the TLC domain (Figure 1.5, Figure 5.1, Chapter 1.4). Posttranslational modification analyses 
were performed with the NetNGlyc1.0/ NetOGlyc3.1 server and the NetPhos3.1 prediction tool 
in order to validate, at which sites the protein is possibly glycosylated or phosphorylated. This 
is of great importance due to modifications, which should be introduced into the protein 
sequence. Here, the generated mutations should not interfere with those sites leading to their 
impairment. The NetNGlyc1.0 prediction revealed two possible glycosylation sites within the 
peptide sequence at position N19 and N81 (Figure 5.1, A/B, black asterisks, Figure A3). The 
possible function of the glycosylated N18 and its contribution to the catalytic activity were later 
on further investigated (Chapter 5.1.3). The NetOGlyc3.1 prediction does not indicate any O-
glycosylated amino acids in the CerS2 protein (data not shown). 
 
Results from the NetPhos3.1 prediction revealed that several amino acid residues within the 
peptide sequence of CerS2 can be phosphorylated (Figure A4). Some of the predicted 
phosphorylation sites within the C-terminus of the CerS2 protein could be confirmed by 
experiments of Sassa et al (2016). It should also be noted that the phosphorylation itself 
influences the catalytic activity of the protein (Sassa et al., 2016). 
 
Next, the CerS2 protein was analysed regarding the presence of a nuclear localisation signal. 
The NLStradamus software tool recognizes a putative NLS region within the peptide sequence 
of the homeodomain, but its value does not reach the threshold-line (Figure 5.1 D, lower 
section). Another result from the NucPred server suggests that this “RRRR-motif” within the 
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homeodomain of the CerS2 peptide sequence could function as an NLS signal (Figure 5.1 D, 
middle section). Since it was known from schlank, the well-characterized ceramide synthase 
from Drosophila melanogaster, that it harbours two NLS motifs (Chapter 1.5), were the second 
one, the NLS2 (RLRR-motif), was proven to be essential for nuclear localization (Voelzmann, 
2013; Sociale et al., 2018.). Following that, we performed another protein sequence alignment 
of CerS2 with schlank to determine whether the NLS1 and/or NLS2 motif is also present in 
CerS2 peptide sequence (Figure 5.1 D). The obtained results indicate that the NLS2 (“RLRR”) 
motif from the fruit fly is highly conserved (from insects to mammals) and present in the CerS2 
peptide sequence (here “RRRR”). Additionally it turned out that those amino acids are the same 
as that predicted by the NucPred server (Figure 5.1 D). 
 
Next, membrane topology predictions indicated that CerS2 has either six or seven 
transmembrane domains (data not shown). The N-terminus is thereby facing the ER lumen, 
based on the predicted glycosylation site and the fact that the enzymes, necessary for its 
glycosylation, are located in the ER lumen (Tidhar et al., 2018). Another representative 
prediction result performed with the Phyre2 server suggests, that the CerS2 protein consists of 
seven TMDMs and that the homeodomain is located between the first and second 
transmembrane domain (Figure 5.1 B). Furthermore it predicted that the C-terminus is facing 
the cytoplasm, which is in line with prediction analyses performed by Tidhar et al. 2018. 
Additionally, it was also shown by nuclear magnetic resonance (NMR) analyses, that the 
homeodomain of CerS5 and 6 can adopt a typical 3D-structure, composed of three -helices 
(Figure 5.1 C; UniProtKB (Q9D6K972cqx.1.A. and Q8C172); Voelzmann, 2013; Sociale et al., 2018). 
Based on these findings protein-blast and alignment analyses were performed with the Swiss-
Model-/ and Phyre2 server to predict the possible structure, which can be adopted by the CerS2 
protein (Figure 5.2 B and C). The findings from the Swiss-Model server clearly indicate that the 
homeodomain of CerS2 has low sequence similarity of 37.97 % to CerS5 (Figure 5.1 C); however 
it suggests that it can adopt the same secondary structure of three alpha helices, which is 
located between the first and second large transmembrane spanning domain. The Phyre2 
prediction supports this assumption (Figure 5.1 B) and it additionally gives an overview, upon 
homology modelling, that the tertiary structure of the CerS2 protein is mainly composed of 
alpha helices (Figure 5.1 B). With all these findings we gained further information about the 
possible protein structure, which is needed for the following steps. 
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Figure 5.1: Bioinformatics analysis of mouse ceramide synthase 2. (A) Graphical representation of the 
CerS2 protein (homeodomain aa 67-128; TLC domain aa 131-332). Predicted 2D model suggests the presence 
of seven transmembrane domains arising from the peptide sequence. N- terminus faces the ER lumen 
(extracellular space). C-terminus is directed against the cytoplasm. Asterisks highlight possible glycosylation 
sites at position N19 and N81. Purple circles depict positions of alpha helices of the homeodomain. (B) Phyre2 
3-D homology modelling results. Homeodomain is shown in light green/blue at the top of the protein. (C) Swiss-
Model homology modelling result. Homeodomain of CerS2 shares 37.93% sequence identity with the CerS5-
template (m2cqx.1.A). Model-Template-Alignment highlighted position of alpha helices. Conserved amino acids 
are in black. 3D-structures predict the possible formation the homeodomain of CerS2 can adopt. (D) Upper 
section show NLStradamus prediction results performed to identify NLS signals within the CerS2 protein. 
Identified signal between aa 100 and 150 does not reach threshold line. Middle section summarize the 
NucPred- NLS prediction results for the identification of an NLS signal (bold faces, yellow). Color-code indicates 
probability. Lower section show results of NLS-prediction based on the sequence alignment of Cers2 and 
schlank (Results were obtained and modified from indicated server, Phyre2 and Swiss Model, NucPred, 
NLStradamus). 
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5.1.2 Mutations in the lag1 and not of the homeodomain affects the catalytic 
activity in vitro 
As it was described at the beginning of Chapter 1.4, all ceramide synthases, except CerS1, are 
composed of two sequence motifs; the N-terminally located homeodomain and the C-
terminally located TLC domain (Figure 1.5). 
In order to investigate the function of the homeodomain and TLC domain independently from 
each other in mice, different constructs were generated and tested in vitro. Each CerS2-
construct suitable for the expression in a mammalian cell culture system carries a defined 
mutation within one of the protein domains (Figure A5). The cDNA of cers2 was amplified via 
PCR and directly cloned into the pcDNA3.1/V5-His TOPO® TA vector (Invitrogen). The defined 
mutations were introduced by mutagenesis PCR. Next, the mutant constructs were either 
overexpressed in HEK293T cells or immortalized MEFs derived from CerS2gt/gt mice. 24 hours 
after transfection, cells were harvested, protein lysates generated and transfection efficiency 
tested via immunoblot analyses. 25 µg of protein lysates were subsequently subjected to the 
de novo synthesis assay and incubated for 20 min with 10 µM NBD-sphinganine [(omega (7-
nitro- 2-1,3-benzoxadiazole-4-yl) (2S,3R)- 2amino- octadecane-1,3-diol)] and 50 µM acyl-CoA 
at 37°C. Reactions were determined by addition of chloroform/methanol; lipids were extracted 
according to the protocol of Bligh & Dyer and separated on methanol HPTLC plates. 
Quantitative analyses of fluorescence intensities were performed in comparison to applied 
standards with ImageJ, Excel, and GraphPad. All values derived from the different assays were 
put as relative ceramide synthase activity. The CerS2H212A/H213A-V5-His expression vector 
construct was already cloned (van Uelft, 2012) and is characterized by the replacement of two 
highly conserved consecutive histidine residues by two alanine residues (aa 212 and 213, Figure 
5.2 A and B). The defined deletion of amino acid residues 79-120 within the homeodomain was 
generated under consideration of a ClustalO sequence alignment with CerS5 and 6; and in 
accordance to similar experiments done with CerS1 and 5 (Figure 5.2 E) (Spassieva et al., 2006). 
Here, the CerS5-stop and CerS5del87-128-stop vector (Gosejacob, 2017) was used as a positive 
control for our truncated CerS2 protein construct. Additionally, it is necessary to mention that 
untransfected HEK 293T cells endogenously express CerS2 and CerS5, which leads to a 
background signal of de novo generated ceramides. Immortalized MEFs derived from 
CerS2gt/gt mice showed no endogenous CerS2 activity, due to the lack of the CerS2 protein. 
Results of immunoblot analyses illustrate that transfected HEK 293 cells or MEFs express the 
CerS2 constructs in the same ratio (Figure 5.2 C and F). Furthermore, overexpression of WT 
CerS2 (Figure 5.2 D and G) and CerS5 (Figure A5) results in increased levels of de novo 
generated ceramide in comparison to controls. Increased activity was undetectable in lysates 
from CerS2H212A/H213A transfected MEFs (Figure 5.2 D). These findings suggest that the two 
histidine residues seem to be necessary to maintain the catalytic activity of CerS2. Therefore, 
the histidine to alanine replacement mutation is suitable to study the effect of a catalytically 
inactive protein where the homeodomain is still present.  
Next, the deletion of amino acids 87-128 within the homeodomain of CerS5 does not result in 
reduced de novo synthase activity (Figure A6) and was therefore used as an internal positive 
control for our experiments. Crude lysates of CerS2Del79-120 transfected HEK293 cells show 
minor reduction in de novo synthase activity against its preferred substrates C24:1 and C22:0-
acylCoA in comparison to WT CerS2 control (Figure 5.2 G). Based on these results we conclude 
that the deletion (aa 79-120) within the homeodomain of the CerS2 peptide sequence and its 
minor effects on the catalytic activity allow the investigation of the possible function of the 
homeodomain in vivo. 
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Figure 5.2: Analysis of ceramide synthase activity in vitro. (A) ClustalO alignment results. Alignment of all 
mouse CerS indicate high conservation of histidine residues within the putative active centre. (B) Amino acid 
modifications introduced into the Lag1 domain of the mouse CerS2 protein. Two consecutive histidine residues 
were replaced by two alanine residues at position 212 and 213. Mutations were introduced by mutagenesis 
PCR. (C) Immunoblot analysis of crude cell lysates with an anti-CerS2 antibody. MEFgt/gt, were either not or 
transiently transfected with CerS2 WT (49.9 kDa) or CerS2H212A/H213A mutant constructs, both C-terminally 
V5 and His tagged (49.7 kDa). GAPDH served as a loading control. (D) NBD-dihydroceramide synthase activity 
assay using NBD-sphinganine and C24:1-acyl-CoA as substrates. Densitometric analysis was performed after 
lipid extraction and separation by thin layer chromatography. (E) Schematic representation of predicted domains 
in mCerS2 (according to swissprot). ClustalO alignment result of the amino acids sequence of the HOX motif 
present in CerS5 and CerS2. Underlined amino acids highlight homeodomain; bold-colored faces depict putative 
alpha helices (according to UniProt blast analysis and protein sequence alignments). (F) Immunoblot analysis 
of control and transiently transfected HEK cells. Proteins were detected with anti-V5 antibody, GAPDH served 
as the loading control. (G) Quantitative analysis of NBD-ceramide synthase activity performed with different 
acyl-CoAs as substrates. (D/G) Data are means ± SEM; n=2-3 (D), n=3-6 (G); unpaired t-test, *P<.05; **P<.01; 
***P<.001. (Data of panel C/D and F/G(C24:1) were already published in Bickert et al., 2018.) 
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5.1.3 Identification of glycosylation sites 
Based on the previously performed bioinformatic analyses a CerS2-N19Q- protein construct 
was additionally generated aimed to verify if the glycosylation itself influences catalytic activity. 
First, transient transfection of the CerS2-WT (control), CerS2H212/213A and CerS2Del79-120 
construct was performed in primary MEFs. Protein lysates of transfected cells were generated 
24 h after transfection and subsequently analysed via immunoblot analyses with or without 
treatment of PNGAseF (Figure 5.3 B). Here we could show that both modified CerS2 proteins 
(H/A and Del) were glycosylated, which results in a band shift after incubation with the amidase 
(Figure 5.3 B). Transfection of HEK cells with the CerS2N19Q construct results in the generation 
of a CerS2 protein with lower kDa mass (appr. 44 kDa) in comparison to the CerS2-WT control 
(appr. 49.9 kDa; Figure 5.3 C). Additionally, activity assays performed with protein lysates of 
CerS2-N/Q or WT transfected cells indicate that the presence or absence of the glycosylation 
does not negatively influence catalytic activity (Figure 5.3 C and D). 
 
 
Figure 5.3: Glycosylation studies of ceramide synthase 2. (A) Shown is the N-terminal sequence section 
from amino acid 8 to 25 of CerS2 wild type and N-glycosylation site modified CerS2. (B) Verification of 
glycosylation. Crude lysates of MEFgt/gt transfected cells were incubated ± PNGaseF and analysed via 
immunoblot analyses performed with anti-CerS2. GAPDH served as a loading control. (C) Immunoblot analysis 
of transfected HEK cells with CerS2N/Q construct. Transfection efficiency was verified anti-V5 staining. GAPDH 
served as a loading control. (D) Quantitative analysis of [3H]-sphinganine/ ceramide synthase assay performed 
with 25µg protein extract from transfected HEK cells. Data are means ±SEM; n=3 (CerS2-V5-His control), n=2 
(CerS2N/Q-V5-His).**, p<0.01; ***, p<0.001. 
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5.2 Generation of two conditional CerS2 gene targeting constructs 
(H212A/H213A and Del79-120) requires a number of cloning steps 
The second part of the thesis focuses on the generation of two conditional mouse lines. Two 
cers2-gene-targeting-vector constructs were designed and generated for homologous 
recombination in ES cells. Blastocyst injection results in the generation of chimeric mice, which 
serve as the basis for the generation of new transgenic mouse lines. 
5.2.1  Bacterial artificial chromosome (BACs) 
The generation of the cers2 gene targeting constructs requires the presence of long homology 
arms flanking both sides of the mutated sequence for correct homologous recombination in 
ES cells. The commercially available BMQ 325-K4, BAC (Source BioScience) should contain the 
genomic locus of cers2, needed for recombination, which was verified via Southern Blot 
analysis. 
5.2.1.1 Southern Blot analysis of the cers2-BAC and probe generation 
Southern blot probes were amplified by PCR with specific primers based on template DNA 
(WT) extracted from mouse liver (C57BL/6N). The generated 5’ probe (5’ SB BAC for/ 5’ SB BAC 
rev) has a size of 477 bp and binds within the first intron. The generated 3’ probe (3’SB BAC 
for/ 3’SB BAC rev) has a size of 415 bp and covers exon10 as well as a part of the downstream 
and upstream intron sequence (Figure 5.4 A). Next, the cers2-containing BAC was extracted 
from an overnight culture and 2 µg BAC DNA was either digested with HindIII, EcoRV or BglII 
respectively. Digested DNA was separated on an agarose gel, blotted onto Hybond-N 
membrane and cross-linked. Next, labelling of probes, hybridisation, and detection of labelled 
DNA fragments was prepared. Finally, the verification of the expected band sizes after 
restriction and separation on an agarose gel showed that the BAC (BMQ 325-K4) contains the 
coding region of the cers2 gene (Figure 5.4 B). Meaning, the 5’ probe detects the expected 
fragments at 3.4 kb upon HindIII digestion and the bigger 7.4 kb fragment, which covers the 
5’ region of the cers2 gene (Figure 5.4 B). On the other hand, analyses performed with the 3’ 
probe after BglII restriction results in the detection of a 6.3 kb fragment as expected (E2-
E11/3’UTR; Figure 5.4 B). The 3’ probe allows also the detection of a 5 kb fragments, which 
covers the middle part of the genomic sequence of cers2 and show partial overlap with the 
bigger fragment detected with the 5’ probe. Based on these findings we conclude that the 
BAC could be used for further cloning steps and the recombination step to integrate the large 
5’UTR region into the gene targeting vector. 
 
 
 
 
Figure 5.4: DIG Southern Blot analysis of CerS2-BAC. (A) Schematic representation of the genomic cers2 
locus. Restriction and binding sites of BAC-probes and the expected fragment sizes are highlighted. (B) 
Autoradiograms of DIG Southern Blot analysis.  
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5.2.2 Generation of the conditional CerS2H212A/H213A vector 
The generation of the conditional gene-targeting vector was done with the aid of different 
expression vectors and cers2 DNA fragments amplified from the BAC clone. Initially, two 
plasmids were generated in nine steps (1-6, 7-9) and combined in a final ligation step (10) 
(Figure 5.5). Finally, the generated vector should introduce two mutations within the coding 
region of CerS2, which leads to the replacement of two histidine residues (aa 212 and 213) by 
two alanine residues in the protein sequence. Furthermore, the use of the endogenous 
promoter in combination with an IRES cassette results in the additional expression of a 
downstream eGFP- reporter protein. 
1st step: (pCR2.1 TOPO:5’SOE): 
The first step depicts the generation of the entry side for the 5’ homology region needed for 
the recombineering step. 
2ndstep: (dual loxP/frt-Neo:5’SOE): 
The 5’HR-SOE fragment was then inserted into the dual loxP/frt-Neo vector, upstream of the 
neomycin resistance cassette. 
3rd step: Truncation of Ampicillin resistance gene: 
Next, the ampicillin resistance gene was truncated, which was necessary for further selection 
steps of positive clones. 
4th step: (5’SOE-frt-Neo_Amp:E3-11 genomic sequence): 
In the next step, the genomic sequence of exon three to eleven (E3-11 wt) was subcloned by 
compatible end ligation (MfeI, EcoRI) between the loxP and frt site upstream of the neomycin 
cassette. 
5th step: (E3-11wt-frt-Neo_Amp:E3-11 H/A): 
Next, the H212/213A fragment was generated and inserted between the loxP and frt site 
downstream of the Neo cassette by PspOMI/NotI compatible end cloning. 
6th step: Recombineering of the 5’ homology region (5’HR-Neo:CerS2): 
After linearization of the frt_Neo_D Amp:CerS2-vector with AatII, the recombination procedure 
extended the 5’ HR to its full length. 
7th step: (pDTA:3’HR): 
The 3’ homologous region (3’HR) was amplified and subcloned into pDTA (diphtheria toxin A) 
containing vector. 
8th step: (pBSK-IRES-eGFP:3’HR-pDTA): 
The 3’HR-pDTA fragment was subcloned downstream of the IRES-eGFP cassette (IRES- internal 
ribosomal entry side, eGFP- enhanced green fluorescent protein). 
9th step: (IRES-eGFP/3’HR-pDTA:frt-SOE): 
The entry site for the 5’HR-Neo:CerS2 vector (Step 1-6) was generated and inserted upstream 
of the IRES-eGFP-3’HR-pDTA cassette. Additionally, the insertion leads to the desired deletion 
of a NotI restriction site. 
10th step: (CerS2H212/213A vector): 
The final step was initially designed as a recombineering step but did not result in the 
generation of any positive clone. Therefore we changed our strategy and performed a normal 
T4-DNA-ligase-mediated ligation, which results in the generation of the final 
CerS2H212A/H213A gene targeting vector (Figure 5.5). 
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5.2.3 Generation of the conditional CerS2Del79-120 vector 
The generation of the conditional gene-targeting vector was completed on the basis of the 
CerS2H212/213A targeting vector and cers2 DNA fragments amplified from the BAC clone 
(Figure 5.6). Finally, the final vector carries a deletion of amino acid 79 to amino acid 120 within 
the homeodomain of the CerS2 protein. With this approach, we attempted to generate a 
truncated CerS2 protein, which should be not affected in its catalytic activity (Figure 5.6). 
1st step: (TOPO blunt: E3-11, aa79-120) 
First exons 3 to 11 were amplified and amino acid residues 79 to 120 deleted in a two-step 
mutagenesis PCR. 
2nd step: (dual loxP/frt-Neo: E3-11, aa79-120) 
The truncated coding from step one was cloned into the dual loxP/frt- Neo vector by 
compatible end cloning (NotI/PspOMI). 
3rd step: (CerS2Del79-120 vector) 
The mutated sequence was inserted into the conditional CerS2H212A/H213A gene targeting 
vector. The insertion of the mutated E3-11,aa79-120 fragment leads to the replacement of the 
E3-11 H/A coding region. The CerS2Del79-120 gene-targeting vector represents the final 
vector. 
 
 
 
Figure 5.6: Generation of the CerS2Del79-120 gene targeting vector. The main cloning steps leading to the 
generation of the CerS2Del79-120 targeting vector are illustrated. The deletion of amino acids 79 to 120 results 
in the truncation of the homeodomain of the CerS2 protein sequence.  
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5.2.4 Analysis of the conditional gene targeting vector constructs 
The integrity of each plasmid generated during the different cloning steps as well as the final 
conditional gene targeting constructs was verified by restriction digestion analysis followed by 
partial sequencing (GATC Biotech). The expected fragment sizes of both targeting constructs 
were confirmed after restriction analysis (Figure 5.7 A and B). Furthermore, verification by 
sequencing revealed the absence of undesirable mutations, which could lead to modifications 
of loxP and frt sites or to further modifications within the peptide sequence. Only one silent 
mutation within exon 4 (mutation: GGG GGA; Gly) was detected. Three further mutations 
had been detected within the sequence of different introns. Two were located in the 5th intron 
between exon 5 and 6 of the WT fragment and the last one in the 9th intron, between exon 9 
and-E10 located in the H/A or Del fragment. 
 
 
Figure 5.7: Agarose gel electrophoresis of the targeting vectors digested by restriction enzymes. (A) 
Analysis of the CerS2H212A/H213A vector. (B) Analysis of the CerS2Del79-120 vector. All fragments show the 
expected size. (C) Overview of fragments resulting from the application of different restriction enzymes. 
 
Finally, the obtained results verify the accurate generation of the CerS2 H212A/H213A vector, 
containing a homologous region at the 5’ end (5’HR) followed by a loxP site and the genomic 
sequence of exon 3 to 11. Furthermore, an frt-flanked neomycin resistance gene followed by 
the 3’located second loxP site, the H212A/H213A mutation fragment, a downstream IRES-
driven eGFP reporter and the 3’HR-DTA selection cassette. On the other hand, the restriction 
and sequencing results also indicate the correct generation of the CerS2Del79-120 vector 
which enclosed also the 5’HR, the 5’loxP the genomic region of E3 to 11, the Neo-cassette, the 
3’loxP followed by the E3 to 11, aa79-120 fragment, followed by an IRES-eGFP cassette, the 
3’HR, and DTA selection cassette.  
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5.3 Generation and analysis of targeted mutations after homologous 
recombination in ES cell clones 
5.3.1 Set up of sensitive PCR for verification of homologous recombination 
The generation of different PCR-test constructs beforehand was necessary to ensure fast and 
reliable PCR-based analyses of correct homologous recombination of stable transfected ES 
cell clones (Figure 5.8). 
First, a 3’HR test vector, which contains additionally 520 bp upstream of the 3’homologous 
region in comparison to both conditional constructs, was generated. A highly sensitive PCR 
was established and showed the expected results, even if only 100 fg genomic DNA was 
present in the reaction mixture (3’ctrl for and 3’ctrl rev). Here, correct 3’ homologous 
recombination leads to the generation of a fragment of 1.9 kb (Figure 5.8 A). Next, the final 
CerS2H212A/H213A-vector was used for the generation of a second PCR to further verify 
correct 5’ homologous recombination of the construct (HA_loxP_2_for and HA_loxP_1_rev; 
Figure 5.8 B). The test PCR showed the expected fragment sizes, which should be detected 
after homologous recombination in a heterozygous cers2H212A/H213A or cers2Del79-120 background 
(WT, 466bp; H/A or Del 548bp). 
 
 
 
Figure 5.8: ES cell clone test PCR. (A) Schematic representation of the 3’HR-control vector used for the 
development of the 3’HR test PCR. Primer binding sites were depicted as arrows. Prolonged 3’ region shown 
in orange. The grey fragment depicts the 3’ homology region used as the template. (lower section) PCR results 
for the amplification of the desired fragment of 1.9 kb. A highly sensitive primer pair detects and amplifies 
fragments down to 100fg DNA in the reaction mixture. (B) Schematic representation of the internal 5’ region 
from the gene targeting constructs used for modification in ES cells. Primer binding sites were depicted as 
arrows (loxP PCR). (lower section) PCR results based on the amplification of the loxP site containing fragments 
of the mutated allele. PCR primer show high sensitivity even with low amounts of DNA in the reaction mixture 
(WT: 466bp; H/A or Del: 584bp). 
5.3.2 Generation and analysis of targeted HMI ES cells reveal the presence of 
several positive ES cell clones 
The generation of genetically modified HMI ES cell clones began with an electroporation step. 
Therefore, both gene targeting vector constructs were linearized by NotI restriction and 350 µg 
of linearized DNA was electroporated into the HMI ES cell line. Next, the homologous 
recombination of the negative diphtheria toxin A (DTA) selection cassette outside of the 3’ 
homology region results in cell death, which minimizes the amount of false positive ES cell 
clones. Furthermore, the application of G-418 supplemented ES cell medium during the first 
ten days of cultivation further reduces the number of false positive clones. Afterwards, growing 
ES cell clones were picked as described (see Chapter 4.3.5.5) and analysed by 3’HR-ctrl PCR 
(3’ctrl for and 3’ctrl rev). Correct 3’ homologous recombination was accompanied by the 
amplification of a 1.9 kb fragment and relevant ES cell clones were further expanded (Figure 
5.9 A). In the next step, ES cell clones were analysed by PCR, regarding the correct homologous 
recombination of the 5’ region of the construct (loxP PCR and 5’HR PCR, Figure 5.9 A). Finally, 
50 out of 364 analysed ES cell clones were positively tested for stable 5’ and 3’ integration of 
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the CerS2H212A/H213A construct on one allele of the cers2 gene. For the second cell line, 550 
ES cell clones were picked, which may have integrated the CerS2Del79-120 mutation into their 
genome. Here, 33 ES cell clones could be identified by 3’ and 5’ HR PCR analyses to be positive 
for correct recombination of the construct (Figure 5.9 B). Next, all positively tested ES cell 
clones were further expanded and subjected to Southern Blot hybridization analyses following 
karyotyping and blastocyst injection (Chapter 5.3.3 - 5.3.5). 
 
 
Figure 5.9: PCR analysis of homologous recombination in ES cells. (A) Verification of correct homologous 
recombination in ES cell clones of the CerS2H212A/H213A gene targeting vector. Shown are the PCR results 
for correct insertion of the 5’ (loxP) and 3’ end of the construct and the PCR results of the long amplification 
PCR of the external 5’ region. (B) PCR analysis of homologous recombination of the CerS2Del79-120 construct 
in ES cells. 5’-loxP, 3’ and 5’ external long amplification PCR results are shown (Figure adopted and modified 
according to Bickert et al., 2018). 
5.3.3 Southern Blot analysis lead to verification of positive ES cell clones 
Briefly, positive selected ES cell clones were expanded and the genomic DNA extracted and 
digested with EcoRV (Figure 5.10 A). Resulting fragments were separated corresponding to 
their size by agarose gel electrophoresis, transferred and immobilized on a membrane. 
Hybridization with radioactively labelled cers2 internal 3’ probes was done as described (see 
Chapter 4.6). For the CerS2 H212A/H213A ES cell clones, a fragment of approximately 3.7 kb 
was detected as expected and represents the wild type allele (Figure 5.10 B). Next, correct 
homologous recombination results in the generation of a heterozygous background, which 
lead to the presence of two bands with almost the same size (EcoRV: 5.1/ 5.2 kb; Figure 5.10 
B). These bands were detectable in all analysed ES cell clones and not present in the WT control 
as expected. Furthermore, heterozygous ES cell clones carrying one mutated cers2Del79-120 allele 
were characterized by the presence of the cers2 WT band at 3.7 kb and two bands at 
approximately 5.1 kb (Figure 5.10 A). The autoradiogram reveal that almost all analysed ES cell 
clones show the presence of the expected fragment sizes (Figure 5.10 C). Clone 129 showed 
only one weak signals for the wild type fragment and no signal for the mutated allele and was 
therefore not further analysed. The same situation was observed for clone 170 and 204. Here, 
only a weak signal for the mutated allele was detectable whereas the wild type signal was 
under the detection limit. Additionally, for clone 123 and 129 a bigger band at approximately 
7 kb was detected, which indicate failures in homologous recombination and those were 
discarded. 
Multiple insertions or integration at the wrong locus were further verified by the application of 
a second internal probe (Figure 5.11 A-C). Genomic DNA was either digested with EcoRV 
(CerS2H/A) or PsiI (CerS2Del). Correct homologous recombination results in the detection of 
either a 5.1 kb fragment (CerS2H/A, Figure 5.11 B) or a 20.8 kb fragment (CerS2Del, Figure 5.11 
C). The GFP probe does not bind within the WT allele. The autoradiogram of cers2H/A-mutated 
ES cell clones showed no indication of the appearance of additional bands, pointing out to 
successful homologous recombination. The same was verified for cers2Del-mutated ES cell 
clones. No additional bands were detected in every examined sample, except the expected at 
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20.7 kb (Figure 5.11 C). However, Southern Blot hybridisation with the internal GFP probe rather 
implicates the absence of a detection signal for clone 53, 92, 123 and 204. Those were not 
further analysed by karyotyping analysis nor used for blastocyst injection. 
 
 
 
Figure 5.10: Southern Blot analysis of homologous recombination in ES cell clones (I). (A) Graphical 
overview of the Southern Blot strategy used for the verification of correct homologous recombination in ES cell 
clones. Internal 3’probes (black bar) as well as the resulting fragment sizes after EcoRV restriction are indicated. 
(B/C) Autoradiogram results from SB analysis of indicated ES cell clones. Genomic DNA was digested with 
EcoRV. The WT allele showed an expected band at 3.7 kb. After recombination, we verified two bands for each 
targeting construct either at 5.1/5.2 kb (CerS2H212A/H213A) or 2x 5.1 kb for the CerS2Del79-120 mutation. 
Results were partially published in Bickert et al., 2018. 
 
 
 
 
Figure 5.11: Southern Blot analysis of homologous recombination in ES cell clones (II). (A) Graphical 
overview of the strategy used for the verification of correct homologous recombination in ES cell clones. Internal 
3’ GFP-probe (black bar), as well as the resulting fragment sizes after EcoRV or PSiI restriction, are indicated. 
(B/C) Autoradiogram results from SB analysis of indicated ES cell clones. Genomic DNA was digested with 
EcoRV. The WT allele showed no band as expected. After recombination we verified one band for each targeting 
construct either at 5.1 kb (CerS2H212/213A) or 20.8 kb for the CerS2Del79-120 mutation respectively. Results 
were partially published in Bickert et al., 2018. 
 
5.3.4 Southern Blot analysis with external probes causes unexpected problems 
Initially, genomic DNA was digested with PsiI/BssSI and subjected to Southern Blot 
hybridisation. Due to unexpected problems with the 5’ external probes (high GC-content), 
which showed no results either generated by PCR or by restriction digestion, we changed our 
strategy. Verification of correct 5’ insertion of the construct was done by a long PCR 
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amplification approach (Figure 5.9). Briefly, the upstream primer (5’ctrl for) binding site is 
outside of the construct whereas the downstream primer (5’ctrl rev) binds within the gene 
targeting locus. As expected, all examined ES cell clones either from the CerS2H212A/H213A 
or the CerS2Del79-120 line showed one specific band at 5.6 kb (5’HR PCR) confirming the 
correct insertion of the 5’ region at the desired genomic locus (Figure 5.9). 
In summary, 12 of 364 analysed ES cell clones (3.29 %) were positively tested for the correct 
homologous recombination of the CerS2H212A/H213A construct. Additionally, 13 out of 550 
ES cell clones (2.36 %) analysed by Southern Blot hybridisation exhibit also the correct 
integration of CerS2Del79-120 construct. 
 
5.3.5 Karyotyping of CerS2H212A/H213A or CerS2Del79-120 ES cells 
ES cell clones positive for one of the mutated alleles were subjected to karyotype analysis in 
order to detect chromosomal abnormalities. Here we focussed on numerical changes and 
analysed whether the correct number of chromosomes is present after recombination events. 
 
 
 
Figure 5.12: Verification of karyotypes. (A) Chromosome spread from ES cell clone #110 (CerS2H/A 
flox/Neo). (B) Chromosome spread of clone #13 from CerS2Del ES cell line. (C) Shown are the mean values of 
spreads counted for each ES cell clone. 25 spreads per CerS2H/A ES cell clone (n=3) were counted. 28 spreads 
per CerS2Del ES cell clone (n=3) were counted. Condensed chromatin stained with Giemsa solution. Bar, 
10 µm. 
 
 
Cells were arrested in the metaphase of mitosis after application of colcemid. Highly 
condensed chromosomes were stained with Giemsa solution and slides analysed by light 
microscopy (Figure 5.12 A and B). At least 20 spreads per sample (ES cell clone) were counted 
and the mean calculated. Figure 5.12 (A-B) demonstrate two representative pictures of 
metaphase spreads, one from each clone subjected to blastocyst injection. The graph depicts 
the summary of counted spreads from all analysed ES cell clones. Each column indicates the 
percentages of counted chromosomes (Figure 5.12 C). 
Finally, ES cell clone number 31, 46, 110 and 113 positive for the CerS2H212/213A allele displayed 
the expected number of 40 chromosomes. For the Del79-120 mutation, clone numbers 10, 13, 
17 and 61 showed the correct number of 40 chromosomes.  
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5.4 Analysis and characterization of the conditional mouse lines 
5.4.1 Generation and breeding of mice with mutated cers2 alleles 
ES cell clones (Sv129P2/OlaHsd), positively tested for the homologous integration of the 
CerS2H212A/H231A allele or the CerS2Del79-120 allele, were subjected to blastocyst injection 
(C57BL/6NCrl, done by W. Krzyzak; LIMES-GRC). Resulting chimeric male mice were bred with 
C57BL6/NCrl mice at the age of seven weeks (Figure 5.13). Germline transmission was 
successful when agouti colored offspring was born (Figure 5.13 B). 
 
 
 
 
Figure 5.13: Generation and analysis of CerS2 conditional mice. (A) Schematic representation of the 
homologous recombination strategy in ES cells for the conditional CerS2H212A/H213A and CerS2Del79-120 
construct. Flp and Cre-recombination results in the deletion of frt-sites or loxP-site flanked regions after breeding 
with the desired mouse line. Flp-recombination leads to deletion of internal neo selection cassette. Cre-mediated 
recombination leads to deletion of the wt fragment of the cers2 gene with neo cassette and thereby to the 
expression of mutated CerS2 allele in the desired tissue. (B) Chimeric mice resulting from blastocyst injection. 
(C) Genotyping analysis. Tail tip gDNA from WT, heterozygous and homozygous mice was analysed in a two 
primer-based PCR to verify the presence of the 5’loxp site. Expected fragment sizes: WT- 402 bp; Flox- 484 bp; 
H/A- and Del- 519 bp. (D) Validation of the 79-120 deletion on the genomic level. Expected fragment sizes: WT- 
887 bp; deletion- 762 bp. (E) Validation of H/A Mutation. PCR analysis on genomic DNA extracted from mouse 
liver, following PvuII restriction of amplified fragments. Expected fragments: PCR amplicon 343 bp; after PvuII 
digestion 222 bp and 121 bp. (F) PCR verification of deletion on cDNA level. Expected fragments sizes: WT, 
Flox (H/A), 424 bp; Del, 298 bp. Resulting fragment size for Del mutation was about 188 bp (Figure adopted 
and modified from Bickert et al., 2018). 
 
 
The graphical overview of the homologous recombination of the wild type locus by the cers2 
gene targeting constructs in ES cells is shown in Figure 5.13 A. Initially, breedings of chimeric 
mice with deleter-Flp mice, lead to the deletion of the neomycin resistance cassette, which 
might influence the transcription of neighbouring loci (Olson et al., 1996). The resulting Flox-
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mice (Flox) represents, on the one hand, the basis of further conditional mice, where the H/A 
and Del mutation can be expressed in a tissue-specific manner upon breeding with the 
appropriate Cre-mouse lines. It should be noted that the Flox mice express the endogenous 
cers2 gene and serve as an additional control in in the following experiments. This was done 
in advance in case if the introduction of the targeting construct influences the expression level. 
In parallel, we set up breedings of heterozygous-chimeric mice with pgk-Cre-expressing mice. 
The Cre recombinase is under control of the ubiquitously expressed phosphoglycerate kinase 
1 promoter (pgk), which results in the deletion of the loxP-flanked CerS2wt-neomycin cassette 
in every tissue. Finally, the CerS2H/A or CerS2Del mutation is expressed under the control of 
the endogenous CerS2 promoter. Furthermore, an eGFP reporter protein separated by an IRES 
cassette (internal ribosomal entry site) will be expressed simultaneously and also under the 
control of the endogenous cers2 promoter. 
For our experiments, we used homozygous animals generated from heterozygous breedings 
of three different mouse lines (Flox/+; H/A/+ and Del/+). With this approach, we obtained 
animals needed for our investigations, as well as littermate controls. First, homozygous wild 
type (WT) animals and Flox (CerS2:CerS2H/A) mice were used as controls. Second, 
homozygous CerS2H/A or Del mice were used to analyse the consequences of the targeted 
mutations. 
Genotyping of all mice was done by PCR regarding the presence or absence of the 5’ loxP site 
(Figure 5.13 C). Additionally, the desired mutations were easily verified by PCR analyses. First, 
the histidine to alanine point mutation at position 212 and 213 within the peptide sequence 
was designed in a way that an additional PvuII restriction site was created (Figure 5.13 E). After 
Nested-PCR amplification, the generated fragment (343 bp) for each sample was extracted 
from agarose gel and restricted with PvuII (done by A. Bickert). As indicated, the mutation leads 
to the generation of an additional PvuII restriction site and thereby to the generation of two 
smaller fragments after digestion (222 bp / 121 bp; Figure 5.13 E). Amplified WT-DNA was 
unsusceptible to digestion. Next, the verification of the deletion within the homeodomain of 
the cers2 gene was based on the amplification of the corresponding cDNA (Figure 5.13 D and 
F). As the results indicate, the obtained fragment of approximately 188 bp was smaller than 
expected (298 bp). Additional sequencing analyses pointed out, that the genomic locus was 
modified as designed, where exon 3 and 4 are still present and that a complete loss of exon3 
and exon4 occurs during transcription (sequence analysis of cDNA). Furthermore, the lack of 
the exon 3 and 4 in the transcribed mRNA results in the deletion of amino acids residues 59 
to 137 within the peptide sequence. This, in turn, affects a much larger region of the 
homeodomain/ protein as it was designed (del 79-120, Figure A7). All these findings are also 
in contrast to those obtained in in vitro experiments (Chapter 5.1.2). 
5.4.2 CerS2H212A/H213A and CerS2Del79-120 mice show an increased 
mortality rate 
Usually, the offspring of heterozygous breedings segregates into the ratio of 1:2:1 (25%: 50%: 
25%). Preliminary analyses regarding the Mendelian ratio gained from CerS2(+/gt) breedings 
indicated that the lack of CerS2 protein somehow alters the ratio of the expected phenotypes. 
This, in turn, lead to further analysis of littermates obtained from Flox, H/A and Del mice. The 
findings from more than 40 breedings of heterozygous Flox mice (+/Flox x +/Flox) show, that 
those were born according to the Mendelian ratio (Figure 5.14 A), although they show a 
reduction in cers2-mRNA level and protein expression (Figure 5.14 A/B). In contrast, results 
obtained from heterozygous H/A (+/HA x +/HA) breedings showed a strong reduction of the 
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expected homozygous CerS2H/A mice (Figure 5.14 A). Results obtained from CerS2Del mice 
were already published and not further investigated (Figure A8, Bicket et al., 2018). Moreover, 
re-evaluation of litter-parameter revealed that CerS2H/A and CerS2Del mice show an 
increased mortality and that the mice die immediately after birth or within the first 14 days 
after birth (Figure 5.14 B); indicating that the mutation (H/A) influences the life expectancy. 
 
 
 
 
Figure 5.14: Mendelian Ratio and mortality rate is altered in CerS2 mutated mice. (A) Resulting percentage 
of offspring gained from heterozygous breedings of CerS2H/A and Flox mice. Total numbers of mice are shown 
in brackets. (B) Analysis of litter rate and corresponding mortality rate of CerS2H/A and -Del mice. Numbers 
were obtained from Mausoleum (software). 
 
 
5.4.3 CerS2H212A/H213A and CerS2Del79-120 proteins were expressed to 
different extent in comparison to endogenous CerS2 
The following experiments (section 5.5.3 – 5.5.4) summarize the first steps in the detailed 
analyses of the newly generated CerS2H212A/H213A and CerS2Del79-120 mice. Parts of this 
experimental section were done in cooperation with Dr. A. Bickert and Dr. P. Kern, and were 
already published (Bickert et al., 2018). Here, only main findings are mentioned in the sake of 
completeness. 
The CerS2 H212A/H213A and CerS2Del79-120 mutation constructs were designed in a way that 
the expression of each mutated CerS2 protein is characterized by the simultaneous expression 
of an enhanced GFP reporter protein under the control of the endogenous CerS2 promoter, 
which is facilitated by an IRES cassette.  
Total protein extracts of liver, kidney, brain and five other tissues from CerS2-WT, -Flox, -H/A 
and CerS2Del mice were generated. The presence of the mutated CerS2 or GFP protein was 
determined by immunoblot analyses using the anti-CerS2 (Kremser et al. 2013) or the anti-GFP 
antibodies (Figure 5.15). For protein extracts from WT and Flox controls, a protein migrating at 
approximately 45 kDa was detected in all analysed tissues, displaying the expression of 
endogenous CerS2. Furthermore, strongest expression was detectable in liver, lung, and spleen 
(Figure 5.15 A; Figure A9). On the other hand, expression of mutated CerS2H/A protein 
(44.9 kDa) was also examined (Figure 5.15 A, Figure A9). However, protein expression levels of 
CerS2 from Flox and H/A mice were significantly reduced in liver, kidney and brain in 
comparison to WT control (Hsp90) (Figure 5.15 A). Furthermore, no Del79-120 protein was 
detectable under normal exposure conditions (Figure 5.15 A). More accurate analysis of 
quantitative mRNA expression revealed that the mutated CerS2-WT, -H/A and -Del transcripts 
were reduced to 50 % in Flox, H/A and Del mice (Figure 5.15 B). These findings are in line with 
the reduced protein levels found in Flox and H/A mice. Sequencing of cers2-Del cDNA 
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transcripts showed complete loss of exon 3 and 4 (data not shown), which would code for a 
protein lacking aa 59-137 (Figure A7). 
Verification of eGFP expression showed the presence of the GFP-reporter protein in all 
analysed tissues from CerS2H/A and CerS2Del mice. This, in turn, implicates specificity of the 
anti-GFP antibody as no protein was detected in the WT and Flox control. Furthermore it 
supports also the assumption that the bicistronic transcripts were expressed to similar extent. 
Additionally, expression levels of CerS4, 5 and 6 were also verified, since it is suggested that 
they can compensate the lack of one CerS by up-regulation of another CerS (Figure 23, C). 
The analyses confirm increased expression levels of CerS5 and CerS6 in CerS2H/A and -Del 
mice in comparison to WT and Flox control. Moreover, in comparison to these findings, the 
expression level of CerS4 remains unaltered in the liver. 
 
 
 
 
 
 
Figure 5.15: Protein expression and mRNA level in mouse liver. (A) Protein expression analyses of mutated 
CerS2 (H/A and Del 79-120) and GFP in Flox, H/A and Del mice. WT mice served as the control. Expression of 
wild type and modified CerS2 protein is lower in Flox and H/A mice in comparison to WT control. Very low CerS2 
protein level were detectable in Del mice and appeared only after strong overexposure. HSP90 serve as loading 
control. The graph shows the densitometric analysis of CerS2 expression relative to WT control. (B) Quantitative 
RT-PCR analysis of CerS2 mRNA expression level. Data are mean values ± SEM (n= 5-6). (C) Immunoblot 
analysis of CerS4, 5 and 6 expression. HSP90 served as the loading control. Shown are relative expression 
levels in comparison to WT control. Data are means ± SEM; Quantification of A/C) was based on two individual 
experiments (n=6). Unpaired t-test, *P<.05; **P<.01; ***P<.001. (Data adopted and modified from Bickert et al., 
2018).  
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5.4.4 Targeted mutations lead to loss of catalytic activity and an altered 
sphingolipid content in CerS2H212A/H213A (and Del79-120) mice 
 
To prove that the catalytic activity is indeed lost in CerS2H/A mice and unaffected in CerS2Del 
mice, it was necessary to perform ceramide synthase activity assays in vitro. In line with the 
loss of protein in CerS2Del mice is the strong reduction of synthase activity, detected in liver 
extracts (Figure 5.16 A). Additionally, the H/A mutation leads to the desired loss of the catalytic 
activity, when liver protein extracts of mouse mutants were analysed. Reduction of CerS2 WT 
protein level in Flox mice results also in reduced ceramide synthase activity. Furthermore, 
activity assays performed with extracts from CerS2H/A and CerS2Del mice showed increased 
activity against C16 and C18 acyl-CoAs, due to elevated protein levels of CerS5 and CerS6 
(Figure 5.16 B). Activity against C14 acyl-CoA remains unaltered (Figure 5.16 B). 
Additional Mass Spectrometry analyses of liver lipids from CerS2-WT, -Flox, -H/A and -Del 
mice indicate that the reduction of CerS2 protein in the genetic background of Flox mice has 
no impact on the sphingolipid levels (Figure A10). On the other hand, the loss of catalytic 
activity and/or protein in CerS2H/A and CerS2Del mice results in the depletion of very long 
chain ceramides, hexosylceramides and sphingomyelin (C22-24) as expected (Figure A10). 
Additionally, the depletion of C22-24 sphingolipids was accompanied by a significant increase 
in C16 (C18)- sphingolipid species and an increase in sphinganine (d18:0) levels (Figure A10). 
Moreover, these obtained results from CerS2H/A and CerS2Del mice are in line with previous 
findings from CerS2gt/gt mice (Imgrund et al., 2009). 
 
 
 
 
 
 
Figure 5.16: Analysis of Ceramide synthase activity in liver. (A) Quantitative analysis from NBD-
sphinganine based ceramide synthase activity assay performed with C22:0 or C24:1 acyl-CoA. Lipids were 
separated and detected on TLC plate, after termination of the reaction. (B) Quantitative TLC results based on 
protein extracts incubated with [4,5- 3H] sphinganine in combination with either C14:0-, C16:0 or C18:0 acyl-
CoA. Data are mean values (n=4, 3). Unpaired t-test, *P<.05; **<.01; ***P<.001 (Figure was taken from Bickert 
et al.,2018). 
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5.4.5 CerS2H212A/H213A and CerS2Del79-120 mice show altered 
transcriptome expression and reduced expression of genes involved in 
lipid metabolism 
In order to gain more insights into the pathophysiological alterations of liver in CerS2H/A and 
CerS2Del mice, transcriptome analyses were performed by Oaklabs on 80x60K Mouse Array 
XS chips (Agilent technologies). Total RNA extracts from liver of CerS2WT, Flox, H/A and Del 
mice (n=4 animals per genotype) were prepared by A. Bickert. Further processing of raw data 
was done in cooperation with Prof. Dr. Joachim L. Schultze (Bickert et al., 2018). The primary 
focus on the bioinformatic results is based on differential expressed genes between CerS2Flox 
(control) and CerS2H/A mice. Here, 1464 genes were up- and 265 down-regulated (Figure 5.17 
A and B). Additionally, differentially expressed genes were further analysed by Gene ontology 
(GO)-enrichment analysis, which allows clustering of genes in respect to cellular processes and 
molecular function they are involved in (Figure 5.17 C). The most prominent down-regulated 
genes belong to lipid metabolic processes, e.g. responsible for fatty acid synthesis (Figure 5.17 
C). Furthermore, these results are in line with previously generated qRT-PCR analyses, which 
showed decreased expression of genes involved in fatty acid- synthesis, - elongation and – 
transport as well as TAG synthesis (Figure A11). Additional analyses of up-regulated genes 
showed over-representation of those related to cell division and DNA conformational changes 
(Figure 5.17 B and C). 
 
 
 
Figure 5.17: Liver transcriptome analysis. (A) Hierarchical clustering of the 1000 genes, showing highest 
differential expression within the data set. (B) Vulcano Plot depicts comparison of 10 most differential down 
(blue) or up-regulated (red) genes between CerS2H/A and Flox mice. (C) GO-enrichment analysis of 
differentially expressed genes derived from the comparison of CerS2H/A and Flox mice. Numbers in brackets 
refer to the amount of genes enriched per GO-term. Blue depicts down- and red bars up-regulated genes. (n=4 
animals per genotype).(Figure adopted and modified from Bickert et al., 2018). 
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5.4.6 Energy metabolism 
5.4.6.1 Body weight and food intake is altered in CerS2H212A/H213A mice 
As it was discussed in the introduction (Chapter 1.6.1), CerS have been shown to be involved 
in the regulation of diet-induced obesity and their comorbidities. Moreover, recent findings 
suggest that the C16/C24 ceramide ratio could possibly serve as a new biomarker for the onset 
and progression of altered energy metabolism resulting in cardiovascular pathologies (Tippetts 
et al., 2018). 
To investigate a possible role of CerS2 and its catalytically inactivation under normal feeding 
conditions, CerS2H/A mice were investigated regarding body weight increase and food intake 
(Figure . CerS2WT and CerS2H/A mice were fed a normal chow (16.9% protein, 4.3% fat and 
4.3% fibres). Male mice, as well as female mice, were investigated separately to rule out sex-
dependent alterations. Measurement of body weight started with eight weeks of age; was 
determined once a week and carried out for eight weeks. Determination of food and water 
intake was performed daily for a period of 14 days. To avoid biased results concerning the 
experimental conditions (e.g. social separation), animals were acclimated to individual cages 
for five days prior to the beginning of the experiment. 
 
 
 
Figure 5.18: Analyses of weight gain and food intake. (A) Comparison of 12-week old WT and CerS2 H/A 
male mice. (B) Comparison of body weights from male and female mice. (C/D) Growth curve illustrating 
genotype-dependent differences in weight gain. Data were depicted as means (±SEM) of eight consecutive 
weeks, with three animals (n=3) per genotype and sex. (E) Average of food intake per day. (F) Average of food 
intake per gram mouse weight. (G) Average of water intake per day. E/F/G; Data were shown as means from 
individual experiments, means ±SEM; unpaired t-test; **P<.01; ***P<.001; WT, n= 3; H/A, n=3. 
 
The obtained results reveal that CerS2 H/A male, as well as female mice, show significantly 
reduced body size and body weight (Figure 5.18 A and B). Moreover, both genders show 
reduced body weight gain in comparison to their WT littermates (Figure 5.18). These findings 
are in line with reduced body sizes of analysed CerS2H/A and CerS2Del mice, and correlate in 
some points also with decreased tissue weights (Figure A8 B and C). Determination of food 
intake (g/day) revealed no differences between CerS2H/A male mice and WT control group 
(Figure 5.18 E). This is in contrast to the observed results from female mice. Here, CerS2H/A 
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female mice eat significantly more than the WT animals (Figure 5.18 E). Based on significantly 
reduced body weights obtained from CerS2H/A mice, we also determined the amount of food 
intake per gram mouse (g food/ g mouse). The results indicate that male mice take up 36 % 
more food per gram body weight than the WT animals (Figure 25, F). The same results were 
obtained for female mice (H/A), which eat about 15 % more than the control group (Figure 
5.18 F). Additional determination of water intake (ml/day) reveals also an increased 
consumption for CerS2H/A mice in comparison to WT mice (Figure 5.18 G). 
5.4.6.2 Storage lipid content and composition is altered in mutated mice 
Based on previous findings, e.g. altered food intake/water consumption of CerS2H/A mice, 
further investigations regarding the intestinal lipid absorption were performed. Additional 
analyses of the storage lipid content of liver, adipose tissue (WAT) and muscle were also done. 
 
 
Figure 5.19: Analyses of storage lipid contents. (A) Representative thin layer chromatography analysis of 
lipid extracts generated from feces and normal chow diet. (B) Quantitative analysis of intestinal lipid absorption 
(WT, n=3; H/A, n=3). (C) Quantification of liver storage lipids (n=6 quantified from two individual TLC plates, 
Bickert et al., 2018). (D) Quantification results obtained from adipose tissue (WAT). (E) Relative storage lipid 
content in muscle extracts. B/D/E, Data are means ±SEM, unpaired t-test; *P.5; **P<.01; ***P<.001. ( C) taken 
from Bickert et al., 2018)  
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Feces of male mice were collected once a week during the period of food (water) intake 
measurements (n=3). Lipid extracts were generated as described and separated on TLC plates. 
Values were depicted as relative amounts in comparison to diet lipid content and indicate 
several differences between CerS2WT and H/A mice (Figure 5.19). Here, 1,3 DAG and TAG level 
of feces extracted from CerS2H/A mice were significantly reduced in comparison to their WT 
littermates (Figure 5.19 A and B). In contrast, 1,2 DAG level was elevated in CerS2H/A when 
compared to WT control. FFA levels remain unaltered between WT and H/A mice. Relative 
amounts of cholesterol-ester and cholesterol were increased in feces of CerS2H/A mice (Figure 
5.19 A and B). 
Next, in comparison and consistent with the decreased weight gain of CerS2H/A mice they 
also showed alterations in adipose tissue and liver storage lipid content (Figure 5.19 C and D). 
CerS2H/A mice exposed a strong decrease in TAG, DAG and FFA levels in liver. Cholesterol-
ester and cholesterol level remain unaltered in liver of CerS2H/A mice (Figure 5.19 C). 
Investigation of adipose tissue showed, on the one hand, a strong reduction in tissue mass 
(Figure 5.19 A; Figure A8), followed by an altered lipid composition. Unexpectedly, TAG level 
was not altered in CerS2H/A mice, whereas DAG, FFA as well as cholesterol-ester and 
cholesterol levels were elevated in comparison to WT animals. 
Finally the storage lipid composition in muscle showed high variance, which does not reach 
significance in any of the quantified lipid species in CerS2H/A mice, i.e. lipid levels were not 
altered (Figure 5.19 E). 
 
5.4.6.3 Liver and adipose tissue of CerS2H212A/H213A mice exhibit altered cell size, 
decreased lipid droplet formation and loss of glycogen content 
In addition to investigations regarding the storage lipid content and coherent development of 
body size and weight, we performed histological analyses of WAT and liver. 
First of all, it was evident that CerS2H/A mice show a significant loss of adipose tissue mass 
(Figure 5.20 A; Figure A8). Further hematoxylin and eosin (H&E)-staining on cryo-sections of 
epididymal WAT indicate further differences between CerS2WT and H/A mice. Adipose tissue 
sections derived from CerS2H/A mice showed normal sized adipocytes interspersed with areas 
of multiple, smaller adipocytes, which were absent in WT control samples (Figure 5.20 C-E). 
Additionally, adipocytes of CerS2H/A genetic background showed significantly reduced cell 
diameter (WT: 75.5µm ± 2.29; H/A: 48.6µm ± 4.2, Figure 5.20 B), concomitant with higher 
density packaging (H/A: >100cells/ROI; WT: 36cells/ROI; Figure 5.20 B). 
Next, analysis of Oil-RedO-staining on liver cryo-sections of CerS2H/A mice were performed 
(Figure 5.21 A-D). Signals derived from the staining patterns highlighted reduced/ lack of lipid 
droplet formation in liver of CerS2H/A mice in comparison to their WT littermates. These 
findings are in line with the reduction in TAG content, quantified by TLC analyses (Figure 5.19 
C). Further verification of glycogen content of liver-paraffin-sections stained with periodic acid 
Schiff-(PAS)- reagent showed also strong reduction in PAS signal in CerS2H/A mice (Figure 
5.21, E-H). Here only few, but strong PAS-positive cells were scattered over the liver nodule. 
All other cells showed a rather pale, weak staining pattern. In contrast are the obtained staining 
signals of CerS2WT liver sections. Here, PAS-staining pattern showed the expected uniform 
distribution of glycogen content over the liver lobules (Figure 5.21 E / G). 
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Figure 5.20: Histological analysis of epididymal adipose tissue. (A) Photographs of representative eWAT 
morphology from CerS2WT and H/A mice. (B) Quantification of adipocyte diameter. Data shown as means 
±SEM (n=4, six cells measured per sample). Unpaired t-test, ***P<.001. (C-E) H&E-staining of eWAT derived 
from 12-week-old male mice. Genotypes and magnifications are indicated. Dotted scares in upper row depict 
the regions of magnification shown in lower row. Scale bars, 200x: 100µm; 600x: 50µm. Abbreviation: eWAT- 
epididymal white adipose tissue. 
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Figure 5.21: Histological analysis of liver sections. (A-D) Oil Red O staining performed in liver sections from 
CerS2WT and H/A mice. (C/D) Magnification of dotted square highlighted in A) and B). WT hepatocytes show 
intracellular lipid droplet accumulation, which is lost or rather strong decreased in hepatocytes of CerS2H/A 
mice. (E-H) Shown are glycogen (PAS) stainings of liver sections from CerS2WT and H/A mice. (E/F) Dotted 
squares represent areas of higher magnification shown in G) and H). (E/G) Hepatocytes show strong PAS-
positive staining, which depicts high glycogen content. (F/H) Hepatocytes show pale. Weak PAS-positive signals 
indicating low glycogen content.  Scale bars correspond to: A/B, E/F: 50µm, C/D, G/H: 20μm. 
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5.4.7 Histological analysis of CerS2H212A/HA213 (and CerS2Del79-120) mice 
indicate alterations in the tissue architecture of some organs 
Detailed investigations concerning the cell-type specific expression pattern of the CerS2 
protein were already performed for most of the tissues on the basis of CerS2gt/gt mice, in 
combination with the application of a highly-specific custom-made anti-CerS2 antibodies 
(Imgrund et al., 2009; Kremser et al.,2013). It was shown that CerS2 is expressed in hepatocytes 
(liver), oligodendrocytes and glial cells (brain), in the respiratory epithelium and pulmonary 
alveoli of the lung as well as in the renal corpuscle and proximal tubular cells of the kidney. 
The following histological investigations, in addition to those of chapter 5.4.6, were performed 
with the aim to verify, whether previous findings could be transferred to the newly generated 
CerS2H/A and Del mice. Tumor formation analyses of 8-week-old mice were done in 
cooperation with Prof. D. Hartmann (Bickert et al., 2018). 
5.4.7.1 Liver of CerS2H212A/H213A and CerS2Del79-120 mice showed loss of liver 
architecture and early onset of tumor formation 
Gross anatomy of liver tissue extracted from 20-week-old CerS2H/A or WT mice does not 
indicate any morphological differences (Figure 5.22 A). Organs show the same structural 
architecture composed of four lobes. Detailed H&E stainings performed on PFA-sections of 
20-week-old mice indicate that livers of CerS2H/A (Del, data not shown) mice were 
characterised by several alterations in contrast to their WT littermates, where no 
histopathological changes of liver architecture were observed (Figure 5.22 B-I). Hepatocytes of 
WT control livers showed the typical arrangement in one-cell-layer thick plates, which were 
separated by sinusoids (Figure 5.22 D and F). Furthermore, the overall architecture of liver 
lobes showed classical shape with a central vein and portal fields (portal vein, hepatic artery 
and bile duct) at the periphery (Figure 5.22 D and F). Moreover, WT hepatocytes are roughly 
polyhedral shaped, containing one or two nuclei. The cytoplasm of all hepatocytes showed 
equal appearance with typical glycogen and lipid-rich content (Figure 5.22 B and C). These 
findings are in contrast to that found in CerS2H/A (and Del) mice. Here, one cell-layer thick 
plates of hepatocytes were irregularly interspersed by cells or cluster of cells, which lack 
sinusoids (Figure 5.22 F/G/I). Additionally, sections indicate a glycogen and lipid-free cell-
content and pale-stained cytoplasm (Figure 5.22 G and H). Moreover, hepatocytes found in 
CerS2H/A mice showed a significant reduction in diameter compared to WT control and on 
the other hand enlarged and irregular stained nuclei (Figure 5.22 B and C). 
In the following step, the presence of tumor cells was also confirmed by proliferating-cell-
nuclear-antigen (PCNA) staining. Sections showed enriched PCNA-positive nuclei in CerS2H/A 
mice (Figure 5.23 A-C). Results were also confirmed by a high expression level of beta-catenin, 
a prominent marker of hepatic tumorigenesis (Figure 5.23 D). All these findings indirectly 
indicate by high expression of either PCNA or beta-catenin a loss of normal liver architecture 
and point out to an onset and development of hepatocellular carcinoma in CerS2H/A mice. 
Analyses of CerS2Del mice showed comparable differences in liver architecture as those found 
in CerS2H/A mice (Bickert et al., 2018). First, Oil-Red O and PAS- staining performed on live -
sections revealed the same loss of lipid droplets and lack of glycogen content as found in 
CerS2H/A mice (data not shown). Findings regarding altered cell morphology and nuclei 
diameter of CerS2Del hepatocytes are in line with those found CerS2H/A mice (data not 
shown). Verification of the tumor marker ,PCNA and beta-catenin, revealed also increased 
expression, which lead to the assumption that CerS2Del mice are as well characterized by an 
early onset of liver-tumor formation (Figure 31, A-D). 
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Figure 5.22: Hepatic histopathology in 20-week-old CerS2H/A mice (H&E stainings). (A) Gross anatomy 
of liver from CerS2WT and H/A mice. (B) Representative pictures of liver sections used to determine the 
diameter of hepatocytes and their nuclei. Graphs depict quantification of hepatocyte diameter found in WT and 
H/A mice or determination of nuclei diameter, which differentiates between mononuclear (MN) and bi-nuclear 
(BN) hepatocytes. Data shown as means ±SEM (hepatocytes: n=3, ten cells measured per sample; Nuclei: n=3, 
ten nuclei per group (MN/BN), per sample were measured). Unpaired t-test, ***P<.001. (C/D) Overview of portal 
fields from WT and H/A mice. Portal field composed of central vein, artery (A) and bile duct (BD).         (E) WT 
liver section, showed normal architecture and distribution of hepatocytes in one-cell layer thick plates. (F) 
Overview of liver section from CerS2H/A mice. Normal hepatocytes (white asterisk) were interspersed with 
hepatocellular carcinoma cells (white dotted line), which results in loss of liver architecture. (G/H) Magnification 
of dotted areas in D) and E). (G) Glycogen- and lipid-rich hepatocytes show roughly polyhedral shape with 
marginal positioned cytoplasm. (H) Altered H/A-liver architecture is depicted by loss of typical morphology of 
hepatocytes, lack of lipid and glycogen-droplets as well as enlarged nuclei diameter.  
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Figure 5.23: Analysis of tumor markers in CerS2WT, Flox, H/A and Del mice. (A) Liver sections were 
stained for the presence of proliferator cell nuclear antigen (PCNA). In WT and Flox showed rare PCNA-positive 
nuclei in contrast to H/A and Del mice. (B) Beta-Catenin staining of liver sections. Arrows indicate regions of 
high expression. (C) CerS2WT liver sections stained with anti-beta-catenin antibodies. Resulting signal are 
restricted to the membranes of hepatocytes (arrows). CerS2H/A mice showed additional cells showing beta-
catenin signals in the cytoplasm (arrow). (D) Immunoblot analysis of PCNA and beta-catenin protein expression 
in liver. Data are means ± SEM, normalized to GAPDH (PCNA) or PDH (beta-catenin); n = 3; Unpaired t-test, 
*P<.05; **P<.01. Scale bars correspond to: A) 25μm, B) 500µm, C) 25µm. (Figure adopted and modified from 
Bickert et al., 2018).  
5.4.7.2 CerS2H212A/H213A mutation does not influence splenic architecture but 
alters glycogen content and macrophage presence 
In the next step, we analysed overall architecture as well as glycogen and macrophage content 
of spleen from CerS2H/A mice. In general, the spleen is not only responsible for clearing blood 
from circulating particles and aged erythrocytes, it also plays an important role as a peripheral 
lymphoid tissue (Grossi & Lydyard, 1998). Initially, histological analysis of H&E staining 
performed on PFA-sections of spleen from CerS2H/A and WT mice showed no differences in 
the overall architecture (Figure 5.24). Both showed the typical separation into red and white 
pulp with interspersed trabeculae (Figure 5.24 A and B). Additional PAS-staining indicated 
decreased PAS-signal in the sub-capsular zone and red pulp of CerS2H/A mice (Figure 32, 
C/D). Immunohistochemical staining performed with an anti-F4/80 antibody indicate also 
reduced F4/80 positive signal (macrophages) in the red pulp of CerS2H/A mice in comparison 
to sections from WT animals (Figure 5.24 E-H). 
Subsequently, the thymus was also examined, which is another important immunological 
organ, since it is the place of thymocyte maturation. Semi-thin sections either stained with H&E 
or F4/80 do not indicate any alterations (data not shown). Thymi of both genotypes show a 
typical architecture/distribution of cells, with larger pale-red stained cells in the medulla and 
dark-blue positive cells in the cortex. H&E staining does not allow differentiation between B-
cell and T-cell content in the cortex. Additionally, no differences were detected in the 
distribution and content of macrophages (F4/80 staining) in any of the analysed CerS2WT or 
H/A thymi sections.  
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Figure 5.24: Histological analyses of spleen. (A/B) H&E staining of PFA-fixed spleen sections derived from 
CerS2H/A and WT mice. Main structural components were highlighted. (C) PAS staining shows strong positive 
signals (yellow circle) in the sub-capsule region and red pulp of WT sections. (D) PAS staining of spleen from 
CerS2H/A mice shows a reduction in PAS-positive signals in the sub-capsular region and the red pulp. (E/F) 
Immunhistochemical staining of F4/80 positive cells. (G/H) Magnification of white dotted square from G and H. 
(G) Strong F4/80 positive signals detected in red pulp. (H) Pale, weak staining of F4/80 positive cells in red pulp. 
Abbreviations: C-capsule; T- trabeculae; RP-red pulp; WP- white pulp. Scale bars correspond to: A/B and E/F 
bar) 100μm, C/D and G/H white bar) 50μm.  
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5.4.7.3 Kidney of CerS2H212A/H213A mice showed reduced glycogen storage 
The kidney is a bilateral organ and involved in the regulation of blood pressure (fluid level), 
waste excretion and reabsorption of nutrients, e.g. of glucose, amino acids, and water. 
The next step was to identify, whether the ablation of catalytic activity of the CerS2 protein and 
the corresponding lack of specific ceramide/sphingolipid species cause alterations of the 
kidney architecture thereby affecting glycogen content. Initially the overall architecture, 
investigated by H&E staining, showed no alterations between CerS2H/A and WT mice (Figure 
5.25 A and B). Differences become only obvious in PAS stainings performed on PFA-sections, 
as expected. Here, the proximal convoluted cells from CerS2WT mice show the typical strong 
PAS-positive signal of the brush border (microvilli), as well as PAS-positive signals of basement 
membranes of the glomeruli. This is in contrast to the obtained pale and weak signals in 
sections of CerS2H/A kidneys (Figure 5.25 C-F); indicating reduced glycogen content or 
possibly altered morphology of those cells. Again, these results are consistent with recent 
findings found in liver and spleen. 
 
Figure 5.25: Histological analyses of kidney. (A/B) H&E-staining of kidney sections depict typical 
architecture. Structural components were highlighted. (C/D) PAS-staining of PFA-sections obtained from WT 
and CerS2H/A mice. (E) Magnification of C. (F) Higher magnification indicates pale, weak staining of kidney 
cells (PC) and glomeruli in CerS2H/A mice. G- Glomerulus, DC- distal convoluted cells, PC- proximal convoluted 
cells. Scale bars correspond to: C/D) 200μm, E/F) 100 μm.  
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5.4.7.4 Histological analysis of large intestine (colon) indicate no differences between 
CerS2H212A/H213A and WT mice 
Previous analysis regarding the storage-lipid content of feces derived from CerS2H/A mice 
indicated alteration in the composition (Chapter 5.4.6.2). To verify if these alterations are based 
on an altered histology of the intestine, we investigated colon sections of several CerS2H/A 
and WT mice. After PFA-fixation, sections were either stained with H&E or PAS (Figure 5.26). 
Analyses of those showed no alterations in overall architecture nor mucine content (heavily 
glycosylated protein) (Figure 5.26 A-D). Here, CerS2H/A and WT animals show typical 
structural organisation of the colon and strong mucine content in goblet cells as expected 
(Figure 5.26, E-H). Whether the sub-cellular structure (e.g. protein composition of the 
plamamembrane) is disturbed to some extend cannot be clarified with the preformed 
stainings. For this reason, it would be appropriate here to conduct in-depth analysis by means 
of electron microscopy. Based on these findings, we initially assume that the uptake of 
nutrients is not altered. 
 
Figure 5.26: Histological analyses of colon sections. (A/B) H&E staining of PFA-fixed colon-sections derived 
from CerS2H/A and WT mice. (C) Magnification of A). (D) Magnification of B), no alterations were observed 
between the two genotypes. Structural components are indicated; V-microvilli, G-goblet cells, L-lamina propria. 
(E/F) PAS-staining of WT and CerS2H/A colon sections. (G) Higher magnification of E). (H) Magnification of F). 
Rich glycogen-content of goblet cells is stained in purple. No differences were obtained between WT and 
CerS2H/A sections. Scale bars correspond to: A/B and E/F bar) 100μm, C/D and G/H white bar) 50μm.   
Results  
83 
5.4.8 Immune status of CerS2H212A/H213A mice 
5.4.8.1 Background and introductory remarks 
The adaptive immunity (differentiation between self and non-self) depends on the presence 
of lymphocytes, e.g. on an ever-changing TCR (T cell receptor) repertoire, that is produced by 
the maturation of new T cells in the thymus as it was described in the introduction (Chapter 
1.7.2). Recent studies revealed that emigration of terminally differentiated thymocytes from the 
thymus into the circulation (periphery) occurs along an S1P (sphingosine-1-phosphate) 
gradient and is suggested as a two-stage process. Briefly, thymocytes undergo a differentiation 
and maturation process which leads to the up-regulation of CD62L (L-selectin, cell adhesion 
molecule) and S1PR1 (sphingosine 1 phosphate receptor 1), among other surface markers. 
Finally, single positive thymocytes migrate into the perivascular space, by passing the 
basement membrane of the surrounding blood vessel from where they enter the bloodstream 
(Figure 8). 
As it was hypothesized and proven for CerS2gt/gt mice, the maintenance of the S1P gradient 
between the thymus, blood and peripheral tissues, e.g. spleen, lymph nodes, is essentially 
necessary and the main key player in the facilitation of thymic egress of single positive 
thymocytes (Rieck et al., 2017). 
In the following section of the present study, analyses were performed to verify, whether these 
findings could be transferred to the newly generated CerS2H/A mice. Detailed investigations 
of the efficiency of thymic egress as well as quantitative measurements of single positive T cells 
in blood and spleen were done. It is also worthy of note, that the reduced body size of 
CerS2H/A mice (Figure 5.27, Figure A8) could have an influence on the absolute cell numbers, 
which are integral parts of the calculations and results. To overcome this bias, cell counts of 
wild type control mice and of respective H/A mutated animals were represented in different 
outputs (Figure 5.29). First, as frequencies or unmodified numbers (cell count/raw data). 
Second, as weight-corrected numbers, which were normalized to the average of mouse 
weights of wild type and H/A mice (cell count per g mouse, weight-corrected data). 
Furthermore, it should be remarked that the results are based on analysis exclusively 
performed with male mice to rule out gender/hormone-specific phenotypes. Additionally, we 
also analysed Flox mice to exclude that the reduced CerS2 protein expression influences the 
thymic egress. The results reveal that Flox mice behave like wild type mice. From this point of 
view, we conclude that the remaining CerS2-WT-protein level is sufficient to maintain the S1P 
gradient in those mice. 
5.4.8.2 CerS2H212A/H213A mutation affects thymic egress of single positive 
thymocytes 
First, to verify if the CerS2H/A mice show the same deficiency in emigration like the CerS2gt/gt 
mice, flow cytometry analyses were performed. Therefore, cells of thymi from wild type, Flox 
and H/A mice were isolated and frequencies as well as total numbers of immature and mature 
single positive thymocytes determined (Figure 5.27, 5.29). Immature cells still need to undergo 
the process of negative selection and are not allowed leaving the thymus in comparison to the 
terminally differentiated, mature single positive T cells. Furthermore, mature single positive T 
cells express the S1PR1 receptor which enables them to migrate along the S1P-gradient. The 
different expression of the surface markers CD62L and CD69 were used to discriminate 
between immature (CD62Llow/CD69high) and mature (CD62Lhigh/CD69intermediate) T cells (Figure 
5.28).  
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Figure 5.27: Characteristics of CerS2H/A mice. (A) Body weights of male wild type (WT, n=9), Flox (Flox, 
n=3) and CerS2 H/A (H/A, n=9) mice at middle age (10-17 weeks). Weight is significantly reduced in CerS2H/A 
male mice. (B/C) CerS2 H/A mutation does not result in reduced thymi weight (n=3, ±SEM), nor reduced total 
thymocyte counts (WT, n=9; Flox, n=3; H/A, n=9; ±SEM). (D/E) Catalytically inactive CerS2 (H/A) protein does 
not influence the spleen weight as well as the total cell counts. (D: WT, n=5; H/A, n=5; ±SEM. E: WT, n=9; Flox, 
n=3; H/A, n=8; ±SEM.). (F) Total PBMCs/ml blood is not altered in CerS2H/A mice (WT, n=6; Flox, n=3; H/A, 
n=6; ±SEM). Dots represent individual mice; wild type, white dots; Flox, grey dots; H/A, black dots. Data were 
pooled from individual experiments. Unpaired t-test, ***P<.001. 
 
 
 
Figure 5.28: Thymi flow cytometry plot. Representative overview of flow cytometric identification of immature 
(CD62LLow/CD69high) and mature (CD62Lhigh/CD69intermediate) CD4+/CD8- and CD4-/CD8+ thymocytes of male WT 
and H/A mice. Numbers indicate percentages of subpopulations within the parental gate. DN, double negative; 
CD8+ (ISP-immature single positive /CD8 SP), CD8 positive cell population composed of CD8+ single positive 
cells and CD8 positive, CD3low cells; CD4SP, CD4 single positive cells, DP double positive.  
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Initially, the determination of thymi weight revealed no significant differences (Figure 5.27 B) 
despite the altered body weight (Figure 5.27 A). Furthermore, the number of total thymocytes 
was also not altered (Figure 5.27 C). Flow cytometric analyses showed that the presence of a 
catalytically inactive CerS2H/A protein in male mice lead to a significant increase in the 
frequency, counts and numbers of mature CD4+/CD8- thymocytes (Figure 5.29 A). In case of 
CD4-/CD8+ thymocytes significant differences were detectable in frequencies; whereas counts 
(raw data) and absolute numbers (weight corrected data) show a tendency of accumulation 
which does not reach significance, upon high variability (Figure 5.29 B). Numbers and weight 
corrected cell counts of immature thymocytes were not affected. Next, quantitative analysis 
regarding the frequency of immature thymocytes of the CD4+subpopulation was significantly 
decreased, whereas immature CD8+ cells were not affected (Figure 5.29 A and B). 
 
 
 
 
Figure 5.29: CerS2H/A-modified mice showed selective accumulation of mature thymocytes. (A) 
Frequencies, counts (raw data) and weight corrected data revealed significant increase in mature single positive 
CD4+/CD8- cells. (B) Frequencies of mature CD8+/CD4- thymocytes show a significant increase. Significance 
is lost after weight correction. (A/B) Frequencies and counts (raw data) of respective single positive cells were 
determined by flow cytometry. For calculation of weight corrected data, total counts of the subpopulation of 
interest was normalized to the corresponding thymi weight/ average of thymi weight (WT). Bar graphs represent 
means ±SEM, dots in scatter plots represent individual mice (unpaired t-test; *P<.05, ***P<.001; WT, white bars, 
dots, n=8; Flox, grey bars and dots, n=3; H/A, black bars and dots, n=7)). (Remark: CD8+ mature, counts 
P=0.1356; CD8+ mature, weight corr. P=0.2059.) 
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5.4.8.3 CD69 surface expression is altered in CerS2H212A/H213A mice 
CD69 and S1PR1 mutually antagonize each other upon transcriptional regulation (Zamora-
Pineda et al., 2016; Saba et al., 2017), i.e. the up-regulation of one cell surface protein leads to 
the down-regulation of the other one. Under normal conditions, CD69 expression is low on 
mature thymocytes, whereas the S1PR1 expression is high, which in turn enables the cells to 
migrate along the S1P gradient and leave the thymus. Based on these considerations and on 
the lack of an adequate antibody for the determination of S1PR1 on the cell surface for flow 
cytometric analysis, we measured the expression level of CD69 as an indicator for S1P/ S1PR1 
(Figure 5.30). 
The results clearly demonstrate that the expression level of CD69 on the cell surface, of both 
CD4+ and CD8+ mature thymocytes, is significantly down-regulated (Figure 5.30 A and B). 
Based on these findings and on the lack of quantitative SP1 measurements, we can only assume 
that the surrounding microenvironment contains either (I) higher amounts of S1P in the H/A 
mutant mice than in the wild type littermates or (II) the T cell development is somehow affected 
which causes the unequal expression of CD69. To exclude an impaired T cell development, we 
preceded with further flow cytometric analyses based on the surface marker CD25 and CD44. 
 
 
 
 
Figure 5.30: CD69 surface expression on thymocytes. CerS2H/A mutation lead to reduced CD69 surface 
expression on mature thymocytes. Thymocytes from indicated genotypes were analysed by flow cytometry and 
CD69 expression depicted as mean fluorescence intensity. CD69 MFIs of immature and mature CD4+/CD8- (A) 
and CD4-/CD8+ (B) respectively were normalized to expression on wild type controls. Data were pooled from 
individual experiments, means ±SEM; unpaired t-test; **P<.01; ***P<.001; WT, n= 8; Flox, n=3; H/A, n=8. 
 
5.4.8.4 Early T cell development is not affected in CerS2H212A/H213A male mice 
The T-cell development describes a tightly controlled process and any malfunction during the 
different stages can cause server diseases like autoimmunity, immunodeficiency and cancer as 
it was extensively discussed in the introduction (see Chapter 1.7). First, bone-marrow-derived 
progenitors migrate into the thymus, where they build up the thymocyte cell population and 
differentiate to mature single positive naïve T-cells. The development (TCR gene configuration) 
starts with the double negative (DN) stage which can be further subdivided into DN1  DN2 
 DN3  DN4 (Figure 5.31 A). Many surface markers were expressed during each stage and 
can be monitored. Here we used the CD25 in combination with the CD44 marker to identify 
cells of each developmental stage (Figure 5.31 A and B) (Hager-Theodorides et al., 2007).  
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Flow cytometry analyses revealed that the mutation of CerS2’s catalytic activity has a negligible 
impact on the T cell development in male mice. The overall frequency, counts and weight 
corrected numbers of DN cells showed no significant changes between wild type and 
CerS2H/A male mice (Figure 5.31 C, left chart). Interestingly and despite the normal DN values, 
analysis of subpopulations DN1 to DN4 showed striking differences. The counts and weight 
corrected counts for DN1 revealed a significant loss of DN1-cells in H/A mice. Furthermore, 
DN2 cells showed a strong decrease in cell counts (P=0.1401) and weight corrected cell counts 
(P=0.0563) but does not reach significance (Figure 5.31 C, middle). Reduction in cell counts of 
DN3 subset reached only significance after weight correction (Figure 5.31 C, right chart). Cells 
counts and weight corrected cell counts of DN4 subset were also decreased but do not reach 
significance (Figure 5.3). 
Additional quantification of double positive (CD4+/CD8+) cell amounts was performed to 
determine whether this mild loss of cells will continue or gain strength with further 
differentiation (Figure 5.31 D). Basically, no difference in frequency, counts and weight 
corrected numbers of double positive (DP) cells were detectable between wild type mice and 
their H/A littermates; pointing out that T cell development and differentiation is unaffected in 
H/A male mice and does not contribute to the accumulation of single positive thymocytes. 
 
 
 
Figure 5.31: T-cell development in CerS2 H/A male mice is not affected by its catalytically inactivation. 
(A) Overview of the differentiation stages of bone-marrow-derived-T-lineage progenitors to mature, naïve T-
cells. Differentiation starts with DN1 stage (CD44+/CD25-). Further differentiation reveal up-regulation of CD25, 
Results  
88 
DN2 stage (CD44+/CD25+). DN3 is characterized by TCRrearrangement and down-regulation of CD44. DN4 
(CD44-/CD25-) end up in DP (double positive, CD4+/CD8+) which undergo further TCR rearrangement and 
develop to terminally differentiated SP (single positive), naïve T-cells (CD4 (MHCII) or CD8 (MHCI)). (B) 
Representative overview of flow cytometric identification of lymphocytes from thymi (left section, CD4+ vs CD8+) 
and expression of CD44 and CD25 of double negative subpopulation (left). (C) Quantification of frequencies, 
counts and cell numbers of different thymi-DN subsets. DN1 show significantly reduced counts and numbers of 
cells. (Data were pooled from individual experiments, means ±SEM. Dots in scatter plot depict individual mice; 
unpaired t-test;*P<.05; **P<.01; ***P<.001; WT, n= 5; H/A, n=3.) (D) Quantification of frequencies and cell 
numbers from DP cells. Analysed subpopulation reveals no difference. Data were pooled from individual 
experiments, means ±SEM; WT, n= 7; Flox, n=3; H/A, n=7. 
 
5.4.8.5 CerS2H212A/H213A mice develop a mild T cell lymphopenia 
 
 
 
Figure 5.32: Quantification of T cell content in spleen and blood. (A) Representative flow cytometry 
analyses of T cells in spleen. (B) Quantification of counts (left chart, raw data) and total numbers (right chart, 
weight corrected data) of CD4+ and CD8+ T cells in the spleen. (WT, n=9; Flox, n=3; H/A, n=9). (C) 
Representative picture of flow cytometry results obtained from T cell analysis of blood. (D) Quantification of 
frequencies and counts of single positive T cells in blood. Frequency of H/A mice reveal reduction in single 
positive T cells (left chart). Weight correction of total number showed reduced T cell content which does not 
reach significance (right chart). Data were pooled from individual experiments, means ±SEM. Each dot in scatter 
plot depicts individual mice; WT, n= 5; Flox, n=3; H/A, n=5. 
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The next step was to identify if the accumulation of egress-competent T cells in the thymus 
leads to a decreased amount of circulating naïve T cells in the periphery (blood/PBMCs) and 
lymphoid tissue (spleen). Here, a reduced number of T cells (T cell lymphopenia) could cause 
severe infections of CerS2H/A mice due to limited immune response mediated by the adaptive 
immune system. Based on these considerations, cells were first subdivided upon the expression 
intensity of CD3 and B220 on the cell surface (Figure 5.32 A). CD3high-expressing cells were 
further analysed regarding the expression of CD4 and CD8 (Figure 5.32 A). 
The organ weight, as well as, the total cell number of splenocytes, is not affected by the 
expression of the mutated CerS2H/A protein (Figure 5.32 D/E). These results are consistent 
with findings from total cell numbers of PBMCs (blood, Figure 5.32 F.), i.e. no alterations were 
observed. Further flow cytometry analyses of splenocytes reveal a mild reduction in the 
frequency of CD3high positive cells, which does not reach significance (Figure 5.32 B). Further 
sub-gating of CD3+ cells, regarding the expression of CD4 and CD8, indicate that counts and 
weight corrected cell counts show a reduction of CD8+ T cells, whereas CD4+ T cells were not 
affected (Figure 5.32 B). 
In contrast, the overall immune cell composition of isolated PBMCs is affected by alterations 
in thymic egress of single positive T cells (Figure 40, C/D). Here, frequencies of T cells were 
significantly reduced, in contrast frequencies of double negative cells (CD3low/CD19low) 
increased, whereas frequencies of B cells remain unaffected (Figure 40, D left graph). 
 
In summary, the present results indicate that the reduced body weight of CerS2H/A mice 
neither has an influence on the organ weight of the thymus or spleen, nor on the number of 
total cell counts. Furthermore, CerS2H/A mice show a significant increase of mature CD4+ and 
CD8+ thymocytes. The accumulation is not based on altered differentiation or developmental 
delay, since counts and weight corrected numbers of double negative/positive cells were not 
affected. Furthermore, the accumulation of T cells in thymus causes a mild reduction in T cell 
content in the periphery (spleen, blood). Moreover, CerS2H/A-mature-single-positive 
thymocytes are characterized by reduced CD69 surface expression levels. These findings 
strongly suggest an altered S1P gradient between the thymus interstitium and blood, since up-
regulated S1PR1 expression mutually antagonizes CD69 surface level. All findings indicate the 
presence of a mild peripheral T cell lymphopenia and are in line with previous findings from 
CerS2gt/gt mice. 
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6 Discussion 
CerS2, a member of the mammalian CerS family (CerS1-6), describes a key enzyme in 
sphingolipid metabolism, which catalyses the production of C22-24 ceramides. Additionally to 
the TLC (TRAM-Lag-CLN8) domain, harbouring the lag1 domain, which essential for catalytic 
activity (Spassieva et al., 2006; Tidhar et al., 2012), CerS2 is characterized by the presence of a 
further domain, the homeodomain. So far, not much is known about the structure and 
orientation as well as the detailed function and molecular mechanisms facilitated by the 
homeodomain in mammals (Mesika et al., 2007; Voelzmann, 2013). Additionally, it is already 
known from recent publications and experiments performed by the Willecke lab (Imgrund et 
al., 2009; Kremser et al. 2013) and Futerman-group (Pewzner-Jung et al., 2010 i/ii) that CerS2 
is ubiquitously expressed. More precisely, results verified expression of CerS2 in hepatocytes 
(liver), oligodendrocytes and glial cells of the brain, in the respiratory epithelium and 
pulmonary alveoli of the lung, as well as in the renal corpuscle and proximal tubular cells in 
kidney, but also to a lower extent in thymus and spleen (Kremser et al., 2013; Kremser, 2016). 
Upon deletion of CerS2, i.e. the loss of catalytic activity, mice lack C22/24/24:1 ceramides and 
sphingolipid species and possibly drives the (compensatory) increase in C16/C18 ceramide 
species. Moreover, CerS2-deficiency results in the development of severe phenotypes, e.g. 
demyelination of neurons in the CNS its comorbidities and development of hepatocellular 
carcinoma (Imgrund et al., 2009; Pewzner-Jung et al., 2010 i/ii). Again, all these findings were 
obtained in mice, which completely lack CerS2-protein expression. Based on that it is nearly 
impossible to distinguish, which of the upcoming phenotypes and alterations are based in the 
loss of catalytic activity (C24-ceramides) and which are a consequence by loss of proper 
homeodomain function. To further investigate the in vivo function of the lag1 motif and the 
homeodomain independently from each other, we aimed to deplete catalytic activity and on 
the other hand, we tried to abolish homeodomain interaction. Therefore, the conditional 
transgenic mouse lines CerS2H212A/H213A and CerS2Del79-120 were established. 
6.1 Bioinformatics analysis and basic experimental setup (CerS2) 
6.1.1 CerS2 – Orientation, Transmembrane topology, and Domain structure 
The successful generation of two conditional mouse lines emphasises the need to understand 
the protein structure and topology, besides the knowledge of how CerS2 might be post-
translational regulated. However, not much is known about the possible orientation of the 
CerS2 protein, its putative 2D-/ 3D-structure and the correct number of transmembrane 
domains and the common knowledge is based on sequence alignments and homology 
prediction analyses. All those findings as well as findings from publication of in vitro 
experiments, performed with all ceramide synthases, resulted in the generation and 
investigation of different CerS2-overexpression constructs to unravel, which targeted mutation 
might be most suitable for following in vivo analysis. 
Posttranslational modifications and localisation of the termini 
First, N-glycosylation prediction tools identified amino acid residue 19(N) and residue 81(N) to 
be possibly glycosylated. Overexpression of CerS2-WT-V5/His and CerS2Del79-120 with 
subsequent PNGaseF treatment of the generated protein lysates resulted in a band shift, i.e. 
reduced mass, for the WT and Del constructs. Based on these results we concluded that both 
proteins were glycosylated. Additionally, a previously tested CerS2Del74-96 construct showed 
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also the ability to be glycosylated (data not shown; van Uelft, 2012). All these constructs have 
a common feature, the lack of amino acid residue 81 and retention of aa19 (N). For that reason, 
it was supposed that only aa19(N) gets glycosylated and not aa81(N). This assumption is further 
strengthened by the loss of nearly the same mass (~3 kDa) in immunoblot analyses in all 
PNGaseF treated protein lysates in comparison to the CerS2WT construct, i.e. counting for only 
one glycosylation site within the protein. Additional generation of an N19Q-CerS2-V5/His 
construct could also further clarify that position 19(N) is glycosylated, since protein extracts 
from overexpressing cells showed a reduced mass in comparison to WT control and treatment 
with PNGaseF does not result in further band shift (data not shown). Ceramide synthase activity 
assay performed with protein lysates from N19Q-CerS2-/ CerS2-WT-V5/His expressing cells, 
showed equal synthase activity, strengthen the assumption that glycosylation is not necessary 
to maintain catalytic activity. These findings were also supported by Mitzutani (2005) where he 
could show that CerS2-(N19Q) is characterized by a, lack of glycosylation, but nothing was 
mentioned about the influence on catalytic activity. Additionally, they could also show that 
CerS5 and 6 were glycosylated in the N-terminus and that loss of glycosylation in CerS6 does 
not negatively influence catalytic activity, which is in line with our findings (Mitzutani et al., 
2005). Taken together these findings also indirectly indicate the localization of the N-terminus 
of CerS2. More precisely, until now no cytoplasmic glycosylation complex has been identified, 
implying that N-terminus has to face the ER-lumen, where to this days the N-glycosylation 
enzymes are located (Stanley et al., 2017). 
Moreover, it was shown by Sassa and collaborators that the mouse as well as human CerS2, 
protein can be C-terminally phosphorylated (S341, T346, S348, S349) and that phosphorylation 
is facilitated by the action of protein kinase CK2 (casein kinase 2; Sassa et al., 2016). 
Furthermore, they could show that lack/degree of phosphorylation influences catalytic activity. 
This interesting fact implicates a further indirect hint concerning the C-terminal localisation. 
Filhol (2003) and Bibby & Lichtfield (2005) identified that the two different subunits () of 
CK2 show either cytoplasmic or nucleocytoplasmic localisation (Filhol et al., 2003; Bibby & 
Lichtfield, 2005). These findings lead to the conclusion that aa341-349 at the C-terminus face 
the cytoplasm, where they are easily accessible for CK2. This, in turn, also implicates that CerS2 
must have an uneven number of transmembrane domains (5 or 7). Unfortunately, this 
assumption could not be further confirmed by transmembrane domain (TMD) prediction 
analyses, due to inconsistent results predicting, five, six or seven TMDs. 
Localisation and function of the homeodomain of CerS2 
Regardless of previous findings, all collected data were re-evaluated regarding the localization 
of the homeodomain within the protein. As a result of these investigations, we can hypothesize 
that the homeodomain is localized between the first and second transmembrane domain. 
Additional findings obtained by homology prediction analyses reveal also that the 
homeodomain of CerS2 has the same probability to adopt a 3D-structure composed of three 
alpha helices, like CerS5 and 6. As this helix-turn-helix motif, where each alpha helix is 
connected by a loop to the following, is a common feature of transcriptional regulators, we 
further assume that CerS2 might regulate the expression of certain genes. However, the 
homeodomain of CerS2,5 and 6 might slightly differ from those of homeotic genes, since some 
alignment analyses predict that the first 15 amino acid residues of the consensus sequence 
may be missing (Levy et al., 2010; Voelzmann, 2013). On the other hand, our considerations 
are in line with recent findings from our group (Sociale et al., 2018). Sociale et al. could show 
that the homeodomain of schlank, the ceramide synthase in the fruit fly, adopt a 3x -helix-
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conformation. Furthermore she also showed that the NLS2 motif within the third alpha helix is 
able to interact with the promoter region of lipase 3. Even more detailed investigations further 
confirmed that the homeodomain of CerS2 is also able to interact with the promoter region 
of lipase 3, when overexpressed in S2 cells. Furthermore, re-expression of CerS2-WT in the fat 
body of KINLS2-mutant flies repressed lipase3 expression and restores the endogenous 
situation to some extent (Sociale et al., 2018). Unfortunately, this current data could not have 
been taken into considerations of generating homeodomain-deletion constructs, since they 
have been made several years ago. 
6.1.2 CerS2 expression vectors for in vitro experiments 
In order to study the functions of the lag1 domain and those of the homeodomain 
independently from each other, bioinformatics analyses (e.g. sequence alignments) supported 
the information, necessary for the generation and testing of different mutation. The different 
constructs (Figure A5) were transiently transfected into HEK 293T cells or immortalized cers2-
deficient MEFs. Overexpression was verified via immunofluorescence analyes of fixed cells, 
immunoblot analyses of protein lysates and in vitro assays. First, the replacement of the two 
highly conserved histidine residues by two alanine residues was done in respect to experiments 
performed with CerS1 (Spassieva et al., 2006). Our findings obtained for the 
CerS2H212A/H213A construct are in line with that of CerS1, where we could show that 
replacement-mutation results in loss of catalytic activity and that they are essentially necessary 
to maintain catalytic activity needed for N-acylation of the long chain base. Additionally, 
immunofluorescence and immunoblot experiments show strong expression of modified 
CerS2H/A protein, which lead to the conclusion that the introduced modification does not 
influence protein glycosylation, expression, and conformation. This, in turn, strengthened the 
assumption that the H/A mutation is suitable to study consequences arising from loss of 
catalytic activity and lack of C22/24-ceramide species independent from homeodomain 
function. 
In contrast, no suitable CerS2-construct could have been initially generated in which the 
catalytic activity was not altered after modification of the homeodomain. With the help of 
published data of CerS5, we finally generated a deletion construct based on protein sequence 
alignments. Briefly, Mesika et al., (2007) showed that aa 87-128 can be deleted within the 
peptide sequence of CerS5, which does not alter its catalytic activity. As indicated in the 
beginning, sequence alignments of CerS2 and CerS5 resulted in the identification of the 
appropriate amino acids within the homeodomain of CerS2 and lead to the generation of the 
CerS2Del79-120 construct. The obtained results regarding the catalytic activity (after transient 
transfection and protein lysate preparation) in in vitro experiments are in line with that 
published for CerS5-(87-128). Here, overexpressed CerS2Del79-120 and CerS2WT constructs 
show similar expression levels as well as similar levels of catalytic activity. Based on that we 
could show that the deletion of certain nucleotides (bp-bp) within the cDNA of cers2 lead (I) 
to the generation of the mutated-CerS2Del97-120 protein and (II) that the mutation does not 
alter catalytic activity, but affect the function of the homeodomain. 
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6.1.3 Future perspective – Unravelling homeodomain function in vitro 
The generation of different CerS2-deletion constructs indicated that the catalytic activity is not 
dependent on the presence of the homeodomain; but that certain deletions negatively 
influence its conformation, thereby affecting protein expression and its function. Within this 
question, it would be helpful to deconstruct the 3D-conformation of the protein and how it is 
exactly integrated in the membrane and which parts are freely accessible. 
Another recent finding verified that eleven residues at the C-terminus (aa291-301) of CerS2 
might be responsible for the acyl chain specificity of each CerS protein (Tidhar et al., 2018). 
This newly identified “acyl-CoA-binding-motif” represents a further domain by which the 
catalytic activity could be regulated, e.g. positive/negative feedback loop dependent on 
substrate availability. Another possibility could be that it depicts an indirect measuring unit, 
which determines the body’s energy status (feeding vs fasting state). This indirect 
measurement of nutrient supply and energy status could additionally affect the intracellular 
localisation of CerS2 and the other CerS proteins, i.e. facilitating shuttling from the ER to the 
nucleus, where the homeodomain might fulfill its function as a transcriptional regulator. 
This assumption and additional function of CerS2 is further supported by recent findings 
obtained from schlank, the Ceramide synthase family member of the fruit fly (Sociale et al., 
2018). Here Sociale et al. could show that schlank is energy-dependent shuttled from the ER 
to the nucleus or vice versa, to force/repress gene expression (Sociale et al., 2018). Therefore, 
the same approach could be used to further investigate and unravel the molecular 
mechanisms resulting in gene expression and are based on homeodomain function of CerS2: 
 (I) Different CerS2-tagged-overexpression constructs need to be generated and 
overexpressed in a suitable cell system. After verification of the expression level (immunoblot), 
catalytic activity (in vitro assay) and subcellular localisation (immunofluorescence) of the 
modified CerS2 proteins, the transfected cells can be challenged by application of different 
concentrations of acyl-CoAs (C16/18/C24:1, 2/5/10µM), sphinganine (2/5µM) and BSA (control); 
and the subcellular localization monitored upon fixation of the cells and immunofluorescence 
analysis with appropriate antibodies. 
 (II) The following constructs could be used: CerS2-NLS2 (RRRR ARAR), which carries 
a mutation within the homeodomain, the CerS2H212D construct, which has a mutation of 
within the Lag1 motif, and the CerS2291-301 (YPLELYPAFFG)-construct, which shows a 
deletion of the putative fatty acid binding region. 
Based on previous findings, we speculate that the CerS2-constructs, modified within the acyl-
CoA binding site, do not correspond to acyl-CoA application and remain in the ER-membrane. 
Additionally, it is suggested that the CerS2-WT, CerS2-NLS2, as well as CerS2H212D proteins 
show an altered subcellular localization (ER  nuclear membrane). Additionally, the CerS2-
NLSII-mutated construct should show an altered localisation but an abrogated DNA-binding 
capability. Meaning, a different sub-cellular localization, would again strengthen the 
assumption that the homeodomain might function as a transcriptional regulator upon nutrient 
stimulation. In the next step, it might be indispensable to elucidate by chromatin 
immunoprecipitation (ChIP) assays whether the different constructs have the potential of DNA-
binding and which genes are affected. It would also be of great interest to see, whether the 
homeodomains of other CerS might also function as a transcriptional regulator. 
  
Discussion  
94 
6.2 Generation and features of the gene targeting constructs & homologous 
recombination in ES cells 
The conditional CerS2H213A/H212A and CerS2Del79-120 exchange vectors used for homologous 
recombination of the cers2 locus in ES cells were shown in Figure 5.5 and 5.6. Both contain at 
their 5’ end the same homology region, which consist of a part of exon1 until exon2 as well as 
a minor part of the intron downstream of exon2 from the cers2 gene. This is followed by the 
remaining genomic region of cers2, which is flanked by two loxP sites and an frt-flanked 
Neomycin-resistance cassette. Downstream of the loxP-flanked region is either the part of the 
construct containing the CerS2H212A/H213A mutation or the CerS2Del79-120 mutation. This 
is followed by an IRES-eGFP cassette and the 3’homology region, required for homologous 
recombination. eGFP was the reporter protein of choice since it smaller in size (720 bp) than 
the ß-galactosidase, lacZ, reporter gene (3kb). Another advantage is shown by the fact that 
eGFP shows a strong fluorescence signal when stimulated by UV-light compared to other 
members of the GFP-family (YFP, CFP; Patterson et al., 2001). This combined with the 
application of specific antibodies against GFP, allows the use of different approaches (e.g. IF 
and IHC) to additionally monitor cers2 expression. 
PCR and Southern blot analyses of ES cell clones were done to verify correct insertion of the 
exchange vectors. In case for the CerS2H212A/H213A line, 12 out of 364 analysed ES-cell clones 
were positively tested. This represents a final recombination rate of 3.29 %. On the other hand, 
13 out of 550 ES cell clones were positively tested for correct recombination (recombination 
rate: 2.36 %). The low recombination efficiency might be due to a relatively inaccessible 
(heterochromatic) region of the mouse genome. Moreover, karyotype analyses were 
performed for a minimum of four positive ES cell clones (Chapter 5.3.5). Finally, blastocyst 
injection of clone #110 (CerS2H212A/H213A) and clone #61 (CerS2Del79-120) resulted in the birth of 
several high-extend-agouti-fur-colored chimeric mice, which were either used for the 
generation of the new CerS2H212A/H213A (CerS2H/A) or the CerS2Del79-120 (CerS2Del)mouse line. 
Backcrossing of CerS2H/A mice with C57BL/6 (N) and Flp-recombinase (B6/J) expressing mice 
lead to the generation of the Flox-control mouse line (Rodriguez et al., 2000), which express 
the CerS2WT gene and lack the neomycin resistance gene. Mice show a C57BL/6 content of 
at least 87.5 %. Additionally, backcrossing of CerS2H/A chimeric mice with C57BL/6 (B6/N) and 
pgk-Cre (B6/J) expressing mice results in the loss of the loxP-flanked, “CerS2WT-frt-neomycin 
fragment” and the expression of the H212A/H213A-mutated cers2 gene. Mice show a C57BL/6 
content of 75 %. Backcrossing of CerS2Del mice with C57BL/6 (B6/N) and pgk-Cre (B6/J) mice 
lead to the replacement of the loxP-flanked “CerS2WT-frt-neomoycin-fragment” by the 
CerS2Del79-120 fragment, with a corresponding C57BL/6 content of 75 %. 
Additionally, all mice were further investigated by PCR-analysis regarding the expression of 
the mutated nicotinamide (NAD) nucleotide transhydrogenase (NNT) gene. Here it was shown 
by Toye and others (Toye et al. 2005; Freeman et al. 2006) that the C57BL/6 J strain is positive 
for this mutation, which affects insulin secretion and glucose tolerance (Raichur et al., 2014; 
Park et al., 2014). To avoid any interaction of this mutation within the background, mice were 
backcrossed to a NNT-mutation-free (i.e. NNT-WT) background. 
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6.3 Biochemical characterization of targeted mutations in transgenic mice 
6.3.1 CerS2 expression in CerS2H212A/H213A mice 
Immunoblot analyses of several mouse tissue lysates verify the expression of the mutated 
CerS2 protein in CerS2H/A mice (Figure 5.15). Results of liver lysates indicate that the protein 
is glycosylated and that the mutation of the genomic locus does not result in abrogated 
transcription, which would have resulted in the loss of protein or altered protein mass. For 
both, CerS2H/A and Flox mice, we detected a protein running at equal height as that of WT 
lysates. This further implicates that genomic manipulation leads to gene expression and 
protein generation. However, the degree of protein expression in CerS2H/A and Flox mice of 
liver and several other tissues was not always comparable to that found in WT mice. In line 
with these findings are also the reduced mRNA levels of CerS2 found in both, CerS2H/A and 
Flox mice (Figure 5.15). Based on these findings we speculate that maybe the remaining loxP 
(H/A) or frt-loxP-flanked-CerS2H/A-locus in Flox mice or the position of the first loxP site within 
the intron between exon2 and 3, somehow interfere with the transcription. In addition; it 
should be noted that the analyses of the genomic locus of CerS2H/A mice as well as the cDNA 
transcripts of cers2H212H/H213A show the presence of the H/A mutation. Moreover, the 
replacement-mutation resulted in the generation of an additional PvuII restriction site, which 
was easily used to determine double histidine to double alanine mutation (Figure5.13). 
Verification of downstream eGFP-reporter protein expression (facilitated by the interaction of 
the endogenous cers2-promoter and the presence of an upstream-IRES-cassette) showed the 
presence of the GFP protein in immunoblot analyses (5.15). GFP-expression levels in CerS2H/A 
mice were comparable to that found in CerS2Del mice. No GFP-expression was detected in 
Flox mice as expected. Based on this, we cannot conclude that eGFP expression reflects the 
endogenous level of CerS2 expression; we can only say that the eGFP reporter protein is 
expressed and is an appropriate way to monitor the overall expression of CerS2 in various 
tissues. 
6.3.2 Protein degradation in CerS2Del79-120 mice 
Surprisingly, verification of CerS2Del protein expression by immunoblot analyses of liver lysates 
and of several other tissues indicated a lack of protein expression. Even after strong 
overexposure, we could hardly detect a CerS2Del protein. This leads to the assumption, that 
the CerS2Del protein is either not translated, or directly degraded after translation. These 
results are in contrast to the findings obtained in in vitro experiments. There we could show 
that deletion of nucleotides 235 to 360 (126bp) within the cDNA sequence of cers2, 
corresponding to aa79-120 of the peptide sequence, results after transiently transfection in 
protein expression where the catalytic activity is not affected. 
Besides that, verification of GFP-reporter protein expression results in the detection of the 
expected band upon normal exposure conditions. Furthermore, expression levels are 
comparable to the signals found in CerS2H/A mice. This in turn leads to the conclusion, that 
the endogenous promoter in combination with the IRES-cassette is working, which enables 
eGFP expression. And, that on the other hand, some unexpected alterations occurred that 
cannot be explained so far, which either adversely affect translation of the cers2 mRNA or 
cause the early degradation of the CerS2Del protein. 
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6.3.3 Catalytic activity and mass spectrometric analyses 
The CerS2H212A/H213A mutation was designed in order to replace two histidine residues 
(imidazole side chains) which function as a coordinating ligand in the catalytic centre, by two 
alanine residues. The alanine residues itself do not have the probability to switch between a 
protonated and un-protonated state, thereby inhibiting ceramide synthesis. Liver extracts were 
generated and results from radioactively-labelled ([4,5-3H]-D-erythro sphinganine) in vitro 
assays indicate that desired HH/AA mutation lead to loss of catalytic activity; and are in line 
with previously performed cell culture experiments (Figure 5.2 and 5.3). 
 Coincident with the loss of CerS2Del protein is the lack of catalytic activity determined 
in liver lysates generated from CerS2Del mice. 
 Moreover, reduced ceramide synthase activity detected in liver lysates of CerS2Flox 
mice are in line with reduced cers2 mRNA and protein levels, but does not proceed into altered 
sphingolipid content. Here, mass spectrometric analyses indicated same ceramide and 
sphingolipid levels like determined for WT control. This indirectly implicates that roughly 50 % 
of the cers2 mRNA and protein are suitable to maintain sphingolipid content. 
On the other hand, catalytic inactivation (H/A) or the lack of CerS2Del protein resulted in a 
strong decrease of C22:0, C24:0 and C24:1 ceramide species in liver extracts. Interestingly, 
observed reductions were accompanied by significant increases in short-chain ceramide levels 
(C16/18). However, increased levels were not able to restore total sphingolipid content. Since 
it is conceivable that the ceramide synthases mutually regulate each other, we subsequently 
examined the mRNA and protein expression levels of CerS4, 5 and 6. Protein expression level 
of CerS4 was not altered (Figure 5.15). On the other hand, immuno blot analyses of liver protein 
extracts showed increased expression levels of CerS5 and 6 (Figure.5.15). Additionally, these 
observations fit into the assumption that CerS5 and 6 are responsible for the increase in C16/18 
sphingolipid levels, suggesting a compensatory mechanism, possibly aimed to reduce 
accumulating amounts of LCB and acyl-CoAs. 
6.3.4 Future perspective – CRISPR/Cas9 vs traditional ES cell culture 
The previously obtained results regarding the newly generated CerS2Del line strengthen the 
assumption that those mice were not suitable to investigate the putative functions of the 
homeodomain. Those mice show with the loss of the remaining nucleotides from exon3 and 
4 in the mRNA, an even bigger deletion within the homeodomain of the protein than intended 
(79-120 vs 59-137). Furthermore, the deletion results in an early stop of translation or rapid 
degradation of the protein, which unfortunately results in mice deficient for CerS2. 
One solution represents the generation of a new mouse line, where the desired mutation 
should be re-defined and possibly be based on recent findings obtained by the analysis 
schlank, the ceramide synthase in the fruit fly (Sociale et al., 2018). At the present time two 
suitable methods are available, homologous recombination of a gene targeting construct or 
the homology-direct-repair with a designed oligonucleotide and gRNA, facilitated by Cas9 
(CRISPR/Cas9). 
The first method, homologous recombination of a conditional vector, allows the investigation 
of the targeted-mutation in a cell-type-specific manner, without affecting the whole organism 
(Figure 6.1). Furthermore, it facilitates monitoring the expression by the integration of an 
additional reporter gene (Bouabe & Okkenhaug, 2013). However, the disadvantages are not 
negligible. First, the approach is expensive and very time consuming (1 year), which requires 
the (I) design and generation of a conditional gene targeting vector, (II) the homologous 
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recombination, as well as the selection and verification of many ES cell clones (>200). Since ES 
cells could show low frequency of recombination events (Deng et al., 1992; Hasty et al., 1991). 
Furthermore, the success depends also on the availability to perform (III) microinjection of 
positive-selected ES cells into blastocysts and the subsequent transfer of those into the uterus 
of pseudopregnant foster mice. Next, breeding (IV) of chimeric mice, that showed coat-color 
chimerism with WT mice to pass the genetic modification onto the offspring and (V) breeding 
with appropriate Cre/ Flp mouse lines to establish the desired tissue-specific mutation, 
describes in additioan very time-consuming aspect. 
Here, the conventional technique could be used for the generation of a CerS2NLSII line based 
on the already existing conditional gene targeting constructs and is illustrated in Figure 6.1. 
Briefly, the generation of the amino acid exchanges (RRRRARAR) can be achieved by the 
application of DpnI-mediated mutagenesis PCR. Here long-oligonucleotides (primer) 
introduce the modifications and simultaneously initiate amplification. The mutated DNA-
fragment can then be transferred by normal cloning steps into the CerS2H/A-vector to 
generate the final CerS2NLSII-vector suitable for homologous recombination in ES cells. 
 
 
 
Figure 6.1: Generation procedure of the CerS2NLS II gene targeting vector. Graphical overview of the 
different cloning steps required for the generation of the CerS2NLSII-gene-targeting vector, which introduced a 
replacement of the RRRR (NLSII) residues by ARAR residues within the homeobox domain.  
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On the other hand, with the application of the CRISPR/Cas9 system (clustered regulatory 
interspaced short palindromic repeats/ CRISPR associated (Cas) protein number 9) one could 
circumvent much of these aspects. The new mice could carry a mutation within the putative 
NLS2-motif (‘RRRR’- ‘ARAR’) of the cers2 gene (Figure 6.2). The application of the CRISPR/Cas9 
technology is suggested to be very efficient and faster than the conventional-gene-targeting 
approach (Hsu et al., 2014; Wang et al., 2013). 
 
 
 
Figure 6.2: CerS2 gene manipulation by CRISPR/CAS9. (A) Schematic representation of predicted domains 
in mCerS2 (according to swissprot). (B) Alignment result of the amino acid sequence of the homeodomain 
present in CerS2. Underlined amino acids highlight homeodomain; bold-coloured faces depict putative NLS2 
(‘RRRR’) signal in CerS2 WT protein. Sequence below shows possible NLS2 mutation. (C) Genomic DNA 
sequence of WT and NLS2 mutated CerS2 region. Mutation results in the introduction of an additional AccI/BstUI 
cleavage site. (D) Alignment result of the amino acid sequence containing two highly conserved histidine 
residues in the lag1 motif. (E) Genomic DNA sequence of CerS2 WT and CerS2H212D replacement. Mutation 
results in deletion of endogenous DraIII restriction site and introduction of a new ClaI site. (F) CRISPR/Cas9 
approach requires the generation of the px330 plasmid (Addgene), containing the desired guide RNA. U6 
promoter is already cloned in frame, as well as the CAS9 endonuclease. The right side depicts the generated 
oligonucleotides suitable for homology direct repair. Px330 vector in combination with one of the 
oligonucleotides is injected into fertilized oocytes. The following founder generation possibly contain WT, 
heterozygous and/or homozygous mice. 
 
Briefly, it requires the presence of a Cas9 endonuclease, a target recognition CRISPR-RNA, 
which shows sequence homology to the region desired for mutation; and a Cas9-recruiting 
tracer RNA; both also termed as single guide RNA (sgRNA). The guide with a ‘protospacer-
adjacent motif (PAM)’, depicts a specific sequence pattern of 20 nucleotides (N) followed by 
an NGG-motif (20N-NGG) (Mali et al., 2013; Young et al., 2015), which has to be mutated in the 
oligonucleotide delivered for homology direct repair. Microinjection of either a plasmid coding 
for the guide RNA and the Cas9 (pX330 vector, Addgene, Mashiko et al., 2014) or co-injection 
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of sgRNA and the mRNA of Cas9 into fertilized oocytes should lead to induction of 
CRISPR/Cas9 machinery. Cas9 is recruited to the desired genomic DNA sequence in a site-
specific manner, mediated by the sgRNA. Next, Cas9 cleaves 3nt upstream of the PAM site, 
which results in double-strand brake (Jinek et al., 2012; Cong et al., 2013; ;Mali et al., 2013), 
which in turn can be repaired by two mechanisms; (I) non-homologous-end-joining (NHEJ) or 
by (II) homology direct repair (HDR) (Young et al., 2015; Chu et al., 2015). The NHEJ utilizes 
host-own proteins for the recognition and repair of the double-strand break and depicts an 
error-prone process, i.e. it results in indels (Young et al., 2015), which is not favourable. The 
second and preferred repair mechanism is the HDR. Here, co-injection of an oligonucleotide, 
which shares sequence homology to the targeted gene, results in direct repair by homologous 
recombination. Modification of the oligonucleotides can result in the insertion of directed 
mutations, which alter gene function; Chu et al., 2015). Furthermore, in combination with the 
Cre/loxP approach one could also generate a conditional CerS2H212D mouse line, which 
expresses a catalytically inactive version of the protein upon breeding with Cre-expressing 
mice (Fig.). Additionally, one has to consider that the efficiency of integration of loxP-site 
containing oligonucleotides by HDR is rather low (Wang et al., 2013; Bishop et al., 2016). 
6.4 Analysis of energy metabolism of CerS2H212A/H213A and CerS2Del79-
120 mice 
One main significant risk of health is the development of obesity and the progression of its 
comorbidities, caused by constant nutrient-oversupply. The recent literature summarizes many 
investigations and findings regarding CerS function and sphingolipid content in the 
development of diet-induced obesity. Among them are studies performed with CerS5 and 6-
deficient mice, indicating that loss of C16:0 ceramide species protects mice from weight gain 
after feeding a high-fat diet (Turpin et al., 2014; Gosejacob et al., 2016). Additionally, CerS5-
deficient mice showed improved glucose-homeostasis and reduced adipose tissue 
inflammation (Gosejacob et al., 2016). On the other hand, heterozygous deletion of CerS2 
expression resulted in reduced C24:0/24:1 ceramide levels and increased C16 sphingolipid 
levels inducing mice to become susceptible to diet-induced obesity and the development of 
steatohepatitis and insulin resistance (Raichur et al., 2014). 
6.4.1 Weight gain and lipid content in CerS2H212A/H213A mice 
To investigate basal consequences arising from homozygous impairment of CerS2´s catalytic 
activity in respect to the development of weight gain and growth, CerS2 WT and H/A mice 
were fed a normal chow. For the first time, we could show that food-intake is altered in male 
as well as female mice, i.e. mice ingest more food per gram body weight than WT littermates 
(Figure 5.18). Surprisingly, the mice gain less weight over time. Additional findings obtained 
from CerS2gt/gt mice are in line with our results (Park et al., 2014). They could verify that CerS2 
depletion protects mice from weight gain (obesity) either fed a low-fat or high-fat diet (Park 
et al., 2014). 
Moreover, analysis of CerS2H/A mice indicate, that loss of catalytic activity impairs hepatic 
storage-lipid levels, which is not based on altered intestinal lipid absorption (Figure 5.19). More 
precisely, TLC analysis of lipid composition of feces from CerS2H/A mice showed a strong 
reduction in 1,2 DAG and TAG level in comparison to WT control samples (Figure 5.19). These 
findings lead to the conclusion that secretion of bile salts as well as pancreatic juice is not 
altered and leads to intestinal lipid digestion. Furthermore, equal FFA content between 
CerS2WT and H/A mice suggests normal absorption by enterocytes. Additional H&E staining 
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on colon sections did not indicate alterations in tissue architecture (Figure 5.26). PAS-staining 
also indicated equal glycogen-content in colon sections of CerS2H/A and WT mice (Figure 
5.26). 
Further investigations of liver- , adipose tissue- and muscle lipid composition highlighted 
several alterations. First, TLC analysis of liver-lipid extracts indicate a strong reduction in TAG, 
DAG and FFA-levels and are in line with findings obtained in CerS2gt/gt mice (Figure 5.19/ 
5.20, Imgrund et al., 2009; Park et al., 2014). Second, OilRedO staining verified also loss of lipid 
droplet formation/accumulation in liver sections of CerS2H/A mice (Figure 5.21). These results 
are also in line with previously published findings of schlank-mutant flies, where the loss of 
catalytic activity leads to reduced TAG level and enhanced lipase3 (TAG lipase) and brummer 
(ATGL lipase) expression (Bauer et al., 2009). In addition, PAS-staining indicated reduced 
glycogen-content; and H&E staining indicated loss of normal liver architecture, reduced 
hepatocyte diameter as well as a reduced number of bi-nucleated hepatocytes besides an 
abnormal increase of nuclei-diameter (Figure 5.22). Findings of liver architecture alterations 
were further supported by immunoblot analysis determining enhanced expression levels of 
tumor marker and indirectly depicted the early onset of liver cancer development and are 
possibly reasonable for destruction of liver architecture. However, it should be noted that 
tumor formation could also be an indirect consequence of an additionally altered signalling 
pathways (Figure 5.23). 
Analysis of CerS2H/A-adipose-tissue mass and lipid composition revealed a reduction in 
weight and surprisingly inhomogeneous distribution of adipocytes with varying cell diameter. 
Furthermore, lipid content showed significantly increased DAG level, next to slightly elevated 
FFA, cholesterol and cholesterol-ester level. These findings somehow differ from that obtained 
in CerS2gt/gt mice, where no alterations were observed (Park et al., 2014). On the other hand, 
these findings are comparable to that found in mutated-schlank (schlankG0061 and 
schlankG0349) larvae (Bauer et al., 2009). As the name implies, schlank-deficiency results in 
slim-shaped larvae and decreased fat accumulation in the fat body in comparison to WT. Based 
on these findings and recent publications, we assume that homeodomain of CerS2, like that 
of schlank, possibly function as a transcriptional regulator of genes involved in lipogenesis and 
lipolysis. More precisely, we assume a decreased repression of lipolysis, resulting in the up-
regulation of lipases, concomitant with decreasing storage lipid levels and reduced adipose 
tissue mass. Simultaneously, depleted glycogen-storages of CerS2H/A mice also fit in this 
assumption. It might describe a possible consequence of altered FFA uptake, arise from higher 
energy-demand of tumor cells or might be a consequence of mitochondrial dysfunction (Park 
et al., 2013). Here, “starvation-condition”, e.g. lack of lipid accumulation in CerS2H/A-
hepatocytes drives breakdown of glycogen to obtain glucose as remaining energy source. This 
assumption is further supported by our own results and those obtained from Park (2013). They 
and we could show that intestinal glucose-absorption/ glycogen-content of enterocytes is not 
altered and that liver gluconeogenesis was increased to satisfy high-energy demand (Park et 
al., 2013). Another possible explanation for an altered lipid uptake and “starvation-like” 
phenotype of hepatocytes could be based on an altered hepatic plasma membrane 
composition as suggested for CerS2gt/gt mice (Park et al., 2013/ 2014). They indicate that loss 
of very-long-chain sphingolipid species (C22-24) possibly results in a compensatory increase 
of short-chain ceramides (C16/18), responsible for altered membrane fluidity. However, 
preliminary experiments performed with membrane sheets of CerS2-derived hepatocytes did 
not indicate alterations in lateral diffusion of overexpressed IR (insulin receptor, Figure A12). 
Based on these findings it is more likely that ablation of specific sphingolipid species was 
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responsible for transmembrane transporter/receptor dysfunction, i.e. proper function depends 
on the interaction of sphingolipid with specific acyl chain length N-acylated to the sphingoid 
long chain base. 
At least, no alterations were observed in TLC analysis of muscle lipid content between 
CerS2H212/213A and WT mice. These findings fit into the assumption that CerS1 and not CerS2 
is the pre-dominantly expressed CerS in muscle; and that catalytic inactivation does not 
negatively influence lipid/energy metabolism in that tissue. 
6.4.2 Transcriptome analysis of liver enzymes involved in lipid synthesis 
Another aim of this study was to link present phenotypic alterations, observed in liver of newly 
generated CerS2H/A mice to up- and down-regulated genes, thereby elucidating involved 
signalling pathways.  
Initially and based on previous findings obtained from analyses of schlank in D. melanogaster 
and CerS2gt/gt mice, we re-capitulate gene expression of those involved in fatty acid uptake, -
synthesis and lipolysis by qRT-PCR analyses (Figure A11, Bauer et al., 2009; Pewzner-Jung 2010ii; 
Sociale et al., 2018). In detail, we could verify that ablation of catalytic activity negatively 
influences the expression of de novo fatty acid synthesis, as well as negatively regulate the 
expression of enzymes involved intra-hepatic TAG synthesis (Figure A11). Moreover, decreased 
C24-ceramide levels somehow induce lipolysis, which might be a mechanism to compensate 
decreased fatty acid uptake. On the other hand, lipolysis depicts the counter-part of de novo 
synthesis and could be influenced by homeodomain function. The detected decreased 
expression levels of ELOVL3 and 6, possibly result in reduced C16-24:0 saturated fatty acid 
(SFA) levels (Sassa & Kihara, 2014), which is hypothetically determined by the newly identified 
“acyl-CoA-binding motif” within the C-terminus of CerS2 (Tidhar et al., 2018). Additionally, we 
assume that this “indirect” measurement of a “fasting-state” induces lipolysis. Since the 
homeodomain of CerS2H/A mice is not affected, it is thought to facilitate this regulatory 
mechanism. We speculate that upon decreased FFA-level, the CerS2H/A protein is shuttled 
from a nuclear localisation to an ER localisation, resulting in the inhibition of gene-repression, 
which in turn initiates lipase generation and ended up in TAG degradation (also see Sociale et 
al., 2018 for comparison). 
6.4.3 Future perspective – conditional CerS2H212A/H213A expression in liver 
and brain 
6.4.3.1 CerS2H212A/H213A expression in liver & energy metabolism 
In this study, the focus of characterising CerS2H/A (Del) mice was initially based on re-
capitulation of already described phenotypes obtained from CerS2gt/gt mice, to decipher 
alterations driven by the loss of catalytic activity. 
In that respect, future studies should either focus on (I) the generation of a liver-specific 
CerS2H/A expressing mouse line or on (II) challenging of already existing mice by high-
carbohydrate diet, to investigate if and how glycogen-content is restored in liver. Additionally, 
it would also be of great interest to investigate the lipid content of enterocytes by OilRedO 
staining and TLC analysis to further support, that either depletion of specific lipid class than 
altered membrane fluidity is responsible for function/dysfunction of CD36/FAT transporter and 
that ablation of catalytic activity possibly does not influence enterocyte lipid composition. 
Moreover, expression of glucose transporter and enzymes involved in 
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gluconeogenesis/glycogen- break down in muscle, adipose tissue and liver could be further 
investigated to gain more insights into glucose homeostasis and to verify if catalytic 
inactivation cause alterations. Additionally, it might be important to analyse serum levels of 
e.g. albumin, leptin, glucose and insulin, to unravel if the mice show further alterations, which 
might explain the increased food intake and reduced weight gain. 
6.4.3.2 CerS2H212A/H213A expression in brain & behavioural test 
It was already suggested that CerS2-deficiency lead to an altered ratio of expected genotypes 
after birth and was proven by analysis of littermates derived from heterozygous breedings of 
CerS2H/A or Del mice. Here, we could show that catalytic inactivation negatively influences 
the yield of homozygous mice (Figure 5.13). Moreover, analyses strengthen the assumption 
that the inactivation of CerS2 also influences the survival rate of homozygous mice (H/A and 
Del) during the first two weeks of lifespan (Figure 5.14). Preliminary findings, based on routine 
observations during the course of single animal assessment, indicate that CerS2H/A and Del 
mice did not only suffer under increased mortality rate, they developed also behavioural 
alterations (Figure 5.14). In detail, 11/62 (17.7%) CerS2H/A mice showed hind limb paraplegia 
and other 7/62 (11.3%) epileptic behaviour, which exacerbate with rising age. Similar numbers 
were obtained for CerS2Del mice, where 14/47 (29.8%) show hind limb paraplegia and 3/47 
(6.38%) an epileptic phenotype. Until now, only liver phenotypes and alterations were 
investigated, but the recent findings in combination with the brain-phenotype (demyelination, 
reduction of myelin-associated protein-MAG) observed in CerS2gt/gt mice strengthen the 
importance to intensify investigations of brain-development in CerS2H/A (Del) mice. More 
precisely, one could generate a mouse line, which exclusively expresses CerS2H/A in 
oligodendrocytes, the cell type in the brain responsible for myelination of never fibres. The 
main advantage of this tissue-specific mutation, results in decreased side effects arising from 
loss of catalytic activity/C22-24 sphingolipid classes in other tissues. Further, lipid content 
analysis by mass spectrometry and activity assay could be used to determine current-lipid state 
and behavioural analyses test (Open-field behavioural habituation, One-trial object 
recognition or Anxiety-like behaviour in the elevated plus-maze) could decipher if and how 
demyelination impairs processing and signalling. 
6.5 Immune status of CerS2H212A/H213A mutated mice 
The precise development, proper differentiation and egress of naïve T cells is of fundamental 
importance to maintain the functions of the adaptive immune system, which are responsible 
for the protection of the organism against invading pathogens or harmful agents (Kenneth et 
al., 2012; Lodish et al., 2016). The main key player in thymic emigration depicts the tightly 
controlled maintenance of a chemically gradient by the sphingolipid S1P, which is present in 
low levels in the thymic interstitium and in high levels at the cortico-medullary junction/ blood 
(Resop et al., 2016; Saba, 2017). Upon positive and negative selection, thymocytes undergo a 
developmental program from immature to mature state. In line with this is the up-regulation 
of certain cell surface marker, that enables them to respond and migrate along the S1P gradient 
and finally to leave the thymus into circulation to become an active part of the adaptive 
immune system. It is known from several studies, that the S1P gradient is kept by the action of 
intracellular S1P lyase in dendritic cells (Schwab, 2017; Zamora-Pineda et al., 2016) and to a 
minor extent also in epithelial thymic cells. On the other hand, the precise regulatory 
mechanisms that control the exact architecture are yet not fully elucidated and require further 
investigations (Yanagida & Hla, 2017). 
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With the present study and the newly generated conditional CerS2H/A mice we wanted to 
recapitulate recent findings performed with non-conditional CerS2gt/gt mice (Rieck et al., 2017). 
Based on the insertion of a gene trap construct into the cers2 gene locus, the mice are depicted 
by a loss of functional CerS2 protein, which is in line with the lack of CerS2-acyl-CoA specific 
ceramides and sphingolipids (Imgrund et al., 2009). Furthermore, mice show a compensatory 
increase in C16 and C18 sphingolipids (Imgrund et al., 2009; Pewzner-Jung et al., 2010 i/ii). 
Moreover, CerS2-deficiency leads to the distortion of the S1P gradient between thymus and 
blood. This, in turn, results in the accumulation of mature single positive T cells and a T cell 
lymphopenia in the periphery (Rieck et al., 2017). They propose a model in which CerS2 
expression in endothelial cells maintains the S1P gradient in the thymus and that it additionally 
limits the level of circulating S1P (Rieck, 2017). Thereby they highlight CerS2 as a novel factor 
for regulation of S1P homeostasis next to SPHKs and SP1 lyase (Rieck, 2017; Pham et al., 2010). 
6.5.1 Early T cell development is not affected in CerS2H212A/H213A male mice 
The adaptive immunity is highly dependent on the thymus and its function to provide a unique 
cell and microenvironment needed for proper T cell development and function (Takahama et 
al., 2006). In this course, bone marrow derived progenitor cells enter the thymus via the 
cortico-medullary junction and undergo several sequential differentiation and proliferation 
steps, which are further characterized by a distinct migration, i.e. each subpopulation covers a 
specific region of the thymus (Ceredig & Rolink, 2006; Zuniga-Pflücker, 2004). Furthermore, 
maturation is explained by the emergence of a divers TCR repertoire and the differentiation 
into the CD4 or CD8 positive lineage. Upon positive and negative selection, non-functional or 
self-reactive T cells were eliminated. Upon that, only about 1-5 % of those cells survive and 
express a functional and self-tolerant TCR. Moreover, they proceeded further signalling to 
complete the development and become part of the peripheral T cell repertoire (Cano & 
Lopera, 2013). 
The recent findings show that ablation of CerS2 catalytic activity does not alter T cell 
development of male mice in general. However, we detected a significant reduction in cells of 
developmental stage DN1 and DN3, whereas DN2 and DN4 showed only tendency of reduced 
amounts. Furthermore, the minor amount of DN cells in CerS2H/A mice does not continue or 
gain strength in the subpopulation of double positive cells. Here, CerS2H/A mutated mice 
show similar frequencies, counts (raw data) and cell numbers after weight correction in 
comparison to their wild type littermates. 
With regard to analysis performed in female mice (data not shown) we could also verify recent 
findings performed with CerS2gt/gt mice (Rieck et al., 2017). So far, female mice show an altered 
T cell development upon mutation of CerS2’s catalytic activity and/or on the occurrence of its 
comorbidities. Additionally, it must be taken into consideration that these findings need further 
support on the basis of low replications and high variability. 
Taken together these findings indicate that CerS2 plays a minor role in the T cell development 
of male mice in comparison to female mice. However, these findings need further 
investigations. First of all, the robust reproduction of results for female mice and later on the 
involvement of CerS2 in the process of hormone-driven thymic and T cell development, by 
quantification of specific sex-related hormone levels in the blood. 
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6.5.2 CerS2H212/213A mutation affects thymic egress of single positive 
thymocytes and induces mild T cell lymphopenia 
The precise mechanisms, which contribute to the generation of the S1P gradient between the 
perivascular space / blood and thymus, were not fully understood so far. However, it is well 
characterized that low S1P levels in the thymic interstitium and high S1P levels in the 
perivascular space/ blood are crucial to allow proper migration and egress of single positive 
mature T cells (Resop et al., 2016; Schwab et al., 205; Yanagida & Hla, 2017). Furthermore, the 
maintenance of this gradient is thought to be the result of a well-controlled, ‘S1P-synthesis-
export-degradation-cycle’ which requires the interaction of different cell types and enzymes 
(Zamora-Pineda, et al., 2016; Resop et al., 2016; Yanaga & Hla, 2017). Furthermore, it was 
verified that uptake via S1PR1 and intracellular S1P degradation, by S1P lyase, in dendritic cells 
is needed to facilitate low interstitial S1P level and to a minor extent the expression of S1P lyase 
and dephosphorylating enzymes in thymic epithelial cells (Zamora-Pineda et al., 2016; Saba, 
2017). On the other hand, high S1P level at the thymic exit site (cortical junction/perivascular 
space) is facilitated by neural crest-derived pericytes, which generate and secrete S1P (Saba, 
2017). Moreover, high level of S1P in blood plasma is maintained by the involvement of many 
cell types (e.g. hepatocytes, erythrocytes), which synthesise and subsequently release S1P 
(Gazit et al., 2016). The transport of S1P is carried out either by HDL and LDL-associated 
apolipoprotein M or by albumin (Gazit et al., 2016). 
The observed results for CerS2H/A mice indicate an accumulation of mature CD4 and CD8 
positive T cells within the thymus. Additionally, those cells were further characterized by the 
down-regulation of CD69, which we used as a marker for high S1PR1 expression due to the 
lack of an appropriate S1PR1 antibody in combination with the fortunate fact that they were 
mutually regulated. Numbers of immature double or single positive thymocytes were not 
affected. On the other hand, further analysis of lymphocyte composition of peripheral 
lymphoid tissues, i.e. spleen and PBMCs (blood) indicate a mild T cell lymphopenia in 
combination with increased numbers of double negative (CD3low/B220low) cells whereas 
numbers of B cells were unaffected. These findings point into the direction, that CerS2H/A 
mice have an impaired thymic egress of mature T cells. Although we have not measured S1P 
level in blood (serum) and thymic parenchyma, we assume a similar distortion of the S1P 
gradient as it was described for CerS2gt/gt deficient mice due to lack of catalytic activity and 
loss of CerS2-specific ceramides and sphingolipids (Imgrund et al., 2009; Rieck et al., 2017). 
Moreover, publications from recent years clearly demonstrate that even minor alterations of 
the S1P gradient formed between thymus and blood or lymph nodes and blood has major 
effects regarding the emigration and migration of T cells. Vogel (2009) demonstrated by the 
application of a S1PL null mice, which lack in S1P lyase activity, that those mice had higher 
proportions of mature CD4+ and CD8+ cells which were additionally depicted by a complete 
loss of CD69 surface expression. Furthermore, the S1PL-/- mice show a complete loss of 
peripheral T cells. Additionally, mice lacking the sphingosine kinases (SPHK 1, 2) maintain 
normal plasma S1P level, but show a strong reduction of S1P in lymph nodes which results in 
the block of lymphocyte egress from LNs and Peyer’s patches (Pham et al.,2010). Moreover, 
not only the precise expression of synthesizing and degrading enzymes, but also the proper 
function of S1P specific receptors has a major influence on the T cell distribution. Resop (2016) 
could show for example that S1PR1 is the main S1P receptor expressed in the human thymus 
and that it plays a major role in thymocyte egress. Additionally, Matloubian (2004) 
demonstrated with the application of mice which lack S1PR1 in hematopoietic stem cells, that 
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they show strong ablation of naïve T cells in circulation and on the other hand an accumulation 
of mature CD4 and CD8 single positive cells within the thymus, whereas numbers of immature 
double positive (CD4+/CD8+) cells were not affected. Furthermore, they pointed out that 
these results are comparable to that found in mice treated with FTY720. FTY720 is a derivative 
of myriocin, which inhibits sphingolipid metabolism and acts as an immunosuppressive drug 
that negatively affects T cell egress (Matloubian et al., 2004; Braumrunker et al., 2007). 
Based on our results and findings performed by others it might be most likely, that loss of 
CerS2’s catalytic activity has a major influence on the maintenance/impairment of the S1P 
gradient. Moreover, the occurrence of weaker accumulation and milder T cell lymphopenia in 
peripheral tissues could have one reason in the low, i.e. mixed C57BL-6/SV129 background of 
the mice. The latter experiments performed with the CerS2gt/gt mice showed at least 93.75 % 
of C57BL/6N or J, with some animals having the NNT mutation in the genome (Ronchi et al., 
2013). Mice used in our experiments were only of at least 75 % C57BL/6N, but tested-free of 
NNT mutation. For further analysis, or cell-type specific CerS2 mutation it should be considered 
to backcross several times in an appropriate genetic background. Additionally, it needs to be 
verified if the S1P-gradient is distorted in the newly generated CerS2H/A mice, by quantitative 
analysis of S1P levels in plasma, thymus and other lymphoid tissues. Furthermore, it should be 
also recapitulated and further investigated in which cell types and to which amount CerS2 is 
expressed to ascertain the precise microenvironment that contributes to the phenotype. 
Additionally, it should be considered to directly measure the surface expression of S1PR1, by 
application of new protocols. 
Nevertheless, the newly generated conditional CerS2H/A mice recapitulated recent findings 
performed with CerS2gt/gt mice (Rieck et al., 2017). Thereby reflecting that ceramide synthase 2 
is a further factor which somehow is involved in the maintenance of the S1P homeostasis and 
an additional modulator in facilitating thymic egress of mature T cell.  
These recent findings also emphasise CerS2 as a potent regulator, in terms of pharmacological 
treatment, to prevent the development of immune-diseases based on reduced numbers of 
naïve T cells. 
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7 Summary 
Ceramide species are the precursor of sphingolipids, which serve as structural components of 
biological membranes or are bioactive molecules. In mammals, ceramides are synthesised by 
a family of ceramide synthases (CerS) 1 to 6. They catalyse the N-acylation of a sphingoid long 
chain base and a fatty acyl-CoA of varying chain length. All ceramide synthases harbour a 
lag1p motif essentially necessary for catalytic activity and all CerS, except CerS1, contain a 
homeodomain of unknown function. 
During this PhD thesis, different CerS2-overexpression constructs were generated and 
investigated to identify mutations suitable to analyse the catalytic function independent from 
homeodomain function of the mCerS2 protein. Consequently, two different CerS2 conditional 
mouse lines were generated, CerS2H212A/H213A (H/A) and CerS2Del79-120 (Del). Both mouse lines 
show a high mortality rate and develop severe phenotypic alterations. 
In H/A mice, the coding region of cers2 was exchanged by a CerS2H212A/H213A-eGFP 
fragment, resulting in the expression of a CerS2 point-mutated protein. Additional IRES-driven 
GPF-expression was used to monitor cers2H/A expression and to verify the presence of the 
CerS2H/A protein. In vitro assays confirmed that catalytic activity of CerS2 is lost in H/A mice. 
Additional qRT-PCR and immunoblot analyses confirmed expression of the CerS2H/A protein 
in all analysed tissues. Expression levels (mRNA or protein) however do not always correlate 
with that of WT control. Furthermore, the H/A replacement-mutation results in alterations of 
lipid and energy metabolism. First, Mass spectrometric analysis showed strong reduction in 
C22/ C24/ C24:1 ceramide species and an increase in long-chain ceramides (C16/C18), which 
does not restore the total sphingolipid content. Analysis regarding the storage lipid content of 
liver highlight significant reduction in TAG, DAG and FFA levels in mutated mice, which is 
accompanied by reduction in white adipose tissue (WAT) mass. Morphological and histological 
investigations of H/A mice revealed reduced body weight as well as size, while adipocyte size 
is even more disproportionately reduced. On standard diet, H/A mice ingest more food, but 
show less weight gain, which is not based on altered intestinal lipid absorption. Liver sections 
showed loss of lipid droplet formation and an unexpected loss of glycogen-content. Moreover, 
catalytic ablation also leads to the development of hepatocellular carcinoma. Transcriptome 
analyses performed in combination with detailed qRT-PCR analyses show down regulation of 
genes involved in lipid metabolism. Immunological analyses of H/A mice showed that 
depletion of catalytic activity and loss of corresponding ceramide species negatively affects 
egress of mature single positive T cells from the thymus into the periphery. Accumulation of 
naïve T cells within the thymus results in a mild T cell lymphopenia. 
The CerS2Del79-120 mutation was verified in cell culture experiments first. After transient 
transfection of the CerS2Del79-120 plasmid, the mutated CerS2 protein was expressed and 
further investigations indicate, that the deletion within the homeodomain had no effect on the 
catalytic activity. Yet, the Del mice show complete loss of the CerS2Del protein, leading to a 
loss of catalytic activity and a lack of C22-24 ceramide species. Del mice show the same 
phenotype as the CerS2gt/gt and H/A mice. 
All findings indicate that the catalytic domain of CerS2 is important for the synthesis of 
C22/C24 ceramide species. It is also necessary to maintain CerS2s regulatory functions in lipid 
and energy metabolism and to facilitate those functions, which allow the thymic egress of 
mature T cells. 
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9 List of abbreviations 
A Alanine  e.g. exempli gratia 
Akt/PKB  protein kinase B  ECL enhanced chemiluminescence 
APC antigen-presenting cell  ECM extracellular matrix 
ASO antisense oligonucleotides  ECM extracellular matrix  
  EDTA Ethylenediaminetetraacetic  
acid 
BAC bacterial artificial chromosome 
 
ER endoplasmic reticulum 
BAT brown adipose tissue   ERT estrogen-receptor 
BCA Bicinchoninic acid  ESCs embryonic stem cells 
BMD Bone marrow derived  
 
 
bp base pairs  FFA free fatty acids 
BSA Bovine serum albumin  
Flp Flippase 
 
 
 
frt-sites Flp-recognition target 
C (terminus) Carboxyl terminus 
 
 
 
C1P ceramide-1-phosphate  GSL glycosphingolipid 
CD cluster of differentiation   GSL  Glycosphingolipids 
cDNA complementary DANN  gt gene trap 
cEC cortical epithelial cells   
  
CERK ceramide kinase  H Histidine 
CerS ceramide synthases  H&E Hematoxylin and eosin staining 
CERT ceramide transport protein  H/A CerS2H212A/H213A mice 
CNS central nervous system   HEK human embryonic kidney cells 
CoA Coenzyme A  HFD high-fat-diet 
CPE ceramide phosphoethanolamine  HOX Homeobox 
CPE ceramide phosphoethanolamine 
 
HRP horse radish peroxidase 
cPLA2 cytosolic phospholipases A2  
 
 
Cre causes recombination  i.e. id est  
  IR Insulin receptor 
DAG diacylglycerol  IRES internal ribosomal entry site 
DCs dendritic cells   
 
 
Del CerS2Del79-120 mice  kb kilo base pairs 
DES dihydroceramide desaturase  kbp kilo base pairs 
DMEM Dulbecco’s modified Eagle medium  kDa kilo Dalton 
DMSO Dimethyl sulfonide  KLF-2 kruppel-like factor 2 
DN double-negative  
  
DNA Deoxyribonucleic acid  Lag Longevity assurance gene 
DNA Deoxyribonucleic acid  Lass longevity assurance gene 
dNTPs Deoxynucleotide triphosphate  
LCB long chain base 
DP double positive  Lip3 lipase3  
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loxP-site locus of X over P1 
 
SEM Standard error of the  
mean  
 
 
SL Sphingolipids 
MAG myelin-associated glycoprotein  
SL sphingolipid 
mEC medullary epithelial cells   
SM sphingomyelin 
MEF Mouse embryonic fibroblasts  
SP single positive  
min minute 
 
SPHK1 or 2 sphingosine kinase 1 and 2 
min Minute 
 
SPT serine palmitoyl transferase 
mRNA messenger RNA 
 
 
 
  
 
T2D type 2 diabetes  
N (terminus) Amino terminus 
 
TAG triacylglycerol  
NBD Nitrobent-2-Oxa.1,3-Diazol-4-yl  
Tfh follicular helper T cell 
NLS nuclear localization signals   
Th T helper cell 
NMR nuclear magnetic resonance,   
TLC thin layer chromatography  
 
 
TLC  TRAM-Lag-CLN8 
Ob obese 
 
TLC domain TRAM-Lag-CLN8 domain 
ON overnight  
 
Treg regulatory T cell 
ORMDL  Orm like 
 
  
  
 
WAT white adipose tissue 
P/S Penicillin/Streptomycin  
WT wilyd type 
PBS Phosphate buffered saline 
   
PC phosphocholine 
   
PCR Polymerase chain reaction    
PE phosphoethanolamine 
   
PI3K phosphatidylinositol 3-kinase 
(PI3K),    
PKCz (Protein kinase C).    
PMSF Phenylmethanesulfonylfluoride    
PP2A protein phosphatase - PP2A    
rpm rounds per minute 
     
   
RT Room temperature    
RT-PCR real time-PCR     
 
   
S1P sphingosine-1-phosphate    
S1PR1-5 S1P receptor 1-5    
SAPs sphingolipid activator proteins    
SCZ subcapsular zone     
SDS Sodium dodecyl sulphate    
SEM standard error of the mean    
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10 Appendix – supplemental Figures 
10.1 Supplemental figures of the Introduction 
 
Figure A1: Main subtypes of long chain bases 
(LCBs). 
Sphingosine can be distinguished from 
sphinganine (dihydrosphingosine) by the 
presence of a double bond at position 4. 
Additionally, sphinganine is exclusively generated 
in the de novo synthesis pathway of ceramides. 
Phytosphingosine is the main SL in plants and 
funghi (Adopted and modified from Hanada et al., 
2003; Alfatah et al., 2019) 
 
 
 
10.2 Supplemental figures of the Methods part 
 
Figure A2: Validation of H213/213A mutation after PvuII digestion. 
(A) Schematic representation of plasmids, before (E3-11 for HA mutation) and after mutagenesis 
PCR (E3-11 HA mutated). PvuII restriction sites of the plasmids were illustrated. (B) PvuII restriction 
digestion analyses performed with un-modified and mutated E3-11 HA plasmids. The DNA fragment 
at approximately 1.5 kb (yellow box) decomposed after PvuII digestion into two smaller fragments 
(0.7/ 0.66 kb) indicated by yellow arrows. Arrows indicate decomposition. Lanes, 1: WT (E3-11 for H 
mutation), 2: non-digested E3-11 HA mutated vector, 3 and 4: two different bacterial clones digested 
with PvuII. 
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10.3 Supplemental figures of the Results 
 
 
 
 
Figure A3: Glycosylation studies of ceramide synthase 2.  
(A) Depicted is the peptide sequence of CerS2 with possible glycosylation sites highlighted in red. 
Below; N-glycosylation prediction analysis results performed with the NetNGlyc1.0 server. Possible 
glycosylation sites were predicted upon the presence of Asn-Pro-Ser/Thr-motif. +++; The ‘potential' 
score is shown as an averaged output of nine neural networks, threshold >0.75. ++; the potential 
score was given in 9/9 neural networks, threshold >0.5. 
 
 
 
 
 
 
Figure A4: NetPhos 3.1a Phosphorylation prediction results.  
Shown is the graphical overview resulting from the NetPhos 3.1a prediction tool. Possible 
phosphorylation sites predicted for the CerS2 protein sequence are indicated. Color- code represents 
different amino acid residues, which could be used for phosphorylation. 
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Figure A5: Generated pcDNA3.1 CerS2 plasmids containing different forms of WT or modified 
cDNA of cers2. (A) Vector card of the pcDNA3.1 containing the WT sequence of cers2. (B) 
pcDNA3.1 CerS2 vector containing the H212A/H213A mutation. (C) pcDNA3.1 CerS2 vector 
containing the cers2, which carries a mutation at the glycosylation site (N19Q) (D) Shown is the 
pcDNA3.1 vector containing the cers2 cDNA coding for the CerS2Del79-120 protein. 
 
 
 
 
 
 
 
 
Figure A6: Analysis of CerS5 activity in vitro. 
Protein lysates of transiently transfected (cerS5-WT, 
CerS5del87-128) HEK cells were generated and 
incubated with NBD-sphinganine and C16-acyl-CoA 
as substrates. The activity assay was performed as 
described. Desitometric analysis was performed 
after lipid extraction and separation by HPTLC. Data 
are means ±SEM; Quantification was based on 
three individual experiments. Unpaired t-test, 
***P<.001. 
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Figure A7: TMHMM (transmembrane) topology- prediction results. Shown is the graphical 
overview of the transmembrane topology-predictions of the CerS2 WT and CerS2Del59-137 protein 
obtained by the TMHMM 2.0 prediction (http://www.cbs.dtu.dk/services/TMHMM-2.0/). The X axis 
indicates the position of amino acid residues. The Y axis indicates the probability to which extent the 
amino acid residues are part of a transmembrane domain (TMD). Blue (inside): cytoplasm facing 
sequences, purple (outside): sequences facing the ER lumen (Adopted and modified according to 
Bickert et al., 2018). 
 
 
 
Figure A8: physiological properties (Mendelian ratio, body weight & organ size): (A) 
Mendelian ratio CerS2 Del mice. Shown are the percentages of WT (black), heterozygous (white) 
and homozygous (grey) mice obtained from heterozygous breedings of +/CerS2Del mice. The total 
number of analysed mice is shown in brackets (adopted and modified from Bickert et al., 2018). (B) 
Ratio of body weight/ body length determined for CerS2 WT, Flox, H/A and Del mice.(n≥11). (C) 
Overview of different tissue weights of CerS2 WT, Flox, H/A and Del mice. Data are means ±SEM; 
unpaired t-test, *P<.05; ***P<.001 (liver: n≥10; other tissues: n≥5) (Adopted and modified according 
to Bickert et al., 2018).  
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Figure A9: Protein expression of endogenous and modified CerS2 protein in different tissues 
of CerS2 WT, Flox, H/A and Del mice. (A-G) Immunoblot results showing CerS2 (and eGFP) 
expression under normal exposure (upper blot). The expression levels of the endogenous CerS2 (45 
kDa) in CerS2 WT (and also in Flox) mice served as controls. Point mutated CerS2 (44.9 kDa) protein 
was detectable in CerS2 H/A mice, no signal was detectable for CerS2 Del mice in any of the 
analysed tissues. Over-exposure of all investigated blots (lower blot) showed a band corresponding 
to the truncated CerS2 (CerS2del59-137; 35.8 kDa) present in CerS2 Del mice. Expression level of 
Del protein is under 1% in comparison to the expression of the CerS2 WT protein found in the Flox 
control mice (CerS2Del79-120 protein appearing at approximately 37 (H) Densitometric analysis and 
quantification of CerS2 expression normalized to HSP90 (after normal-exposure). Data are means ± 
SEM, (n=3); Unpaired t-test, *P<.05; **P<.01; ***P<.001. gWAT – gonadal white adipose tissue; iBat 
– interscapular brown adipose tissue; igWAT – inguinal white adipose tissue (Adopted and modified 
according to Bickert et al., 2018). 
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Figure A 10: Mass spectrometric analyses of liver sphingolipid content in CerS2 WT, Flox, 
H/A and Del mice. (A) Quantification of ceramide (Cer), (B) hexosylceramide (Hex-Cer) and (C) 
sphingomyelin (SM) species with incorporated sphingosine (d18:1). (D) Analysis of less abundant 
Long chain base species with incorporated sphinganine (d18:0) and sphingadiene (d18:2). (E) 
Quantification of total levels of LCBs, ceramides, hexosylceramides and sphingomyelins. Data are 
means ± SEM, (n=4); Unpaired t-test, *P<.05; **P<.01; ***P<.001 (Adopted and modified according 
to Bickert et al., 2018). 
 
 
Figure A 11: Quantitative Real-Time (qRT)-PCR analyses of genes involved in hepatic lipid 
homeostasis. Transcript levels of several genes involved in lipid anabolic-, catabolic- and regulatory 
processes were determined in CerS2 WT, Flox, H/A and Del mice normalized to PPIA (Peptidylprolyl 
isomerase A) and HPRT (Hypoxanthine-guanine phosphoribosyltransferase) expression (n=5-7). 
Data are means ± SEM; *, p<0.05; **, p<0.01; ***, p<0.001. (Adopted and modified according to 
Bickert et al., 2018).  
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Figure A 12: Lateral diffusion of the Insulin receptor in membrane sheets of primary MEFs 
derived from CerS2H/A mice. Fluorescence recovery (FRAP) experiment was performed in 
collaboration with Elisa Merklinger, Prof. Lang. No obvious differences were obtained in the capability 
of the transfected IR-GFP to diffuse within the plasma membrane. 
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schlank      -----MDILNEFSNVFWSTHIWLPPNTTWADIAPGSRPDVVHANYKDLIWPIPFAAVVML 55 
CerS2m       -------MLQTLYDYFWWERLWLPVNLTWADLEDK-D-GRVYAKASDLYITLPLALLFLV 51 
CerS5m       MATAAAETLGLLWGWLWSESFWLPQNVSWADLEGPGD-GYGYPRAQHVLSVFPLAVCIFS 59 
CerS6m       --------MAGILAWFWNERFWLPHNVTWADLKNTEE--ATFPQAEDLYLAFPLAFCIFM 50 
                     :  :   :*   :*** * :***:         . . ..:   :*:*  .:  
 
schlank      VRYTLERFWISPVGKSLGIRSSRPKKAANVPILEKTYAKSTRL-DKKKLVPLSKQTDMSE 114 
CerS2m       IRYFFELYVATPLAALLNVKEKTRLRAPPNATLEHFYQTSGKQPKQVEVDLLSRQSGLSG 111 
CerS5m       VRMLFERFIAKPCALRVGIKDSPVNKVEPNDTLEKVFVSVTKYPDEKRLKGLSKQLDWSV 119 
CerS6m       VRLIFERFIAKPCAIALNIQANGPQTAQPNAILEKVFTAITKHPDEKRLEGLSKQLDWDV 110 
             :*  :* :  .* .  :.:: .    .     **: :    :  .: .:  **:* . .  
 
schlank      REIERWWRLRRAQDKPSTLVKFCENTWRCIYYLYSFIFGVIVLWDKPWFWDVKSCWYGYP 174 
CerS2m       RQVERWFRRRRNQDRPSLLKKFREASWRFTYYLIAFVAGMAVTVDKPWFYDLRKVWEGYP 171 
CerS5m       RKIQCWFRHRRNQDKPPTLTKFCESMWRFTYYLCIFCYGIRFLWSMPWFWDTRQCWYNYP 179 
CerS6m       RSIQRWFRQRRNQEKPSTLTRFCESMWRFSFYLYVFSYGVRFLKQTPWLWNTRHCWYNYP 170 
             *.:: *:* ** *::*  * :* *  **  :**  *  *: .  . **::: :  * .** 
 
schlank      HQSISNDIWWYYMISMSFYWSLTGTQFFDVKRKDFWQMFIHHMVTLLLMSLSWVCNLHRV 234 
CerS2m       IQSIIPSQYWYYMIELSFYWSLLFSIASDVKRKDFKEQIIHHVATIILLCFSWFANYVRA 231 
CerS5m       YQPLSRELYYYYITQLAFYWSLMFSQFIDVKRKDFLMMFIHHMIGIMLTTFSYVNNMVRV 239 
CerS6m       YQPLTADLHYYYILELSFYWSLMVSQFTDIKRKDFGIMFLHHLATIFLITFSYVNNMARV 230 
              * :  .  :**: .::*****  :   *:*****   ::**:  ::*  :*:. *  *. 
 
schlank      GSLVLVVHDCADIFLEAAKLTKYAKYQKLCDAIFAIFTVVWIVTRLGFYPRIIYSSS-VE 293 
CerS2m       GTLIMALHDASDYLLESAKMFNYAGWKNTCNNLFIVFAIVFIITRLVIMPFWILHCTMIY 291 
CerS5m       GALIFCLHDFADPLLEAAKMANYARRERLCTTLFVIFGAAFIVSRLAIFPLWILNTTLFE 299 
CerS6m       GTLVLCLHDSADALLEAAKMANYAKFQKMCDLLFVMFAVVFITTRLGIFPLWVLNTTLFE 290 
             *:*:: :** :* :**:**: :**  :. *  :* :*  .:* :** : *  :   : .  
 
schlank      APRILPMFPAYYIFNSLLLMLLVLHVIWTYMILKIVVDSLQKGLMSGDIRSSDSEDLTDS 353 
CerS2m       PLELYPAFFGYYFFNFMMAVLQMLHIFWAYFILRMAHKFI-TGKLIEDERSDREETESS- 349 
CerS5m       SWEIIGPYPSWWLFNALLLILQVLHAIWSYLIVQTASKALSRGKVSKDDRSDVESSSEE- 358 
CerS6m       SWEIVGPYPSWWVFNLLLLLLQGLNCFWSYLIVKIACKTVSKGKVSKDDRSDIESSSDD- 349 
               .:   : .::.** :: :*  *: :*:*:*:: . . :  * :  * **. ..   .  
 
schlank      SGNARLTNGSARSKNKSISSAPSDKGSAGGAGSRAGARVATTERREE------------- 400 
CerS2m       EGEETA-AG------AGAKSRLLANGHPILNNNH-----------PKND----------- 380 
CerS5m       EDETT--HK------NNLSGSSSSNGANCMNGYMGGSHLAEEQGTCKATGNLHFRASPHL 410 
CerS6m       EDSEP--PG------KKPHSSTTTNGTSGTNGYLLTGP-------CSVDD---------- 384 
             ...                .    :*     .              .              
 
schlank      ---- 400 
CerS2m       ---- 380 
CerS5m       HSCD 414 
CerS6m       ---- 384 
 
Figure A 13: Protein sequence alignment performed with schlank, CerS2/5 and 6: Identical 
residues are indicated with asterisks (*) and similar residues with a ‘:’ or a ‘.’. The colon depicts amino 
acids with more similarity to each other than those labeled with a dot. ( Alignments were performed 
with the CLUSTALW multiple alignment program (ExPASy).  
 
 
